VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 3 (22-31 enero / 2024)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

COVID-19 Vaccine-Induced Protection More Persistent in Children vs Adults

Jan 22. In the 6 months following COVID-19 infection, vaccination, or both, SARS-CoV-2-specific immunoglobulin (Ig) G and neutralizing antibodies (nAbs) persist at higher levels in children than in adults. However, in all age groups, hybrid immunity is associated with more robust IgG responses than previous infection alone. These study results were published in the Journal of the Pediatric Infectious Diseases Society.

"COVID-19 antibody responses and neutralization activity were more robust in children than in adults up to 6 months following vaccination, but hybrid immunity was more protective than prior infection alone across all age groups."

Researchers conducted a study to compare SARS-CoV-2 spike-specific IgG levels and nAb activity between children and adults following COVID-19 infection, vaccination, or both. Study patients were enrolled at the time of infection or vaccination and divided into 3 groups for longitudinal serologic testing. The 3 groups included patients with confirmed COVID-19 infection, those who were vaccinated with no prior infection, and those who were both previously infected and vaccinated. Time since vaccination was considered the date that the last primary series dose was administered, and a generalized additive mixed model was used to predict antibody decay.

The researchers collected blood samples from 669 patients (age range, 40 days to 55 years) between June 2020 and December 2022. Overall, 330 were positive for COVID-19 infection, 180 were previously vaccinated, and 159 had hybrid immunity. Approximately half (49.3%) of the population were younger than 18 years.

These data demonstrate the robust and persistent immunologic response of SARS-CoV-2 vaccination in children and emphasize the benefit of vaccination after SARS-CoV-2 infection.

Following COVID-19 onset, no significant age-based differences were observed in spike-specific IgG levels at 1 month. However, following vaccination, children had significantly higher spike-specific IgG levels relative to both adolescents and adults at this time (both P <.001).

At 6 months following COVID-19 onset, unvaccinated preschool children (age, <5 years) had significantly higher levels of spike-specific IgG relative to adults (P <.001). However, there was no significant difference in IgG levels observed between school-aged (age range, 5-11 years) children and adolescents (age range, 12-17 years) relative to adults at this time.

Fuente: Infectious Disease Advisor. Disponible en https://acortar.link/v9BphK

Brazil to launch vaccination campaign as dengue surges

Jan 23. Brazil will start a vaccination campaign against dengue fever in February, authorities said, as a sharp rise in cases of the potentially deadly disease raised fears of a runaway outbreak.

The country of 203 million people, which approved the new "Qdenga" vaccine in December, will be the first in the world to offer it through the public health system, officials said.

However, the number of available doses remains limited by a shortage of supply from its developer, Japanese pharmaceutical company Takeda, Brazil's health ministry said.

"The first shipment of 750,000 doses of the anti-dengue vaccine has arrived in Brazil," the ministry said in a statement Sunday.

In all, Brazil expects to receive 6.5 million doses this year of the two-dose vaccine, which is tailored for children.

The World Health Organization recommended last year that Qdenga be issued to children ages six to 16 in dengue hotspots.

The European Union, Indonesia and Thailand have also approved the vaccine.

Brazil saw a 57-percent increase in dengue cases last year from 2022. And it registered 56,000 cases in the first two weeks of 2024, double the number from 2023.

Six people have died of the disease so far this year in the South American country.

Mosquito-borne dengue, which can cause hemorrhagic fever, infects an estimated 100 million to 400 million people yearly, although most cases are mild or asymptomatic, the WHO says.

Climate change may be helping the disease spread. A recent report in the medical journal The Lancet found dengue transmission will increase by 36 percent if global temperatures rise two degrees Celsius by 2100.

Fuente: Medical Xpress. Disponible en https://acortar.link/9pTjAD

Moderna inicia procedimiento de licitación de vacunas de la COVID-19 en Europa

24 ene. Moderna ha iniciado un procedimiento de licitación de vacunas con tecnología ARNm contra la COVID-19 ante la Autoridad de Preparación y Respuesta a Emergencias Sanitarias (HERA) de la Comisión Europea (CE).

HERA se creó como un servicio de la CE para fortalecer la capacidad de Europa para prevenir, detectar y responder rápidamente a emergencias sanitarias transfronterizas.

El procedimiento de licitación iniciado permitirá a los Estados miembros asegurar el acceso a una cartera diversificada de vacunas COVID-19 basadas en ARNm en 2024 y más allá.

La tecnología ARNm ha demostrado su eficacia para el desarrollo de la vacuna contra la COVID-19. Incluso, la firma ha actualizado su vacuna para la temporada de vacunación a 2023.

Las partes interesadas clave en Europa, como la Agencia Europea de Medicamentos, han expresado la necesidad de una cartera diversificada de vacunas contra la COVID-19 de cara a la temporada de vacunación de 2024.

¿Qué dicen los analistas?

Según Tipranks, Moderna cuenta con la revisión de 17 analistas divididas en 9 compras, 6 mantener y 2 ventas.

El precio objetivo promedio es de 129.18 dólares con un pronóstico alto de 310 dólares y un pronóstico bajo de 55 dólares. El precio objetivo promedio representa un cambio del 26.75% con respecto al cierre del martes.



Moderna cerraba el martes al alza en los 101.68 dólares. Las medias móviles de 70 y 200 periodos rodean al precio, RSI al alza en los 54 puntos y las líneas del MACD a la baja, camino por encima hacia el nivel de cero.

Nuestro equipo de análisis sigue los mercados en tiempo real y realiza carteras de inversión (tendenciales, global macro y de fondos de inversión) , análisis , informes independientes y herramientas para que los inversores inviertan con información y análisis profesional.

En estrategias de Inversión llevamos más de 19 años haciendo que los inversores logren rentabilizar sus inversiones de forma recurrente.

Fuente: Estrategias de Inversión. Disponible en https://acortar.link/4AqBY2

¿El neumococo está de vuelta?

25 ene. El neumococo “desapareció” temporalmente durante la pandemia. Y no lo hizo en realidad como podría intuirse, es decir, porque dejase de circular como consecuencia de las medidas no farmacológicas establecidas en el control del SARS-CoV-2, ya que las tasas de portadores permanecieron inalteradas, sino porque desaparecieron sus socios necesarios, ciertos virus estacionales. Sin embargo, el neumococo está de vuelta, también en España. En el el estudio de Covadonga Pérez-García y colaboradores, se arroja luz sobre la dinámica cambiante de los serotipos de la enfermedad neumocócica invasiva (IPD) en España, donde se analiza el impacto de las vacunas conjugadas y la pandemia de COVID-19 en la prevalencia de serotipos específicos en diferentes grupos de edad, abarcando desde 2009 hasta 2023.

El estudio del grupo de José Yuste muestra que la incidencia de IPD en niños está ya por encima de los niveles de incidencia prepandémicos, y en adultos prácticamente al mismo nivel. Antes de la pandemia de COVID-19, la introducción de la vacuna PCV13 (neumocócica conjugada) tuvo un impacto significativo en la disminución de los serotipos cubiertos por esta vacuna. Sin embargo, esta disminución trajo consigo la emergencia de otros serotipos. En adultos, el serotipo 8 comenzó a predominar, representando una

proporción creciente de casos de IPD. Este serotipo, históricamente menos común, se ha asociado con enfermedades más graves. En niños, el serotipo 24F, no incluido ni en la PCV13 ni en ninguna de las vacunas neumocócicas de nueva generación, ha emergido con fuerza, lo que supone una preocupación importante. Lo más llamativo en 2023 es el aumento del serotipo 3 en ambos grupos de edad, niños y adultos. Este serotipo ha sido notoriamente desafiante en cuanto a su respuesta a las vacunas PCV, destacándose por su prevalencia y virulencia. El aumento de serotipos específicos de la vacuna PCV13, como el serotipo 4 en jóvenes adultos y el serotipo 3 en niños y adultos, es preocupante, ya que deberían ser prevenibles por las PCV actuales. El número creciente de IPD causados por serotipos 8, 22F, 10A y 11A en años recientes es también preocupante.

El resurgimiento de casos de enfermedad neumocócica invasiva en 2022 y 2023, afectando a todos los grupos de edad y alcanzando niveles comparables al período prepandemia, confirma que la enfermedad neumocócica ha vuelto como una causa principal de infección del tracto respiratorio inferior. Las nuevas PCV con cobertura más amplia deberían controlar parcialmente el problema al extender la cobertura potencial contra algunos de estos serotipos prevalentes. En cualquier caso, estos hallazgos refuerzan la necesidad de una vigilancia epidemiológica continua y una adaptación dinámica de las estrategias de vacunación.

Fuente: LIVE MED. Disponible en https://acortar.link/UtToDo

Cofepris aprueba uso de emergencia de vacuna Patria contra COVID-19

26 ene. Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) aprobó el uso de emergencia de vacuna Patria contra COVID-19, durante la sesión del Comité de Moléculas Nuevas (CMN) llevada a cabo este 26 de enero.

"El resultado de la votación de los expertos convocados en esta sesión del Comité de Moléculas Nuevas es una opinión favorable para la solicitud del laboratorio Avimex para la vacuna AVX/COVID-12 Patria, indicada para la inmunización activa de personas de 18 años y mayores para la prevención de la enfermedad por coronavirus, COVID-19", anunciaron.

Los expertos determinaron que Patria es una vacuna segura y que, en este aspecto, es equiparable al resto de inmunológicos que cuentan con aprobación de la autoridad sanitaria en territorio mexicano.

"La tasa de eventos adversos es baja y la mayoría de los eventos adversos es de severidad leve y eso brinda un perfil de seguridad que es comparable con el resto de vacunas que están aprobadas en México, esto se demostró tanto en información preclínica como en ensayos clínicos", refirió el Comité de Moléculas Nuevas.

No obstante, la autoridad sanitaria determinó que se requerirá farmacovigilancia estricta para evaluar el perfil de seguridad a largo plazo. Esto debido a que se trata de una innovación.

En cuanto a las ventajas de Patria respecto a otras vacunas, en la sesión se destacó que requiere ser almacenada a una temperatura de entre 2 y 8 grados, lo cual implica una cadena de frío menos compleja.

“Fortalecerá nuestras opciones de vacunación y es un desarrollo importante que podrá ser beneficioso para los mexicanos. Se destaca además que podrá ayudar a la aplicación universal y al acceso de vacunas para todas las personas sin restricción, incluyendo zonas más remotas del país considerando la cadena de frío”, se mencionó en la reunión del Comité de Moléculas Nuevas.

Sumado a ellos, los especialistas coincidieron que el análisis de la respuesta inmune presentado por Avimex fue adecuado y consideraron adecuada la información relacionada con la respuesta celular.

Para emitir la opinión técnica sobre Patria, el CMN analizó los datos sobre inmunogenicidad (humoral/ celular), la evidencia de seguridad disponible y su contribución al fortalecimiento de las opciones de vacunación contra COVID-19 en México en apego a los estándares y recomendaciones internacionales, incluidos los de la Organización Mundial de la Salud (OMS).

Con base en estos criterios, el CMN de la Cofepris emitió una opinión favorable para la vacuna Patria. Los votantes fueron Arturo Reyes Sandoval, Lena Ruiz Azuara, Miguel Ángel Jorge Guevara Fonseca, Rosana Pelayo Camacho y Sergio Ponce de León Rosales.

Así fue el desarrollo de Patria, la primera vacuna mexicana contra COVID-19

Avimex en coordinación con el Consejo Nacional de Humanidades, Ciencias y Tecnologías (Conacyt) inició el desarrollo de la vacuna en 2020. Con la plataforma NDV se utilizó la secuencia de la proteína S del virus SARS-CoV-2 en diversas configuraciones, entre las cuales la configuración AVX/COVID-12 resultó ser la mejor candidata.

En 2021 fue aprobado el primer ensayo clínico en humanos y, luego de dos fases, se comprobó la seguridad de la vacuna, pues no suscitó efectos adversos graves en un grupo de vacunas previamente inmunizadas con otros biológicos.

Finalmente en mayo de 2023 el laboratorio presentó datos preliminares favorables sobre la etapa final de desarrollo clínico y demostró el cumplimiento de los estándares establecidos por la OMS.

Sin embargo, fue hasta enero de este año que la Cofepris anunció una sesión del CMN para analizar la vacuna. La opinión favorable es el primer paso en el proceso de autorización para su uso de emergencia en población de México.

Por unanimidad la Cofepris emitió opinión favorable para la vacuna mexicana contra COVID-19 (Foto: EFE)

Fuente: INFOBAE. Disponible en https://acortar.link/QyG2aK

Trial estimates single typhoid vaccine dose highly effective in African children

Jan 26. One dose of the conjugate typhoid vaccine has an estimated efficacy of 78.3% in children ages 9 months to 12 years and remained strong over 4 years of follow-up, concludes a phase 3 randomized controlled trial conducted in Africa and published in The Lancet.

Mr. Ilkin / iStock

Typhoid is a life-threatening bacterial infection spread by consuming contaminated food or drinks. Malawi rolled out the vaccine for children younger than 15 years in May 2023.

A team led by the Malawi-Liverpool-Wellcome Program and the University of Maryland recruited 28,130 healthy children in Malawi, randomly assigning half to receive one dose of the Vi polysaccharide conjugated to tetanus toxoid vaccine (Vi-TT) and half to a meningococcal (MenA) control vaccine from February to September 2018.

Effectiveness waned 1.3% per year

At a median follow-up of 4.3 years, the rate of blood culture –confirmed typhoid fever was 24 39.7 cases per 100,000 person-years in the Vi-TT group, compared with 110 (182.7) in the MenA group.

In the intention-to-treat population, vaccine effectiveness (VE) of Vi-TT was 78.3% (95% confidence interval [CI], 66.3% to 86.1%), with 163 vaccinations needed to prevent one case. By age-group, VEs were 70.6% (95% CI, 6.4% to 93.0%) for children ages 9 months to 2 years; 79.6% (95% CI, 45.8% to 93.9%) for those ages 2 to 4; and 79.3% (95% CI, 63.5% to 89.0%) for those ages 5 to 12. VE waned 1.3% each year.

In a University of Maryland news release, Mark Gladwin, MD, university vice president for medical affairs, said, "The research could not come at a more critical time when Malawi and other African countries are struggling with climate change, extreme weather events and increased urbanization patterns, which are likely to contribute to increases in enteric diseases, including typhoid."

In a commentary, Birkneh Tilahun Tadesse, MD, PhD, and colleagues at the International Vaccine Institute in South Korea, said, "Coordinated interventions involving the vaccination of children and adults with safe and effective typhoid vaccines and improvements in water, sanitation, and hygiene (WASH) practices could have a pivotal role in supporting elimination efforts."

Fuente: CIDRAP. Disponible en https://acortar.link/ijQX0I

Incepta launches Evimar-13 for chronic diseases

Jan 26. Incepta Pharmaceuticals Limited launched Evimar-13, a pneumococcal conjugate vaccine that marks a significant step in preventing pneumococcal infections recently.

Incepta has already launched Pneumococcal polysaccharide vaccine in Bangladesh market last year as Prenovax 23. With the launching of Evimar13, now people get the complete package of pneumonia vaccine, said a press release.

These two vaccines are not only fills a crucial gap in the availability in Bangladesh but also represent a significant milestone in the country's healthcare.

Pneumonia and other Pneumococcal infections pose a considerable risk to public health especially to the chronic care people like Asthma, COPD patients, Cardiac patients, Kidney disease patients etc. So there is strong demand of this vaccine from the doctor community to combat the life-threatening pneumococcal infections.

To mark this momentous occasion, a scientific seminar was conducted on Thursday at Inter Continental by the Bangladesh Lung Foundation.

The seminar, titled 'Respiratory Vaccines,' brought together esteemed experts, including professor Md Ruhul Amin, professor Mohammad Mohiuddin Ahmad, Dr Mohammad Abdus Shakur Khan, Dr AKM Akramul Haque and Dr Golam Sarwar LH Bhuiyan to discuss the impact of pneumococcal diseases, the role of Evimar-13 in prevention, and the broader implications for public health.

The seminar was chaired by prof of respiratory medicine and ex-director of National Institute of Diseases of the Chest and Hospital and BLF president Dr Md Ali Hossain.

The seminar started with the welcome address of Dr Md Shahen, member secretary of BLF followed by the goodwill speech which has been deliberated by Dr EH Arefin Ahmed, executive director of Incepta Pharmaceuticals Ltd. Dr Arjuman Sharmin Winny, along with other eminent figures, provided valuable insights into the challenges and opportunities associated with this ground-breaking vaccine.

Fuente: NEW AGE Health. Disponible en https://acortar.link/sKrqkp

ECDC calls on revaccinating elderly against COVID-19

Jan 27. Around 19.4 million people aged 60 or older in European countries have received a vaccine dose against COVID-19 since September 2023, the European Centre for Disease Prevention and Control (ECDC) said on Friday.

The ECDC has stressed the urgency of revaccinating the elderly against COVID-19. Approximately 5.5 million of the vaccine doses were given to people aged 80 or over during the period from Sept. 1, 2023 to Jan. 15, 2024, the ECDC said.

Vaccination efforts should continue to focus on protecting people at risk of progression to severe disease, for example, people aged over 60 years, other vulnerable individuals irrespective of age, and pregnant women, the ECDC said in a press release.

Healthcare workers should also be considered as a priority group for COVID-19 revaccination, the ECDC added.

The median COVID-19 vaccination coverage among those aged 60 and over was 11.1 percent, with high variation among countries, the ECDC reported.

In three of the 24 reporting countries, coverage was above 50 percent in this age group.

Among those aged 80 and older, the median coverage for vaccination was 16.3 percent, with eight of the 24 countries reporting coverage above 50 percent. Meanwhile, one country had coverage above 80 percent in this age group: Denmark with 88.2 percent.

Fuente: Xinhua. Disponible en https://acortar.link/iiFT9D

31-Valent Pneumococcal Conjugate Vaccine Candidate Completes Phase 2 Enrollment

Jan 29. Anyone can get pneumococcal disease, but some people are at increased risk. To better protect children and seniors from disease, innovative vaccine candidates are conducting clinical trials in 2024.

From Pixabay

Currently, two kinds of pneumococcal vaccines are recommended in the U.S. - Pneumococcal conjugate vaccines (PCVs, specifically PCV15 and PCV20) and Pneumococcal polysaccharide vaccine (PPSV23).

However, even with U.S. FDA-approved vaccines broadly available, approximately 5,000 deaths are related to pneumococcal disease each year in the U.S.

To address this health issue, Vaxcyte, Inc. today announced the completion of enrollment in its Phase 1/2 clinical study evaluating VAX-31, a next-generation 31-valent PCV and the broadest-spectrum pneumococcal vaccine candidate in the clinic today.

This vaccine candidate is designed to prevent invasive pneumococcal disease (IPD).

Vaxcyte expects to announce topline safety, tolerability, and immunogenicity data from the Phase 1/2 study in the third quarter of 2024.

"Completing the enrollment of the VAX-31 study with more than one thousand adults 50 years and older is a significant step for our PCV franchise, and we look forward to announcing topline safety, tolerability, and immunogenicity data in the third quarter of this year," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte, in a press release.

"VAX-31, the broadest-spectrum PCV in the clinic, has the potential to address a significant public health need by covering approximately 95% of IPD circulating in the U.S. adult population while maintaining coverage of previously circulating strains that are currently contained via ongoing vaccination."

Fuente: Precision Vaccinations. Disponible en https://acortar.link/Gb6CuX

Pfizer lanza Abrysvo, su vacuna para el VRS indicada para lactantes y mayores de 60 años

30 ene. Pfizer ha comunicado que su vacuna frente al virus respiratorio sincitial (VRS), Abrysvo, ya está disponible en España y financiada por el Sistema Nacional de Salud (SNS) para inmunizar a los lactantes.

"La lucha contra el virus respiratorio sincitial (VRS) cuenta desde ahora con una nueva herramienta de prevención: la vacuna Abrysvo, desarrollada por Pfizer e indicada en mujeres embarazadas, para proteger a los lactantes y para mayores de 60 años."

Abrysvo es una vacuna bivalente contra la proteína F en prefusión (RSVpreF) del VRS que es capaz de conferir protección tanto a lactantes mediante la inmunización activa a las mujeres embarazadas como a adultos mayores. La evidencia muestra que es capaz de evitar enfermedades de las vías respiratorias inferiores (ERVBI) en ambos grupos poblacionales, que son responsables de un gran impacto sanitario y asistencial.

Se trata de la primera y única vacuna autorizada que se ha diseñado y estudiado específicamente para la inmunización de embarazadas y ahora su uso está aprobado para administrar una sola dosis de la vacuna entre las semanas 24 y 36 de gestación, indicación incluida en la Cartera Común de Servicios del SNS. Por su parte, la financiación del uso en adultos mayores de 60 años, autorizada por la Agencia Europea de Medicamentos (EMA), aún no cuenta con el visto bueno del Ministerio de Sanidad.

Inmaculada Cuesta, enfermera, matrona, miembro del grupo de 'Educadores en vacunas' y secretaria de la Asociación Nacional de Enfermería y Vacunas (Anenvac), ha trasladado la importancia de que las mujeres en edad fértil hayan recibido todas las vacunas incluidas en el calendario sistemático. Además, Cuesta ha recordado que la evidencia científica ha demostrado que, gracias a los avances tecnológicos, la vacunación en embarazadas es segura tanto para la mujer como para el feto. Por ese motivo es importante su inmunización para protegerla a ella, dados los cambios fisiológicos del embarazo, que pueden afectar a la inmunidad, como al propio feto. Mediante esta vacunación, una porción de los anticuerpos que genera la madre "se transmiten al feto en desarrollo a través de la placenta, ofreciendo al bebé un escudo vital contra el VRS en los primeros seis meses de vida, precisamente cuando es más vulnerable".

Por su parte, María Garcés Sánchez, pediatra en el Centro de Salud Nazaret (Valencia) y miembro del Comité Asesor de Vacunas de la Asociación Española de Pediatría (CAV-AEP), ha puesto de manifiesto que la bronquiolitis por VRS en el lactante es un cuadro muy frecuente y de especial gravedad en el lactante menor de 6 meses, dado que su sistema inmunológico es muy inmaduro para defenderse del virus y su aparato respiratorio es muy sensible a la enfermedad. Esta experta ha señalado que no hay tratamiento efectivo contra el virus, una vez que ha generado la bronquilitis, por lo que solo es posible aportar "medidas de sostén". Esta situación da lugar en el sistema sanitario a "una onda epidémica que genera una importante presión asistencial en hospitales y centros de atención primaria".

Además, Garcés expuso que haber sufrido de infección por VRS está vinculado a un mayor riesgo de enfermedad neumocócica y otros trastornos del ámbito pulmonar. Por ello, valoró la comercialización de esta vacuna como "una gran noticia para los profesionales, pero principalmente para los padres ya que es la razón de mayor ingreso en bebés".

Ángel Gil, profesor de Medicina Preventiva y Salud Pública de la Universidad Rey Juan Carlos de Madrid abordó la problemática que el VRS genera en los pacientes adultos.

Este experto recordó que a partir de los 60 años el sistema inmune empieza a perder funcionalidad, por lo que cualquier mecanismo que lo prepare ante una infección resulta relevante. Gil explicó que hasta la pandemia de la covid no estaban disponibles test rápidos que pudieran distinguir entre gripe, VRS o covid y ha sido a partir de este momento cuando se han tenido pruebas del impacto del VRS en ancianos. Gracias a las vacunas, este experto ha confirmado que se "evitará lo más importante: hospitalización y muerte".



Participantes en la presentación de Abrysvo ante los medios de comunicación.

Una vez que ya se cuentan con vacunas de la gripe, covid y VIR, Gil reclamó que cuando se acerque la época otoñal se pase de recomendar la vacunación de gripe a hacerlo de vacunación frente a las infecciones respiratorias agudas (IRAs) que coexisten, con el objetivo de ganar efectividad.

El VRS es la causa de aproximadamente 245.000 ingresos hospitalarios anuales en niños menores de cinco años en la Unión Europea, produciéndose la mayoría de los casos en niños menores de un año. Al mismo tiempo, la incidencia de la enfermedad entre los adultos mayores también es significativa pues, cada año, el virus provoca más de 270.000 hospitalizaciones y alrededor de 20.000 muertes en personas mayores de 60 años, de ellas, unas 6.000 en España.

Como ha asegurado José Chaves, director médico de Pfizer en España, se sienten "orgullosos de poder presentar hoy en España nuestra vacuna frente al VRS, una innovación que, estamos seguros, proporcionará una protección significativa frente al VRS a poblaciones vulnerables como los lactantes y adultos mayores y contribuirá a reducir el impacto de esta afección respiratoria en el sistema sanitario".

Además, Chaves ha explicado que están trabajando en vacunas combinadas entre los tres principales virus respiratorios, que causan importantes problemas de salud y provocan la saturación de los centros sanitarios en invierno.

Fuente: DiarioFarma . Disponible en https://acortar.link/DHnxNN

GSK seeks to extend RSV vaccine use in adults aged 50-59

Jan 30. The European Medicines Agency (EMA) has accepted GSK's regulatory application seeking expansion of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, to include adults aged 50 to 59 years.

If approved, the vaccine would become the first to be available for protecting this age group against RSV.

Arexvy is currently indicated for use in individuals aged 60 years and above to prevent RSV-associated lower respiratory tract disease in Europe.

The application is based on positive data from a Phase III trial, which demonstrated non-inferior immune responses in adults aged 50 to 59 compared to those aged 60 and above.

This observer-blind, placebo-controlled, randomised study analysed immune responses in participants aged 50 to 59 without pre-defined chronic diseases compared with those of adults aged 60 and older.

The trial's primary endpoints were RSV-A and RSV-B neutralisation titres [levels in the bloodstream] one-month post-vaccination in the 50-59 age group versus the older cohort.

The study met these endpoints, indicating a comparable immune response between the two age groups.

A decision from the European regulatory authority is anticipated in the second half of 2024.

GSK's RSV vaccine could soon be available for adults aged 50-59 at risk of RSV disease. Credit: GSK plc.

The vaccine, which includes the recombinant glycoprotein F stabilised in the prefusion conformation, is combined with AS01E adjuvant.

It has already received approval in Japan, the US, the UK and Canada for the same indication. Reviews for regulatory approval in additional countries are ongoing.

GSK is the first company to seek regulatory approval for an RSV vaccine in the 50-59 year demographic.

The expansion could provide significant protection for adults in this age range who are at an increased risk of severe RSV disease due to underlying health conditions.

The latest development comes after the company agreed to acquire asthma drug specialist Aiolos Bio in a $1.4bn deal to bolster its respiratory and inflammatory asset pipeline.

Fuente: Pharmaceutical Technology. Disponible en https://acortar.link/JZXvXG

Documento con importante información sobre vacunas de COVID-19 en madres y embarazadas fue publicado

30 ene. Se publicó anexo de la Guía de Campo de Inmunización Materno Neonatal de la Organización Panamericana de la Salud (OPS), con relevante información sobre las vacunas COVID-19.

La evidencia ha demostrado que las embarazadas corren un mayor riesgo de COVID-19 grave (hospitalización, ingreso en unidades de cuidados intensivos, necesidad de asistencia ventilatoria o muerte) que las personas no embarazadas.

La infección por SARS-CoV-2 durante el embarazo también se ha asociado a resultados adversos como parto prematuro, bebés con bajo peso al nacer, muerte fetal e ingreso en unidades de cuidados intensivos neonatales.

Además, se ha documentado el riesgo de transmisión postnatal de la infección por SARS-CoV-2 de madres infectadas u otros cuidadores a los lactantes, y los lactantes tienen un mayor riesgo de hospitalización que los niños mayores.

Las vacunas COVID-19 son seguras cuando se administran durante el embarazo en todos los trimestres de gestación y el puerperio, y protegen eficazmente a las mujeres embarazadas, las madres y sus recién nacidos.

La OPS recomienda la vacunación de las mujeres embarazadas y las madres, por considerar que son un grupo de alta prioridad, debido a los riesgos que conlleva la infección en este grupo.

Este documento presenta información sobre COVID-19, las vacunas disponibles y su inmunogenicidad, eficacia, seguridad y contraindicaciones. Finalmente, se presentan algunas estrategias para su implementación en América Latina y el Caribe con el fin de aumentar la cobertura de inmunización en esta población objetivo.

En particular, se señala que las estrategias de comunicación para promover la inmunización contra el COVID-19 en embarazadas y madres debe hacer hincapié en las pruebas de seguridad y eficacia de la vacuna y en los beneficios para las madres y los recién nacidos.

Al igual que en la guía original, los destinatarios de este anexo son los gestores y el personal de los servicios de salud maternoinfantil y de los programas de inmunización, los profesionales de salud en general, las mujeres embarazadas y madres, y los medios de comunicación.

Fuente: Organización Panamericana de la Salud. Disponible en https://acortar.link/XDIgZm

IFRC Global COVID-19 study: vaccine bank an 'essential element' of next pandemic response

Jan 31. Governments need to prepare for the next pandemic by establishing an international 'vaccine bank' which ensures the availability and distribution of vaccines equitably in all regions of the world.

That's the central recommendation of a new report following a huge study into the impact of COVID-19 and authorities' reactions to it. The report is being released exactly four years on from the IFRC's first Global COVID emergency appeal, on 31st January 2020.

The International Federation of the Red Cross and Red Crescent (IFRC) commissioned researchers from the Humanitarian Observatory, an IFRC reference centre hosted by the Argentine Red Cross, to carry out a major research project. For it, they'd carried out interviews with 16,027 people, working in collaboration with 90 Red Cross and Red Crescent National Societies.

People from different sectors were asked about their experiences during the COVID-19 pandemic. Strategic partners from the private sector and trade unions also collaborated in conducting the surveys.

Participants were chosen to represent people working or active in six societal sectors - healthcare, academia/ education, transport, non-governmental organisations (NGOs), the corporate sector and the media. The study looked for both common trends and contrasts across geographies and sectors. Its aim was to develop recommendations so that the next pandemic can be handled better than the last.

The study – '**Insights Gained by Strategic Sectors During the Pandemic**' – found:

Nearly 70% of people in all sectors and regions had a high fear of catching COVID-19. People in the Americas and/or working in healthcare had the highest fear.

More than half of all respondents said their personal finances were affected by the pandemic.

54% of participants interviewed said their government handled the pandemic well. The percentage was highest across Africa and lowest across the Americas.

Almost half of all respondents working in healthcare and the media felt 'discriminated against' for the role they played during the pandemic.

The vast majority of interviewees said they received no priority for vaccinations despite the important roles they played during the pandemic.

The main recommendations of the report include:

Creating a global vaccine and antidote bank to ensure the availability and distribution of supplies equitably in all regions.

Establishing priorities for vaccination or delivery of medicines to those who enable the world's citizens to receive food, medical care, news and education.

Carrying out a communication campaign from a supranational body that values the actions of the essential sectors to legitimise their tasks and recognize their work.

José Scioli, Director of the Humanitarian Observatory of the Argentine Red Cross said:

"Some of the answers to the main challenges require establishing efficient processes on a global scale. That is why it is so central to take these global lessons to ensure that we can all – as humanity as a whole - learn from our experience and emerge stronger. We are convinced that we are capable of learning from our past to improve the present and future. With the insights from the Humanitarian Observatory's study, we can promote the exchange of information to improve our societies."

Xavier Castellanos, IFRC Under Secretary General said:

"The COVID-19 pandemic led to the biggest worldwide disruption to normal life in a generation. But its impacts were disproportionate. Often, for example, vaccines were distributed on the basis of money, not need. Those who contributed most to helping the vulnerable through the pandemic were too often treated the worst. This important study offers a path to handling the next pandemic better. Its ambition and scale means its recommendations carry weight. "

The full report can be downloaded in English, and via the 'Descargar Informe' link in Spanish, French and Arabic.

Fuente: IFRC. Disponible en https://acortar.link/9j7s0v

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

@finlayediciones

https://ediciones.finlay.edu.cu/

Artículos científicos publicados en Medline

Filters activated: Publication date from 2024/01/22 to 2024/01/31. “vaccine” (Title/Abstract) 581 records.

Strongyloidiasis.
Gordon CA, Utzinger J, Muhi S, Becker SL, Keiser J, Khieu V, Gray DJ. Nat Rev Dis Primers. 2024 Jan 25;10(1):6. doi: 10.1038/s41572-023-00490-x. PMID: 38272922

Virology-the path forward.
Rasmussen AL, Gronvall GK, Lowen AC, Goodrum F, Alwine J, Andersen KG, Anthony SJ, Baines J, Banerjee A, Broadbent AJ, Brooke CB, Campos SK, Caposio P, Casadevall A, Chan GC, Cliffe AR, Collins-McMillen D, Connell N, Damania B, Daugherty MD, Debbink K, Dermody TS, DiMaio D, Duprex WP, Emerman M, Galloway DA, Garry RF, Goldstein SA, Greninger AL, Hartman AL, Hogue BG, Horner SM, Hotez PJ, Jung JU, Kamil JP, Karst SM, Laimins L, Lakdawala SS, Landais I, Letko M, Lindenbach B, Liu S-L, Luftig M, McFadden G, Mehle A, Morrison J, Moscona A, Mühlberger E, Munger J, Münger K, Murphy E, Neufeldt CJ, Nikolich JZ, O'Connor CM, Pekosz A, Permar SR, Pfeiffer JK, Popescu SV, Purdy JG, Racaniello VR, Rice CM, Runstadler JA, Sapp MJ, Scott RS, Smith GA, Sorrell EM, Speranza E, Streblow D, Tibbetts SA, Toth Z, Van Doorslaer K, Weiss SR, White EA, White TM, Wobus CE, Worobey M, Yamaoka S, Yurochko A. J Virol. 2024 Jan 23;98(1):e0179123. doi: 10.1128/jvi.01791-23. Epub 2024 Jan 3. PMID: 38168672

Dengue.
Paz-Bailey G, Adams LE, Deen J, Anderson KB, Katzelnick LC. Lancet. 2024 Jan 24:S0140-6736(23)02576-X. doi: 10.1016/S0140-6736(23)02576-X. Online ahead of print. PMID: 38280388

[Pretravel medical consultation].
Spindler R, Rothe C. Inn Med (Heidelb). 2024 Feb;65(2):137-149. doi: 10.1007/s00108-023-01642-7. Epub 2024 Jan 26. PMID: 38276977

Vaksinasjonsdekning mot covid-19 etter fødeland og underliggende risiko for alvorlig sykdomsforløp.
Delalic L, Hussaini L, Gjefsen HM, Gleditsch R, Winje BA, Godøy AA. Tidsskr Nor Laegeforen. 2024 Jan 22;144(1). doi: 10.4045/tidsskr.23.0334. Print 2024 Jan 23. PMID: 38258714

The Microbiota in Long COVID.
Álvarez-Santacruz C, Tyrkalska SD, Candel S. Int J Mol Sci. 2024 Jan 22;25(2):1330. doi: 10.3390/ijms25021330. PMID: 38279329

Injuries and medical emergencies among international travellers.
Potin M, Carron PN, Genton B. J Travel Med. 2024 Jan 28;31(1):taad088. doi: 10.1093/jtm/taad088. PMID: 37405992

Correction.
[No authors listed] Hum Vaccin Immunother. 2024 Dec 31;20(1):2307699. doi: 10.1080/21645515.2024.2307699. Epub 2024 Jan 28. PMID: 38282336

PCSK9-directed therapies: an update.
Katzmann JL, Laufs U. Curr Opin Lipidol. 2024 Jan 22. doi: 10.1097/MOL.0000000000000919. Online ahead of print. PMID: 38277255

Sexual and Gender Minorities' Vaccine Uptake and Behavioral Change in Response to the Mpox Outbreak in the United States: August 2022 Through November 2022.
Grov C, Zohra F, Mirzayi C, Stief M, D'Angelo AB, Dearolf M, Westmoreland DA, Carneiro P, Nash D, Carrico AW. Clin Infect Dis. 2024 Jan 23:ciad793. doi: 10.1093/cid/ciad793. Online ahead of print. PMID: 38262167

Glycosylation in malaria parasites: what do we know?
Gowda DC, Miller LH. Trends Parasitol. 2024 Jan 22:S1471-4922(23)00311-2. doi: 10.1016/j.pt.2023.12.006. Online ahead of print. PMID: 38262838

Identification and prioritisation of potential vaccine candidates using subtractive proteomics and designing of a multi-epitope vaccine against Wuchereria bancrofti.
Aarthy M, Pandiyan GN, Paramasivan R, Kumar A, Gupta B. Sci Rep. 2024 Jan 23;14(1):1970. doi: 10.1038/s41598-024-52457-x. PMID: 38263422

The HLA-II immunopeptidome of SARS-CoV-2.
Weingarten-Gabbay S, Chen DY, Sarkizova S, Taylor HB, Gentili M, Hernandez GM, Pearlman LR, Bauer MR, Rice CM, Clauser KR, Hacohen N, Carr SA, Abelin JG, Saeed M, Sabeti PC. Cell Rep. 2024 Jan 23;43(1):113596. doi: 10.1016/j.celrep.2023.113596. Epub 2023 Dec 20. PMID: 38117652

Autoimmune pancreatitis-New evidence for clinical management strategies.
Ammer-Herrmenau C, Hamm J, Neesse A. United European Gastroenterol J. 2024 Jan 25. doi: 10.1002/ueg2.12537. Online ahead of print. PMID: 38271283

COVID-19 vaccines and beyond.
Liu Y, Li D, Han J. Cell Mol Immunol. 2024 Jan 26. doi: 10.1038/s41423-024-01132-2. Online ahead of print. PMID: 38273150

Neonatal BCG: a time for change.
Pillay T, Toldi G, Hussain A, Magwenzi MM, Satodia P, Radcliffe R. Arch Dis Child Educ Pract Ed. 2024 Jan 23;109(1):19-24. doi: 10.1136/archdischild-2021-323239. PMID: 36008111

Trigeminal Postherpetic Neuralgia: From Pathophysiology to Treatment.
Niemeyer CS, Harlander-Locke M, Bubak AN, Rzasa-Lynn R, Birlea M. Curr Pain Headache Rep. 2024 Jan 23. doi: 10.1007/s11916-023-01209-z. Online ahead of print. PMID: 38261232

Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning.
Röltgen K, Boyd SD. Annu Rev Pathol. 2024 Jan 24;19:69-97. doi: 10.1146/annurev-pathmechdis-031521-042754. Epub 2023 Sep 22. PMID: 37738512

Willingness to take human papillomavirus vaccine and its associated factors among school adolescent girls: A case of school-based dose one human papillomavirus vaccine campaign in Dire Dawa, Ethiopia.

Kassie N, Sema A, Amsalu B, Sintayehu Y, Abie A, Mengist B, Yibabie S, Talie E. SAGE Open Med. 2024 Jan 23;12:20503121231225333. doi: 10.1177/20503121231225333. eCollection 2024. PMID: 38268947

AI and the future of vaccine development.
Koff WC, Anandkumar A, Poland GA. Vaccine. 2024 Jan 30:S0264-410X(24)00071-9. doi: 10.1016/j.vaccine.2024.01.059. Online ahead of print. PMID: 38296704

Oral immunization with *Shigella sonnei* WRSs2 and WRSs3 vaccine strains elicits systemic and mucosal antibodies with functional anti-microbial activity.
Shrivastava S, Agnememel AB, Ndungo E, Islam D, Liang Y, Frenck RW Jr, Pasetti MF. mSphere. 2024 Jan 30;9(1):e0041923. doi: 10.1128/msphere.00419-23. Epub 2023 Dec 22. PMID: 38132716

Relationship between religiosity and HPV vaccine initiation and intention in urban black and hispanic parents.
Coleman DC, Markham C, Guilamo-Ramos V, Santa Maria D. BMC Public Health. 2024 Jan 23;24(1):265. doi: 10.1186/s12889-024-17653-4. PMID: 38263012

Three novel pentavalent meningococcal vaccines.
Steffen R, Caumes E. J Travel Med. 2024 Jan 28;31(1):taad152. doi: 10.1093/jtm/taad152. PMID: 38006362

Covid19Vaxplorer: A free, online, user-friendly COVID-19 vaccine allocation comparison tool.
Trejo I, Hung PY, Matrajt L. PLOS Glob Public Health. 2024 Jan 22;4(1):e0002136. doi: 10.1371/journal.pgph.0002136. eCollection 2024. PMID: 38252671

The association between influenza vaccine effectiveness and egg-based manufacturing technology: literature review and US expert consensus.
Chatterjee A, Ambrose K, Canaday DH, Delair S, Ezike N, Huber VC, Jhaveri R, Nyquist AC, Sporer A, Varman M, Vivekanandan R, Wojcik R, Jandhyala R. Curr Med Res Opin. 2024 Feb;40(2):335-343. doi: 10.1080/03007995.2023.2284386. Epub 2024 Jan 24. PMID: 38054898

Human Rabies Treatment-From Palliation to Promise.
Lacy M, Phasuk N, Scholand SJ. Viruses. 2024 Jan 22;16(1):160. doi: 10.3390/v16010160. PMID: 38275970

State-of-the-art drug delivery system to target the lymphatics.
Khaire OT, Mhaske A, Prasad AG, Almalki WH, Srivastava N, Kesharwani P, Shukla R. J Drug Target. 2024 Jan 22:1-34. doi: 10.1080/1061186X.2024.2309671. Online ahead of print. PMID: 38253594

Determinants of COVID-19 vaccine-induced myocarditis.
Rose J, Hulscher N, McCullough PA. Ther Adv Drug Saf. 2024 Jan 27;15:20420986241226566. doi: 10.1177/20420986241226566. eCollection 2024. PMID: 38293564

Personalized mRNA vaccine boosts melanoma immunotherapy.
O'Leary K. Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006-4. Online ahead of print. PMID: 38273121

What makes SARS-CoV-2 unique? Focusing on the spike protein.
Qian J, Zhang S, Wang F, Li J, Zhang J. Cell Biol Int. 2024 Jan 23. doi: 10.1002/cbin.12130. Online ahead of print. PMID: 38263600

Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines.
Yang M, Zhang Z, Jin P, Jiang K, Xu Y, Pan F, Tian K, Yuan Z, Liu XE, Fu J, Wang B, Yan H, Zhan C, Zhang Z. Int J Pharm. 2024 Jan 25;650:123695. doi: 10.1016/j.ijpharm.2023.123695. Epub 2023 Dec 9. PMID: 38081560

Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques.
Huang L, Zhao T, Zhao W, Shao A, Zhao H, Ma W, Gong Y, Zeng X, Weng C, Bu L, Di Z, Sun S, Dai Q, Sun M, Wang L, Liu Z, Shi L, Hu J, Fang S, Zhang C, Zhang J, Wang G, Loré K, Yang Y, Lin A. Emerg Microbes Infect. 2024 Jan 23:2309985. doi: 10.1080/22221751.2024.2309985. Online ahead of print. PMID: 38258878

Self-Assembling Polypeptides in Complex Coacervation.
Sathyavageeswaran A, Bonesso Sabadini J, Perry SL. Acc Chem Res. 2024 Jan 22. doi: 10.1021/acs.accounts.3c00689. Online ahead of print. PMID: 38252962

Effectiveness of Bivalent mRNA Booster Vaccine Against COVID-19 in Korea.
Yoon JG, Sohn JW, Choi WS, Wie SH, Lee J, Lee JS, Jeong HW, Eom JS, Seong H, Nham E, Choi YJ, Noh JY, Song JY, Cheong HJ, Kim WJ. J Korean Med Sci. 2024 Jan 22;39(3):e15. doi: 10.3346/jkms.2024.39.e15. PMID: 38258360

Emergency Approval Mechanisms for Human Vaccines in India.
Mehrotra N, Manchikanti P. Pharmaceut Med. 2024 Jan 24. doi: 10.1007/s40290-023-00513-8. Online ahead of print. PMID: 38265630

Humoral and cellular immune response in patients of liver cirrhosis and immunocompetent recipient of ChAdOx1nCoV-19 Vaccine (Covishield).
Dandu H, Goel A, Kumar M, Malhotra HS, Katiyar H, Agarwal M, Kumar N, Pandey P, Rani S, Yadav G. Clin Exp Med. 2024 Jan 27;24(1):24. doi: 10.1007/s10238-023-01258-z. PMID: 38280060

Systematic review of cost projections of new vaccine introduction.
Levin A, Yeung KHT, Hutubessy R. Vaccine. 2024 Jan 25:S0264-410X(24)00024-0. doi: 10.1016/j.vaccine.2024.01.024. Online ahead of print. PMID: 38278630

Strategies to reduce the risks of mRNA drug and vaccine toxicity.
Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Nat Rev Drug Discov. 2024 Jan 23. doi: 10.1038/s41573-023-00859-3. Online ahead of print. PMID: 38263456

Vaccine hesitancy among physicians: a qualitative study with general practitioners and paediatricians in Austria and Germany.
Wojczewski S, Leitner KM, Hoffmann K, Kutalek R, Jirovsky-Platter E. BMJ Open. 2024 Jan 22;14(1):e077411. doi: 10.1136/bmjopen-2023-077411. PMID: 38262649

Recent progress in mRNA cancer vaccines.
Yao R, Xie C, Xia X. Hum Vaccin Immunother. 2024 Dec 31;20(1):2307187. doi: 10.1080/21645515.2024.2307187. Epub 2024 Jan 28. PMID: 38282471

Safety and Reactogenicity of COVID-19 Vaccination in Severe Alpha-1 Antitrypsin Deficiency.
McElvaney OJ, Cleary B, Fraughen DD, Kelly G, McElvaney OF, Murphy MP, Branagan P, Gunaratnam C, Carroll TP, Goss CH, McElvaney NG. Chronic Obstr Pulm Dis. 2024 Jan 25;11(1):3-12. doi: 10.15326/jcopdf.2023.0432. PMID: 37676644

A Systematic Review of the COVID Vaccine's Impact on the Nervous System.
Yella VT, Pareek S, Meena B, Sasanka KSBSK, Thangaraju P, T Y SS. Curr Drug Saf. 2024 Jan 24. doi: 10.2174/0115748863273931231121072231. Online ahead of print. PMID: 38275049

Tumor-derived microvesicles for cancer therapy.
Yang S, Zheng B, Raza F, Zhang S, Yuan WE, Su J, Qiu M. Biomater Sci. 2024 Jan 29. doi: 10.1039/d3bm01980b. Online ahead of print. PMID: 38284828

Restoring immune tolerance in pemphigus vulgaris.
Ahmed AR, Kalesinskas M, Kaveri SV. Proc Natl Acad Sci U S A. 2024 Jan 30;121(5):e2317762121. doi: 10.1073/pnas.2317762121. Epub 2024 Jan 23. PMID: 38261616

COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign.
Mead MN, Seneff S, Wolfinger R, Rose J, Denhaerynck K, Kirsch S, McCullough PA. Cureus. 2024 Jan 24;16(1):e52876. doi: 10.7759/cureus.52876. eCollection 2024 Jan. PMID: 38274635

Strengthening COVID-19 vaccine confidence & demand during the US COVID-19 emergency response.
Abad N, Bonner KE, Kolis J, Brookmeyer KA, Voegeli C, Lee JT, Singleton JA, Quartarone R, Black C, Yee D, Ramakrishnan A, Rodriguez L, Clay K, Hummer S, Holmes K, Manns BJ, Donovan J, Humbert-Rico T, Flores SA, Griswold S, Meyer S, Cohn A. Vaccine. 2024 Jan 23:S0264-410X(24)00029-X. doi: 10.1016/j.vaccine.2024.01.029. Online ahead of print. PMID: 38267329

Combined deficient response to polysaccharide-based and protein-based vaccines predicts a severe clinical phenotype.
Cockx M, Haerynck F, Hoste L, Schrijvers R, Van der Werff Ten Bosch J, Dillaerts D, Thomas D, Schaballie H, Bucciol G, Robberechts W, Patel D, Berbers G, Desombere I, Geukens N, Meyts I, Bossuyt X. Clin Chem Lab Med. 2023 Sep 21;62(1):138-149. doi: 10.1515/cclm-2023-0626. Print 2024 Jan 26. PMID: 37731388

WRIB Poster Awards winners 2023.
Getz J, McGrath S, Hui G. Bioanalysis. 2024 Jan 25. doi: 10.4155/bio-2024-0012. Online ahead of print. PMID: 38270403

Uveal melanoma: Recent advances in immunotherapy.
Sorrentino FS, De Rosa F, Di Terlizzi P, Toneatto G, Gabai A, Finocchio L, Salati C, Spadea L, Zeppieri M. World J Clin Oncol. 2024 Jan 24;15(1):23-31. doi: 10.5306/wjco.v15.i1.23. PMID: 38292657

Musculoskeletal infections through direct inoculation.
Sabir N, Akkaya Z. Skeletal Radiol. 2024 Jan 30. doi: 10.1007/s00256-024-04591-w. Online ahead of print. PMID: 38291151

Comparative Biodistribution Study of Baculoviral and Adenoviral Vector Vaccines against SARS-CoV-2.
Lee HD, Chun J, Kim S, Aleksandra N, Lee C, Yoon D, Lee HJ, Kim YB. J Microbiol Biotechnol. 2024 Jan 28;34(1):185-191. doi: 10.4014/jmb.2308.08042. Epub 2023 Oct 11. PMID: 37830223

Clinical and Preclinical Methods of Heat-Stabilization of Human Vaccines.
Williamson GL, Bachelder EM, Ainslie KM. Mol Pharm. 2024 Jan 30. doi: 10.1021/acs.molpharmaceut.3c00844. Online ahead of print. PMID: 38288698

High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1.
Bolland W, Michel V, Planas D, Hubert M, Staropoli I, Guivel-Benhassine F, Porrot F, N'Debi M, Rodriguez C, Fourati S, Prot M, Planchais C, Hocqueloux L, Simon-Lorière E, Mouquet H, Prazuck T, Pawlotsky J-M, Bruel T, Schwartz O, Buchrieser J. J Virol. 2024 Jan 23;98(1):e0135123. doi: 10.1128/jvi.01351-23. Epub 2023 Dec 13. PMID: 38088562

Characteristics and burden of acute COVID-19 and long-COVID: Demographic, physical, mental health, and economic perspectives.
Leitner M, Pötz G, Berger M, Fellner M, Spat S, Koini M. PLoS One. 2024 Jan 22;19(1):e0297207. doi: 10.1371/journal.pone.0297207. eCollection 2024. PMID: 38252638

Optimized Refolding Buffers Oriented Humoral Immune Responses Versus PfGCS1 Self-Assembled Peptide Nanoparticle.
Nourani L, Lotfi A, Vand-Rajabpour H, Pourhashem Z, Nemati F, Mehrizi AA. Mol Biotechnol. 2024 Jan 24. doi: 10.1007/s12033-023-01044-y. Online ahead of print. PMID: 38267696

Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort.
Murahwa AT, Mudzviti T, Mandishora RSD, Chatindo T, Chanetsa P, Pascoe M, Shamu T, Basera W, Luethy R, Williamson AL. Viruses. 2024 Jan 22;16(1):162. doi: 10.3390/v16010162. PMID: 38275972

Is Vaccination Approaching a Dangerous Tipping Point?
Marks P, Califf R. JAMA. 2024 Jan 23;331(4):283-284. doi: 10.1001/jama.2023.27685. PMID: 38180773

Injectable Nano-in-Gel Vaccine for Spatial and Temporal Control of Vaccine Kinetics and Breast Cancer Postsurgical Therapy.
Liu T, Si X, Liu L, Ma S, Huang Z, Zhang Y, Song W, Zhang Y, Chen X. ACS Nano. 2024 Jan 30;18(4):3087-3100. doi: 10.1021/acsnano.3c08376. Epub 2024 Jan 18. PMID: 38235966

Ethics of college vaccine mandates, using reasonable comparisons.
Lam LL, Nichols T. J Med Ethics. 2024 Jan 23;50(2):140-142. doi: 10.1136/jme-2022-108852. PMID: 36997309

Economic burden of COVID-19 for employers and employees in the United States.
Sell H, Schaible K, Gouveia-Pisano JA, Yehoshua A, Malhotra D, Di Fusco M, Cha-Silva AS, Andersen KM, Nicholls L, Landi SN, Rolland C, Judy J. J Med Econ. 2024 Jan 31:1-37. doi: 10.1080/13696998.2024.2309835. Online ahead of print. PMID: 38294896

Description of maternal and neonatal adverse events in pregnant people immunised with COVID-19 vaccines during pregnancy in the CLAP NETWORK of sentinel sites. Nested case-control analysis of the immunization-associated risk: A study protocol.
Macías Saint-Gerons D, Castro JL, Colomar M, Rojas E, Sosa C, Ropero AM, Serruya SJ, Pastor D, Chiu M, Velandia-Gonzalez M, Abalos E, Durán P, Gomez Ponce de León R, Tomasso G, Mainero L, Rubino M, De Mucio B. BMJ Open. 2024 Jan 29;14(1):e073095. doi: 10.1136/bmjopen-2023-073095. PMID: 38286697

Cross-sectional survey evaluating the psychological impact of the COVID-19 vaccination campaign in patients with cancer: The VACCINATE study.
Tregnago D, Avancini A, Belluomini L, Trestini I, Sposito M, Insolda J, Bianchi F, Sava T, Gaiani C, Del Piccolo L, Guarnieri V, Verlato G, Tfaily A, Vesentini R, Zuliani S, Pilotto S, Milella M. PLoS One. 2024 Jan 25;19(1):e0290792. doi: 10.1371/journal.pone.0290792. eCollection 2024. PMID: 38271378

Comparative Evaluation of Recombinant and Acellular Pertussis Vaccines in a Murine Model.
Kang KR, Kim JA, Cho GW, Kang HU, Kang HM, Kang JH, Seong BL, Lee SY. Vaccines (Basel). 2024 Jan 22;12(1):108. doi: 10.3390/vaccines12010108. PMID: 38276680

Bayesian safety surveillance with adaptive bias correction.
Bu F, Schuemie MJ, Nishimura A, Smith LH, Kostka K, Falconer T, McLeggon JA, Ryan PB, Hripcsak G, Suchard MA. Stat Med. 2024 Jan 30;43(2):395-418. doi: 10.1002/sim.9968. Epub 2023 Nov 27. PMID: 38010062

SNX32 is a host restriction factor that degrades African swine fever virus CP204L via the RAB1B-dependent autophagy pathway.
Yang W, Li L, Zhang J, Wu J, Kang W, Wang Y, Ding H, Li D, Zheng H. J Virol. 2024 Jan 23;98(1):e0159923. doi: 10.1128/jvi.01599-23. Epub 2024 Jan 3. PMID: 38169281

COVID-19 and outcomes in Chinese peritoneal dialysis patients.
Liao R, Zhou X, Ma D, Wang S, Fu P, Zhong H. Perit Dial Int. 2024 Jan 24:8968608231221952. doi: 10.1177/08968608231221952. Online ahead of print. PMID: 38265011

A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.
Haranaka M, Young Song J, Huang KC, de Solom R, Yamaji M, McElwee K, Kline M, Aizawa M, Peng Y, Scully I, Kogawara O, Gruber WC, Scott DA, Watson W. Vaccine. 2024 Jan 23:S0264-410X(24)00008-2. doi: 10.1016/j.vaccine.2024.01.004. Online ahead of print. PMID: 38267330

Comparative immunogenicity and safety of SpikoGen®, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: An immuno-bridging clinical trial.

Tabarsi P, Mamishi S, Anjidani N, Shahpari R, Kafi H, Fallah N, Yazdani B, Ebrahimi A, Roshanzamir K, Ebrahimi H, Oveisi S, Soltani A, Petrovsky N, Barati S. Int Immunopharmacol. 2024 Jan 25;127:111436. doi: 10.1016/j.intimp.2023.111436. Epub 2023 Dec 25. PMID: 38147778

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions.
Feldman RG, Antonelli-Incalzi R, Steenackers K, Lee DG, Papi A, Ison MG, Fissette L, David MP, Maréchal C, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Clin Infect Dis. 2024 Jan 25;78(1):202-209. doi: 10.1093/cid/ciad471. PMID: 37698366

Facebook Post Credibility as a Predictor of Vaccine Hesitancy in the US.
Aleksandric A, Dangal A, Nilizadeh S, Mustata Wilson G. Stud Health Technol Inform. 2024 Jan 25;310:981-985. doi: 10.3233/SHTI231111. PMID: 38269955

Disparities and effectiveness of COVID-19 vaccine policies in three representative European countries.
Xie W, Shi L, Liu M, Yang J, Ma M, Sun G. Int J Equity Health. 2024 Jan 30;23(1):16. doi: 10.1186/s12939-024-02110-w. PMID: 38287322

Antibody and transcription landscape in peripheral blood mononuclear cells of elderly adults over 70 years of age with third dose of COVID-19 BBIBP-CorV and ZF2001 booster vaccine.
Zhang Y, Zhao L, Zhang J, Zhang X, Han S, Sun Q, Yao M, Pang B, Duan Q, Jiang X. Immun Ageing. 2024 Jan 27;21(1):11. doi: 10.1186/s12979-023-00408-x. PMID: 38280989

Enhanced detection of antigen-specific T cells by a multiplexed AIM assay.
Lemieux A, Sannier G, Nicolas A, Nayrac M, Delgado GG, Cloutier R, Brassard N, Laporte M, Duchesne M, Sreng Flores AM, Finzi A, Tastet O, Dubé M, Kaufmann DE. Cell Rep Methods. 2024 Jan 22;4(1):100690. doi: 10.1016/j.crmeth.2023.100690. Epub 2024 Jan 15. PMID: 38228152

The attenuated African swine fever vaccine HLJ/18-7GD provides protection against emerging prevalent genotype II variants in China.
Wang Z, Zhang J, Li F, Zhang Z, Chen W, Zhang X, Sun E, Zhu Y, Liu R, He X, Bu Z, Zhao D. Emerg Microbes Infect. 2024 Dec;13(1):2300464. doi: 10.1080/22221751.2023.2300464. Epub 2024 Jan 22. PMID: 38164797

From defense to offense: Modulating toll-like receptors to combat arbovirus infections.
Lani R, Thariq IM, Suhaimi NS, Hassandarvish P, Abu Bakar S. Hum Vaccin Immunother. 2024 Dec 31;20(1):2306675. doi: 10.1080/21645515.2024.2306675. Epub 2024 Jan 23. PMID: 38263674

Systemic Immune Modulation by Gastrointestinal Nematodes.
Kasal DN, Warner L, Bryant A, Tait-Wojno E, von Moltke J. Annu Rev Immunol. 2024 Jan 26. doi: 10.1146/annurev-immunol-090222-101331. Online ahead of print. PMID: 38277692

Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study).
Molnár GA, Vokó Z, Sütő G, Rokszin G, Nagy D, Surján G, Surján O, Nagy P, Kenessey I, Wéber A, Pálosi M, Müller C, Kásler M, Wittmann I, Kiss Z. BMJ Open Diabetes Res Care. 2024 Jan 24;12(1):e003777. doi: 10.1136/bmjdrc-2023-003777. PMID: 38267204

Comparisons of Pediatric and Adult SARS-CoV-2-Specific Antibodies up to 6 Months after Infection, Vaccination, or Hybrid Immunity.
Kim M, Cheng WA, Congrave-Wilson Z, Marentes Ruiz CJ, Turner L, Mendieta S, Jumarang J, Del Valle J, Lee Y, Fabrizio T, Allen EK, Thomas PG, Webby R, Gordon A, Pannaraj PS. J Pediatric Infect Dis Soc. 2024 Jan 29;13(1):91-99. doi: 10.1093/jpids/piad107. PMID: 38016076

Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 - Veterans Health Administration, March-September 2022.
Monach PA, Anand ST, Fillmore NR, La J, Branch-Elliman W. MMWR Morb Mortal Wkly Rep. 2024 Jan 25;73(3):57-61. doi: 10.15585/mmwr.mm7303a2. PMID: 38271286

University-age vaccine mandates: reply to Lam and Nichols.
Høeg TB, Krug A, Baral S, Jamrozik E, Keshavjee S, Lemmens T, Prasad V, Makary MA, Bardosh K. J Med Ethics. 2024 Jan 23;50(2):143-145. doi: 10.1136/jme-2023-109163. PMID: 37225414

The association between influenza vaccination, cardiovascular mortality and hospitalization: A living systematic review and prospective meta-analysis.
Liu R, Fan Y, Patel A, Liu H, Du X, Liu B, Di Tanna GL. Vaccine. 2024 Jan 23:S0264-410X(24)00053-7. doi: 10.1016/j.vaccine.2024.01.040. Online ahead of print. PMID: 38267331

Immune responses to mRNA-based vaccines given as a third COVID-19 vaccine dose in people living with HIV-a literature review.
Knudsen ML, Nielsen SD, Heftdal LD. APMIS. 2024 Jan 26. doi: 10.1111/apm.13379. Online ahead of print. PMID: 38275143

Pragmatic Adaptive Trial for Respiratory Infection in Children (PATRIC) Clinical Registry protocol.
Pavlos R, Bhuiyan MU, Jones M, Oakes D, O'Brien S, Borland ML, Doyle S, Richmond P, Martin AC, Snelling TL, Blyth CC. BMJ Open. 2024 Jan 25;14(1):e074308. doi: 10.1136/bmjopen-2023-074308. PMID: 38272557

The impact of risk perception and institutional trust on COVID-19 vaccine hesitancy in China.
Chen G, Yao Y, Zhang Y, Zhao F. Hum Vaccin Immunother. 2024 Dec 31;20(1):2301793. doi: 10.1080/21645515.2024.2301793. Epub 2024 Jan 28. PMID: 38282324

Global landscape of COVID-19 research: a visualization analysis of randomized clinical trials.
Zyoud SH. Clin Exp Med. 2024 Jan 22;24(1):14. doi: 10.1007/s10238-023-01254-3. PMID: 38252392

Factors impacting sustained coverage in the context of donor transitions: experience from Sri Lanka.
Perera PN, Amarasinghe SN, Fonseka SH, Abeysinghe N, Rannan-Eliya RP. Health Policy Plan. 2024 Jan 23;39(Supplement_1):i33-i49. doi: 10.1093/heapol/czad099. PMID: 38258892

Immunogenicity of High-Dose Versus MF59-Adjuvanted Versus Standard Influenza Vaccine in Solid Organ Transplant Recipients: The Swiss/Spanish Trial in Solid Organ Transplantation on Prevention of Influenza (STOP-FLU Trial).
Mombelli M, Neofytos D, Huynh-Do U, Sánchez-Céspedes J, Stampf S, Golshayan D, Dahdal S, Stirnimann G, Schnyder A, Garzoni C, Venzin RM, Magenta L, Schönenberger M, Walti L, Hirzel C, Munting A, Dickenmann M, Koller M, Aubert JD, Steiger J, Pascual M, Mueller TF, Schuurmans M, Berger

C, Binet I, Villard J, Mueller NJ, Egli A, Cordero E, van Delden C, Manuel O. Clin Infect Dis. 2024 Jan 25;78(1):48-56. doi: 10.1093/cid/ciad477. PMID: 37584344

Complete biosynthesis of the potent vaccine adjuvant QS-21.
Martin LBB, Kikuchi S, Rejzek M, Owen C, Reed J, Orme A, Misra RC, El-Demerdash A, Hill L, Hodgson H, Liu Y, Keasling JD, Field RA, Truman AW, Osbourn A. Nat Chem Biol. 2024 Jan 26. doi: 10.1038/s41589-023-01538-5. Online ahead of print. PMID: 38278997

Long-term Cardiovascular, Cerebrovascular, and Other Thrombotic Complications in COVID-19 Survivors: A Retrospective Cohort Study.
Lim JT, Liang En W, Tay AT, Pang D, Chiew CJ, Ong B, Lye DCB, Tan KB. Clin Infect Dis. 2024 Jan 25;78(1):70-79. doi: 10.1093/cid/ciad469. PMID: 37746872

Nanoparticles for stimulation of neutrophil extracellular trap-mediated immunity.
Vaseruk A, Bila G, Bilyy R. Eur J Immunol. 2024 Jan 26:e2350582. doi: 10.1002/eji.202350582. Online ahead of print. PMID: 38279592

Role of biomarkers and molecular signaling pathways in acute lung injury.
Niri P, Saha A, Polopalli S, Kumar M, Das S, Chattopadhyay P. Fundam Clin Pharmacol. 2024 Jan 26. doi: 10.1111/fcp.12987. Online ahead of print. PMID: 38279523

Edible Vaccines: A Patent-Driven Exploration of Immunization Technologies.
Kashyap S, Kamboj S, Kamboj R, Guarve K, Kamboj S. Recent Pat Biotechnol. 2024 Jan 25. doi: 10.2174/0118722083275041231219060829. Online ahead of print. PMID: 38279742

Supporting National Immunization Technical Advisory Groups (NITAGs) in development of evidence-based vaccine recommendations and NITAG assessments - New tools and approaches.
Hadler SC, Shefer AM, Cavallaro KF, Ebama M, Tencza C, Kennedy ED, Ndiaye S, Shah A, Torre L, Bresee JS. Vaccine. 2024 Jan 23:S0264-410X(24)00035-5. doi: 10.1016/j.vaccine.2024.01.035. Online ahead of print. PMID: 38267328

Porcine endogenous retroviruses in xenotransplantation.
Denner J. Nephrol Dial Transplant. 2024 Jan 27:gfae023. doi: 10.1093/ndt/gfae023. Online ahead of print. PMID: 38281060

Pregnant women with acute respiratory distress syndrome triggered by COVID-19.
Aslam TN, Barratt-Due A, Fiane AE, Friis CM, Hofsø K, Kåsine T, Romundstad L, Laake JH. Tidsskr Nor Laegeforen. 2024 Jan 16;144(1). doi: 10.4045/tidsskr.23.0615. Print 2024 Jan 23. PMID: 38258709

The effects of Chinese proprietary medicine and vaccination on patients with COVID-19: a retrospective study in Macao.
Mo H, Zhou MF, Lao EPL, Chan KK, Lai ON, Ho MI, Wong KW, Ho KM, Sio KT, Fong KL, Zhao YH, Cheang SI, Lo IL. Chin Med. 2024 Jan 23;19(1):15. doi: 10.1186/s13020-023-00877-8. PMID: 38263035

Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2.

Bruch EM, Zhu S, Szymkowicz L, Blake T, Kiss T, James DA, Rak A, Narayan K, Balmer MT, Chicz RM. Sci Rep. 2024 Jan 23;14(1):2038. doi: 10.1038/s41598-024-52499-1. PMID: 38263191

A systemic approach to identify non-abundant immunogenic proteins in Lyme disease pathogens.
Yaş OB, Coleman AS, Lipman RM, Sharma K, Raghunandanan S, Alanazi F, Rana VS, Kitsou C, Yang X, Pal U. mSystems. 2024 Jan 23;9(1):e0108723. doi: 10.1128/msystems.01087-23. Epub 2023 Dec 11. PMID: 38078774

Comparison design and evaluation power in cohort and self-controlled case series designs for post-authorization vaccine safety studies.
Sato S, Kawazoe Y, Katsuta T, Fukuda H. PeerJ. 2024 Jan 23;12:e16780. doi: 10.7717/peerj.16780. eCollection 2024. PMID: 38282861

Implications of the 375W mutation for HIV-1 tropism and vaccine development.
Verdejo-Torres O, Vargas-Pavia T, Fatima S, Clapham PR, Duenas-Decamp MJ. J Virol. 2024 Jan 23;98(1):e0152223. doi: 10.1128/jvi.01522-23. Epub 2024 Jan 3. PMID: 38169306

Balancing functions of regulatory T cells in mosquito-borne viral infections.
Sann S, Kleinewietfeld M, Cantaert T. Emerg Microbes Infect. 2024 Dec;13(1):2304061. doi: 10.1080/22221751.2024.2304061. Epub 2024 Jan 25. PMID: 38192073

MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma.
Chen D, Zhang R, Huang X, Ji C, Xia W, Qi Y, Yang X, Lin L, Wang J, Cheng H, Tang W, Yu J, Hoon DSB, Zhang J, Gao X, Yao Y. Biomark Res. 2024 Jan 31;12(1):14. doi: 10.1186/s40364-024-00560-6. PMID: 38291499

Effects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profile.
New J, Cham J, Smith L, Puglisi L, Huynh T, Kurian S, Bagsic S, Fielding R, Hong L, Reddy P, Eum KS, Martin A, Barrick B, Marsh C, Quigley M, Nicholson LJ, Pandey AC. J Immunother Cancer. 2024 Jan 31;12(1):e008233. doi: 10.1136/jitc-2023-008233. PMID: 38296596

VP1 codon deoptimization and high-fidelity substitutions in 3D polymerase as potential vaccine strategies for eliciting immune responses against enterovirus A71.
Hsieh W-S, Chao C-H, Shen C-Y, Cheng D, Huang S-W, Wang Y-F, Chen C-C, Chen S-H, Hsu L-J, Wang J-R. J Virol. 2024 Jan 23;98(1):e0155823. doi: 10.1128/jvi.01558-23. Epub 2024 Jan 4. PMID: 38174926

Evaluation of Intussusception Following Pentavalent Rotavirus Vaccine (RotaTeq) Administration in 5 African Countries.
Tate JE, Mwenda JM, Keita AM, Tapsoba TW, Ngendahayo E, Kouamé BD, Samateh AL, Aliabadi N, Sissoko S, Traore Y, Bayisenga J, Sounkere-Soro M, Jagne S, Burke RM, Onwuchekwa U, Ouattara M, Bikoroti JB, N'Zue K, Leshem E, Coulibaly O, Ouedraogo I, Uwimana J, Sow S, Parashar UD; African Intussusception Surveillance Network. Clin Infect Dis. 2024 Jan 25;78(1):210-216. doi: 10.1093/cid/ciad492. PMID: 37596934

Flavonoids derived from medicinal plants as a COVID-19 treatment.
Sopjani M, Falco F, Impellitteri F, Guarrasi V, Nguyen Thi X, Dërmaku-Sopjani M, Faggio C. Phytother Res. 2024 Jan 29. doi: 10.1002/ptr.8123. Online ahead of print. PMID: 38284138

Progress in the treatment of anal cancer: an overview of the latest investigational drugs.
Yu J, Kim RD. Expert Opin Investig Drugs. 2024 Jan 26:1-13. doi: 10.1080/13543784.2024.2311191. Online ahead of print. PMID: 38275174

COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities.
Bardosh K, Krug A, Jamrozik E, Lemmens T, Keshavjee S, Prasad V, Makary MA, Baral S, Høeg TB. J Med Ethics. 2024 Jan 23;50(2):126-138. doi: 10.1136/jme-2022-108449. PMID: 36600579

Selection on synonymous sites: the unwanted transcript hypothesis.
Radrizzani S, Kudla G, Izsvák Z, Hurst LD. Nat Rev Genet. 2024 Jan 31. doi: 10.1038/s41576-023-00686-7. Online ahead of print. PMID: 38297070

Lessons learned: COVID-19 vaccinations and people with disabilities.
Rattay K, Thierry JM, Yeargin-Allsopp M, Griffin-Blake S, Rice CE, Chatham-Stephens K, Remley K. Vaccine. 2024 Jan 23:S0264-410X(24)00028-8. doi: 10.1016/j.vaccine.2024.01.027. Online ahead of print. PMID: 38267333

Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data.
Dreyfus J, Munnangi S, Bengtsson C, Correia B, Figueiredo R, Stark JH, Zawora M, Riddle MS, Maguire JD, Jiang Q, Ianos C, Naredo Turrado J, Svanström H, Bailey S, DeKoven M. Vaccine. 2024 Jan 22:S0264-410X(24)00050-1. doi: 10.1016/j.vaccine.2024.01.037. Online ahead of print. PMID: 38262807

Evaluation of the serum levels of CCL2, CCL3, and IL-29 after first and second administrations of the COVID-19 vaccine (Oxford-AstraZeneca).
Bagheri-Hosseinabadi Z, Kaeidi A, Rezvani M, Taghipour Khaje Sharifi G, Abbasifard M. Immunobiology. 2024 Jan 28;229(2):152789. doi: 10.1016/j.imbio.2024.152789. Online ahead of print. PMID: 38290406

Serotype-Dependent Inhibition of *Streptococcus pneumoniae* Growth by Short-Chain Fatty Acids.
Lim S, Lee D, Jeong S, Park JW, Im J, Choi B, Gwak D, Yun CH, Seo HS, Han SH. J Microbiol Biotechnol. 2024 Jan 28;34(1):47-55. doi: 10.4014/jmb.2309.09003. Epub 2023 Nov 20. PMID: 38044707

A description of a pre-emptive typhoid Vi capsular polysaccharide vaccination campaign after the 2015 earthquake in Nepal and vaccine effectiveness evaluation.
Dhoubhadel BG, Sawada I, Shrestha D, Fukuya Y, Raya GB, Nébié EI, Hayashi Y, Pasakhala R, Suzuki M, Morimoto K, Parry CM, Ariyoshi K. Trop Med Health. 2024 Jan 29;52(1):14. doi: 10.1186/s41182-024-00580-w. PMID: 38281965

Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice.
Cervantes-Torres J, Cabello-Gutiérrez C, Ayón-Núñez DA, Soldevila G, Olguin-Alor R, Diaz G, Acero G, Segura-Velázquez R, Huerta L, Gracia-Mora I, Cobos L, Pérez-Tapia M, Almagro JC, Suárez-Güemes F,

Bobes RJ, Fragoso G, Sciutto E, Laclette JP. Appl Microbiol Biotechnol. 2024 Jan 27;108(1):179. doi: 10.1007/s00253-023-12927-0. PMID: 38280035

Cryptic vaccine-associated adverse events: The critical need for a new vaccine safety surveillance paradigm to improve public trust in vaccines.
Poland GA, Black S. Vaccine. 2024 Jan 30:S0264-410X(24)00070-7. doi: 10.1016/j.vaccine.2024.01.058. Online ahead of print. PMID: 38296703

A multi-epitope subunit vaccine based on CU/ZN-SOD, OMP31 and BP26 against Brucella melitensis infection in BALB/C mice.
Wang Y, Wu A, Xu Z, Zhang H, Li H, Fu S, Liu Y, Cui L, Miao Y, Wang Y, Zhumanov K, Xu Y, Sheng J, Yi J, Chen C. Int Immunopharmacol. 2024 Jan 25;127:111351. doi: 10.1016/j.intimp.2023.111351. Epub 2023 Dec 19. PMID: 38113688

Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
Ji Y, Sui X, Miao W, Wang C, Wang Q, Duan Z, Wei B, Wu D, Wei M, Shao J, Zheng X, Zhu T. Vaccine. 2024 Jan 30:S0264-410X(24)00097-5. doi: 10.1016/j.vaccine.2024.01.073. Online ahead of print. PMID: 38296705

Measles, mumps, rubella and varicella antibodies among international and domestic university students.
Dyda A, Broome A, Rawlinson W, Mahimbo A, Saha A, Kefalas B, Seale H, Macintyre CR, Zwar N, Gidding HF, Heywood AE. J Travel Med. 2024 Jan 28;31(1):taae004. doi: 10.1093/jtm/taae004. PMID: 38195239

Invasive Pneumococcal Disease and Potential Impact of Pneumococcal Conjugate Vaccines Among Adults, Including Persons Experiencing Homelessness-Alaska, 2011-2020.
Steinberg J, Bressler SS, Orell L, Thompson GC, Kretz A, Reasonover AL, Bruden D, Bruce MG, Fischer M. Clin Infect Dis. 2024 Jan 25;78(1):172-178. doi: 10.1093/cid/ciad597. PMID: 37787072

General Vaccination Readiness in Japan: Results from the JASTIS 2023 Study.
Machida M, Inoue S, Tabuchi T. Jpn J Infect Dis. 2024 Jan 24;77(1):34-39. doi: 10.7883/yoken.JJID.2023.261. Epub 2023 Oct 31. PMID: 37914292

Attitudes towards COVID-19 vaccination in adults with haematological malignancies.
Blennerhassett R, Hamad N, Grech L, Kwok A, Choi T, Forsyth C, Jagger J, Opat S, Harris S, Chan BA, Nguyen M, Bain N, Day D, Segelov E; CANVACCS investigators. Acta Haematol. 2024 Jan 30. doi: 10.1159/000536548. Online ahead of print. PMID: 38290477

Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
Pal R, Ferrari MG, Honda-Okubo Y, Wattay L, Caple J, Navarrete J, Andersen H, Petrovsky N. Vaccine. 2024 Jan 22:S0264-410X(24)00034-3. doi: 10.1016/j.vaccine.2024.01.034. Online ahead of print. PMID: 38262808

Impact of social distancing from the COVID-19 pandemic on the immuno-inflammatory response of older adults.

Nery GB, de Araujo CAR, da Silva GB, Bittar H, Bordallo VP, Amaral JB, Hardt M, Marti L, Birbrair A, Jimenez M, Bastos MF, Nali LHS, Longo PL, Laurentino GC, Bachi ALL, Heller D. BMC Geriatr. 2024 Jan 26;24(1):99. doi: 10.1186/s12877-024-04699-7. PMID: 38273281

Influence of Community Determinants on Barriers and Facilitators to COVID-19 Vaccine Uptake: Regional Stakeholders' Perspectives.
Russ S, Bennett N, van Wijngaarden E, Hill E, Liu Y. Vaccine. 2024 Jan 24:S0264-410X(24)00051-3. doi: 10.1016/j.vaccine.2024.01.039. Online ahead of print. PMID: 38272763

Immunoinformatics approaches in developing a novel multi-epitope chimeric vaccine protective against Saprolegnia parasitica.
Choudhury A, Kumar P, Nafidi HA, Almaary KS, Wondmie GF, Kumar A, Bourhia M. Sci Rep. 2024 Jan 27;14(1):2260. doi: 10.1038/s41598-024-52223-z. PMID: 38278861

The Cost of Seasonal Influenza: A Systematic Literature Review on the Humanistic and Economic Burden of Influenza in Older (≥ 65 Years Old) Adults.
Langer J, Welch VL, Moran MM, Cane A, Lopez SMC, Srivastava A, Enstone A, Sears A, Markus K, Heuser M, Kewley R, Whittle I. Adv Ther. 2024 Jan 23. doi: 10.1007/s12325-023-02770-0. Online ahead of print. PMID: 38261171

Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data.
Schelling J, Einmahl S, Torgler R, Schade Larsen C. Expert Rev Vaccines. 2024 Jan 30. doi: 10.1080/14760584.2024.2311359. Online ahead of print. PMID: 38288983

The current state of pertussis vaccination in pregnancy around the world, with recommendations for improved care: Consensus statements from the Global Pertussis Initiative.
Olson-Chen C, Swamy GK, Gonik B, Forsyth K, Heininger U, Hozbor D, von König CHW, Chitkara AJ, Top KA, Muloiwa R, van der Schyff M, Tan TQ. Int J Gynaecol Obstet. 2024 Jan 22. doi: 10.1002/ijgo.15311. Online ahead of print. PMID: 38251722

Multi-epitopes vaccine design for surface glycoprotein against SARS-CoV-2 using immunoinformatic approach.
Arshad SF, Rehana R, Saleem MA, Usman M, Arshad HJ, Rizwana R, Shakeela S, Rukh AS, Khan IA, Hayssam MA, Anwar M. Heliyon. 2024 Jan 10;10(2):e24186. doi: 10.1016/j.heliyon.2024.e24186. eCollection 2024 Jan 30. PMID: 38298616

Recombinant BCG vaccine expressing multistage antigens of *Mycobacterium tuberculosis* provides long-term immunity against tuberculosis in BALB/c mice.
Fang D, Wang R, Fan X, Li M, Qian C, Cao B, Yu J, Liu H, Lou Y, Wan K. Hum Vaccin Immunother. 2024 Dec 31;20(1):2299607. doi: 10.1080/21645515.2023.2299607. Epub 2024 Jan 23. PMID: 38258510

Pertussis seasonal variation in Northern Vietnam: the evidence from a tertiary hospital.
Pham NT, Bui QT, Tran DM, Larsson M, Pham MP, Olson L. BMC Public Health. 2024 Jan 24;24(1):286. doi: 10.1186/s12889-024-17705-9. PMID: 38267959

mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review.

Boretti A. Clin Exp Med. 2024 Jan 27;24(1):23. doi: 10.1007/s10238-023-01264-1. PMID: 38280109

World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update.
Laranjo L, Lanas F, Sun MC, Chen DA, Hynes L, Imran TF, Kazi DS, Kengne AP, Komiyama M, Kuwabara M, Lim J, Perel P, Piñeiro DJ, Ponte-Negretti CI, Séverin T, Thompson DR, Tokgözoğlu L, Yan LL, Chow CK. Glob Heart. 2024 Jan 22;19(1):8. doi: 10.5334/gh.1278. eCollection 2024. PMID: 38273995

Combined biolistic and cell penetrating peptide delivery for the development of scalable intradermal DNA vaccines.
So RB, Li G, Brentville V, Daly JM, Dixon JE. J Control Release. 2024 Jan 25;367:209-222. doi: 10.1016/j.jconrel.2024.01.031. Online ahead of print. PMID: 38244841

Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
Hamad Saied M, van Straalen JW, de Roock S, Verduyn Lunel FM, de Wit J, de Rond LGH, Van Nieuwenhove E, Vastert BJ, van Montfrans JM, van Royen-Kerkhof A, de Joode-Smink GCJ, Swart JF, Wulffraat NM, Jansen MHA. Vaccine. 2024 Jan 22:S0264-410X(24)00059-8. doi: 10.1016/j.vaccine.2024.01.047. Online ahead of print. PMID: 38262809

Pandemic lessons for the 2024 US presidential election.
Yamey G, Diez Roux AV, Clark J, Abbasi K. BMJ. 2024 Jan 29;384:q150. doi: 10.1136/bmj.q150. PMID: 38286471

mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.
Trivedi V, Yang C, Klippel K, Yegorov O, von Roemeling C, Hoang-Minh L, Fenton G, Ogando-Rivas E, Castillo P, Moore G, Long-James K, Dyson K, Doonan B, Flores C, Mitchell DA. Genome Med. 2024 Jan 25;16(1):17. doi: 10.1186/s13073-024-01281-z. PMID: 38268001

A universal design of restructured dimer antigens: Development of a superior vaccine against the paramyxovirus in transgenic rice.
Ma F, Xu Q, Wang A, Yang D, Li Q, Guo J, Zhang L, Ou J, Li R, Yin H, Li K, Wang L, Wang Y, Zhao X, Niu X, Zhang S, Li X, Chai S, Zhang E, Rao Z, Zhang G. Proc Natl Acad Sci U S A. 2024 Jan 23;121(4):e2305745121. doi: 10.1073/pnas.2305745121. Epub 2024 Jan 18. PMID: 38236731

A novel strategy for an anti-idiotype vaccine: nanobody mimicking neutralization epitope of porcine circovirus type 2.
Deng Y, Sheng Y, Zhang G, Sun Y, Wang L, Ji P, Zhu J, Wang G, Liu B, Zhou E-M, Cai X, Tu Y, Hiscox JA, Stewart JP, Mu Y, Zhao Q. J Virol. 2024 Jan 25:e0165023. doi: 10.1128/jvi.01650-23. Online ahead of print. PMID: 38271227

Within-host evolutionary dynamics and tissue compartmentalization during acute SARS-CoV-2 infection.
Farjo M, Koelle K, Martin MA, Gibson LL, Walden KKO, Rendon G, Fields CJ, Alnaji FG, Gallagher N, Luo CH, Mostafa HH, Manabe YC, Pekosz A, Smith RL, McManus DD, Brooke CB. J Virol. 2024 Jan 23;98(1):e0161823. doi: 10.1128/jvi.01618-23. Epub 2024 Jan 4. PMID: 38174928

Erratum to "Examining vaccine hesitancy among a diverse sample of Canadian adults" [Vaccine 42(2) (2024) 129-135].

Burns KE, Dubé È, Nascimento HG, Meyer SB. Vaccine. 2024 Jan 30:S0264-410X(24)00061-6. doi: 10.1016/j.vaccine.2024.01.049. Online ahead of print. PMID: 38296702

Fitness models provide accurate short-term forecasts of SARS-CoV-2 variant frequency.
Abousamra E, Figgins M, Bedford T. medRxiv. 2024 Jan 22:2023.11.30.23299240. doi: 10.1101/2023.11.30.23299240. Preprint. PMID: 38076866

Potentially inappropriate prescriptions and potential prescription omissions in older people living with HIV.
Fernández-Fradejas J, Delgado-Silveira E, González-Burgos E, Álvarez-Díaz AM, Vélez-Díaz-Pallarés M. HIV Med. 2024 Jan 23. doi: 10.1111/hiv.13616. Online ahead of print. PMID: 38258538

Chemically Modified Platforms for Better RNA Therapeutics.
Shi Y, Zhen X, Zhang Y, Li Y, Koo S, Saiding Q, Kong N, Liu G, Chen W, Tao W. Chem Rev. 2024 Jan 29. doi: 10.1021/acs.chemrev.3c00611. Online ahead of print. PMID: 38284616

An Oral Nanomedicine Elicits *In Situ* Vaccination Effect against Colorectal Cancer.
Zu M, Ma Y, Zhang J, Sun J, Shahbazi MA, Pan G, Reis RL, Kundu SC, Liu J, Xiao B. ACS Nano. 2024 Jan 30;18(4):3651-3668. doi: 10.1021/acsnano.3c11436. Epub 2024 Jan 19. PMID: 38241481

Development of novel HPV therapeutic vaccine constructs based on engineered exosomes and tumor cell lysates.
Rezaei F, Bolhassani A, Sadat SM, Arashkia A, Fotouhi F, Milani A, Pordanjani PM. Life Sci. 2024 Jan 23;340:122456. doi: 10.1016/j.lfs.2024.122456. Online ahead of print. PMID: 38266814

The regulations of telomerase reverse transcriptase (TERT) in cancer.
Liu M, Zhang Y, Jian Y, Gu L, Zhang D, Zhou H, Wang Y, Xu ZX. Cell Death Dis. 2024 Jan 26;15(1):90. doi: 10.1038/s41419-024-06454-7. PMID: 38278800

Individual predictors of vaccine hesitancy in the Italian post COVID-19 pandemic era.
Vicario CM, Mucciardi M, Faraone G, Lucifora C, Schade HM, Falzone A, Salehinejad MA, Craparo G, Nitsche MA. Hum Vaccin Immunother. 2024 Dec 31;20(1):2306677. doi: 10.1080/21645515.2024.2306677. Epub 2024 Jan 30. PMID: 38289323

Synthetic Cell Lines for Inducible Packaging of Influenza A Virus.
Phan T, Ye Q, Stach C, Lin YC, Cao H, Bowen A, Langlois RA, Hu WS. ACS Synth Biol. 2024 Jan 23. doi: 10.1021/acssynbio.3c00526. Online ahead of print. PMID: 38259154

The spike protein of the apathogenic Beaudette strain of avian coronavirus can elicit a protective immune response against a virulent M41 challenge.
Keep S, Stevenson-Leggett P, Webb I, Fones A, Kirk J, Britton P, Bickerton E. PLoS One. 2024 Jan 24;19(1):e0297516. doi: 10.1371/journal.pone.0297516. eCollection 2024. PMID: 38265985

In vivo assembly of epitope-coated biopolymer particles that induce anti-tumor responses.
Jenika D, Pounraj S, Wibowo D, Flaxl LM, Rehm BHA, Mintern JD. NPJ Vaccines. 2024 Jan 23;9(1):18. doi: 10.1038/s41541-023-00787-8. PMID: 38263169

Recent advances in chemometric modelling of inhibitors against SARS-CoV-2.
Wang Q, Lu X, Jia R, Yan X, Wang J, Zhao L, Zhong R, Sun G. Heliyon. 2024 Jan 9;10(2):e24209. doi: 10.1016/j.heliyon.2024.e24209. eCollection 2024 Jan 30. PMID: 38293468

The intersection of virus infection and liver disease: A comprehensive review of pathogenesis, diagnosis, and treatment.
Ren M, Lu C, Zhou M, Jiang X, Li X, Liu N. WIREs Mech Dis. 2024 Jan 22:e1640. doi: 10.1002/wsbm.1640. Online ahead of print. PMID: 38253964

A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity.
Cao H, Li H, Luan N, Zhang H, Lin K, Hu J, Song J, Liu C. Vaccine. 2024 Jan 22:S0264-410X(24)00069-0. doi: 10.1016/j.vaccine.2024.01.057. Online ahead of print. PMID: 38262810

Targeted Nanoparticles: the Smart Way for the Treatment of Colorectal Cancer.
Abdellatif AAH, Alshubrumi AS, Younis MA. AAPS PharmSciTech. 2024 Jan 24;25(1):23. doi: 10.1208/s12249-024-02734-9. PMID: 38267656

Clinical Characteristics of Children Infected with SARS-CoV-2 Omicron (B.1.1.529) in China's Shanghai.
Shu J, Jia L, Zhang P, Wang R, Wang M, Sun X, Peng Y, Wang P, Li X, Tang Z, Han T, Ju T, Wei Y, Pang W, Gao C, Xia Z. Int J Gen Med. 2024 Jan 23;17:245-251. doi: 10.2147/IJGM.S429870. eCollection 2024. PMID: 38283077

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans.
Mayer L, Weskamm LM, Fathi A, Kono M, Heidepriem J, Krähling V, Mellinghoff SC, Ly ML, Friedrich M, Hardtke S, Borregaard S, Hesterkamp T, Loeffler FF, Volz A, Sutter G, Becker S, Dahlke C, Addo MM. NPJ Vaccines. 2024 Jan 26;9(1):20. doi: 10.1038/s41541-023-00801-z. PMID: 38278816

Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.
Abela IA, Schwarzmüller M, Ulyte A, Radtke T, Haile SR, Ammann P, Raineri A, Rueegg S, Epp S, Berger C, Böni J, Manrique A, Audigé A, Huber M, Schreiber PW, Scheier T, Fehr J, Weber J, Rusert P, Günthard HF, Kouyos RD, Puhan MA, Kriemler S, Trkola A, Pasin C. mBio. 2024 Jan 25:e0272223. doi: 10.1128/mbio.02722-23. Online ahead of print. PMID: 38270455

Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects.
Hodel K, Fonseca A, Barbosa I, Medina C, Alves B, Maciel C, Nascimento D, Oliveira-Junior G, Pedreira L, de Souza M, Godoy AL. Curr Pharm Biotechnol. 2024 Jan 22. doi: 10.2174/0113892010264503231108070917. Online ahead of print. PMID: 38258769

Working under short timescales to deliver a national trial: a case study of the ComFluCOV trial from a statistician's perspective.
Harris R, Thirard R, Baos S, Lazarus R, Todd R, Kirwan J, Joyce K, Hutton D, Clout M, Cappel-Porter H, Culliford L, Rogers CA. Trials. 2024 Jan 23;25(1):79. doi: 10.1186/s13063-023-07879-9. PMID: 38263245

A Predictive Model of Vaccine Reactogenicity Using Data from an In Vitro Human Innate Immunity Assay System.

Pullen RH 3rd, Sassano E, Agrawal P, Escobar J, Chehtane M, Schanen B, Drake DR 3rd, Luna E, Brennan RJ. J Immunol. 2024 Jan 26:ji2300185. doi: 10.4049/jimmunol.2300185. Online ahead of print. PMID: 38276072

The effect of COVID-19 infection on patients with rheumatic diseases in China.
Lai P, Chen H, Yan Y, Du M, Zhao Z, Wang D, Liang J, Geng L, Xu X, Sun L. Clin Rheumatol. 2024 Jan 29. doi: 10.1007/s10067-023-06825-z. Online ahead of print. PMID: 38285376

Antimicrobial resistance and the great divide: inequity in priorities and agendas between the Global North and the Global South threatens global mitigation of antimicrobial resistance.
Mendelson M, Laxminarayan R, Limmathurotsakul D, Kariuki S, Gyansa-Lutterodt M, Charani E, Singh S, Walia K, Gales AC, Mpundu M. Lancet Glob Health. 2024 Jan 23:S2214-109X(23)00554-5. doi: 10.1016/S2214-109X(23)00554-5. Online ahead of print. PMID: 38278160

Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation.
Palmer TJ, Kavanagh K, Cuschieri K, Cameron R, Graham C, Wilson A, Roy K. J Natl Cancer Inst. 2024 Jan 22:djad263. doi: 10.1093/jnci/djad263. Online ahead of print. PMID: 38247547

Toward the Scalable, Rapid, Reproducible, and Cost-Effective Synthesis of Personalized Nanomedicines at the Point of Care.
Young H, He Y, Joo B, Ferguson S, Demko A, Butterfield SK, Lowe J, Mjema NF, Sheth V, Whitehead L, Ruiz-Echevarria MJ, Wilhelm S. Nano Lett. 2024 Jan 24;24(3):920-928. doi: 10.1021/acs.nanolett.3c04171. Epub 2024 Jan 11. PMID: 38207109

Should vaccination status be a consideration during secondary triage?
Jarratt Barnham I. J Med Ethics. 2024 Jan 22:jme-2023-109386. doi: 10.1136/jme-2023-109386. Online ahead of print. PMID: 38050108

Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination.
Nziza N, Deng Y, Wood L, Dhanoa N, Dulit-Greenberg N, Chen T, Kane AS, Swank Z, Davis JP, Demokritou M, Chitnis AP, Fasano A, Edlow AG, Jain N, Horwitz BH, McNamara RP, Walt DR, Lauffenburger DA, Julg B, Shreffler WG, Alter G, Yonker LM. Nat Commun. 2024 Jan 30;15(1):905. doi: 10.1038/s41467-024-45181-7. PMID: 38291080

A modified recombinant adenovirus vector containing dual rabies virus G expression cassettes confers robust and long-lasting humoral immunity in mice, cats, and dogs.
Zhang Y, Fang L, Wang Z, Zhang C, Zhao J, Daemi HB, Zhang M, Yuan L, Han X, Li L, Fu ZF, Zhou M, Zhao L. Emerg Microbes Infect. 2024 Dec;13(1):2300461. doi: 10.1080/22221751.2023.2300461. Epub 2024 Jan 22. PMID: 38164714

The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial.
Schuster JE, Hamdan L, Dulek DE, Kitko CL, Batarseh E, Haddadin Z, Stewart LS, Stahl A, Potter M, Rahman H, Kalams SA, Bocchini CE, Moulton EA, Coffin SE, Ardura MI, Wattier RL, Maron G, Grimley M, Paulsen G, Harrison CJ, Freedman JL, Carpenter PA, Englund JA, Munoz FM, Danziger-Isakov L, Spieker

AJ, Halasa NB; Pediatric HCT Flu Study. Clin Infect Dis. 2024 Jan 25;78(1):217-226. doi: 10.1093/cid/ciad534. PMID: 37800415

Ex vivo photothermal treatment-induced immunogenic cell death for anticancer vaccine development.
Yu SH, Yoon I, Kim YJ. Int Immunopharmacol. 2024 Jan 25;127:111450. doi: 10.1016/j.intimp.2023.111450. Epub 2023 Dec 28. PMID: 38157695

Revamping the BCG revaccination strategy: Records to recall, or just call it phoenix?
Antas PRZ, Flores-Valdez MA, Locht C. Hum Vaccin Immunother. 2024 Dec 31;20(1):2300158. doi: 10.1080/21645515.2023.2300158. Epub 2024 Jan 29. PMID: 38287731

SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency.
Li Y, Choudhary MC, Regan J, Boucau J, Nathan A, Speidel T, Liew MY, Edelstein GE, Kawano Y, Uddin R, Deo R, Marino C, Getz MA, Reynolds Z, Barry M, Gilbert RF, Tien D, Sagar S, Vyas TD, Flynn JP, Hammond SP, Novack LA, Choi B, Cernadas M, Wallace ZS, Sparks JA, Vyas JM, Seaman MS, Gaiha GD, Siedner MJ, Barczak AK, Lemieux JE, Li JZ. Sci Transl Med. 2024 Jan 24;16(731):eadk1599. doi: 10.1126/scitranslmed.adk1599. Epub 2024 Jan 24. PMID: 38266109

Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study.
Cherry N, Adisesh A, Burstyn I, Charlton C, Chen Y, Durand-Moreau Q, Labrèche F, Ruzycki S, Turnbull L, Zadunayski T, Yasui Y. Vaccine. 2024 Jan 25:S0264-410X(24)00064-1. doi: 10.1016/j.vaccine.2024.01.052. Online ahead of print. PMID: 38278628

Current status and future of cancer vaccines: A bibliographic study.
Yu R, Zhao F, Xu Z, Zhang G, Du B, Shu Q. Heliyon. 2024 Jan 11;10(2):e24404. doi: 10.1016/j.heliyon.2024.e24404. eCollection 2024 Jan 30. PMID: 38293405

Covid-19 pandemic and equity of global human papillomavirus vaccination: descriptive study of World Health Organization-Unicef vaccination coverage estimates.
Casey RM, Akaba H, Hyde TB, Bloem P. BMJ Med. 2024 Jan 29;3(1):e000726. doi: 10.1136/bmjmed-2023-000726. eCollection 2024. PMID: 38293682

Predicting COVID-19 Outbreaks in Correctional Facilities Using Machine Learning.
Malloy GSP, Puglisi LB, Bucklen KB, Harvey TD, Wang EA, Brandeau ML. MDM Policy Pract. 2024 Jan 29;9(1):23814683231222469. doi: 10.1177/23814683231222469. eCollection 2024 Jan-Jun. PMID: 38293655

Surface Cross-Linking by Macromolecular Tethers Enhances Virus-like Particles' Resilience to Mucosal Stress Factors.
Ali A, Ganguillet S, Turgay Y, Keys TG, Causa E, Fradique R, Lutz-Bueno V, Chesnov S, Tan-Lin CW, Lentsch V, Kotar J, Cicuta P, Mezzenga R, Slack E, Radiom M. ACS Nano. 2024 Jan 30;18(4):3382-3396. doi: 10.1021/acsnano.3c10339. Epub 2024 Jan 18. PMID: 38237058

Vaccination coverage and adverse events following a reactive vaccination campaign against hepatitis E in Bentiu displaced persons camp, South Sudan.

Nesbitt RC, Asilaza VK, Gignoux E, Koyuncu A, Gitahi P, Nkemenang P, Duncker J, Antier Z, Haile M, Gakima P, Wamala JF, Loro FB, Biem D, Rull M, Azman AS, Rumunu J, Ciglenecki I. PLoS Negl Trop Dis. 2024 Jan 22;18(1):e0011661. doi: 10.1371/journal.pntd.0011661. Online ahead of print. PMID: 38252655

Policy makers believe money motivates more than it does.
Jilke S, Keppeler F, Ternovski J, Vogel D, Yoeli E. Sci Rep. 2024 Jan 22;14(1):1901. doi: 10.1038/s41598-024-51590-x. PMID: 38253624

Oral mucosal vaccination using integrated fiber microneedles.
Creighton RL, Faber KA, Tobos CI, Doan MA, Guo T, Woodrow KA. J Control Release. 2024 Jan 29:S0168-3659(24)00077-4. doi: 10.1016/j.jconrel.2024.01.062. Online ahead of print. PMID: 38295993

Modeling geographic vaccination strategies for COVID-19 in Norway.
Chan LYH, Rø G, Midtbø JE, Di Ruscio F, Watle SSV, Juvet LK, Littmann J, Aavitsland P, Nygård KM, Berg AS, Bukholm G, Kristoffersen AB, Engø-Monsen K, Engebretsen S, Swanson D, Palomares AD, Lindstrøm JC, Frigessi A, de Blasio BF. PLoS Comput Biol. 2024 Jan 31;20(1):e1011426. doi: 10.1371/journal.pcbi.1011426. Online ahead of print. PMID: 38295111

Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19.
Knox HB, Dykes LA, Scott LA, Presley BC, Lambert LC. Ann Pharmacother. 2024 Jan 30:10600280231222465. doi: 10.1177/10600280231222465. Online ahead of print. PMID: 38288555

Suboptimal MMR Vaccination Coverages-A Constant Challenge for Measles Elimination in Romania.
Stanescu A, Ruta SM, Cernescu C, Pistol A. Vaccines (Basel). 2024 Jan 22;12(1):107. doi: 10.3390/vaccines12010107. PMID: 38276679

Hepatitis C virus modified $sE2_{F442NYT}$ as an antigen in candidate vaccine facilitates human immune cell activation.
Haga Y, Meyer K, Sung MMH, Reagan EK, Weissman D, Ray R. J Virol. 2024 Jan 23;98(1):e0180923. doi: 10.1128/jvi.01809-23. Epub 2023 Dec 12. PMID: 38084956

Maternal pertussis immunization and the blunting of routine vaccine effectiveness: a meta-analysis and modeling study.
Briga M, Goult E, Brett TS, Rohani P, Domenech de Cellès M. Nat Commun. 2024 Jan 31;15(1):921. doi: 10.1038/s41467-024-44943-7. PMID: 38297003

Case Report: Fecal Microbiota Transplantation for the Treatment of Generalized Eczema Occurring After COVID-19 Vaccination.
Huang T, Lv Y, Wang W, Chen Y, Fan L, Teng Z, Zhou X, Shen H, Fu G. Clin Cosmet Investig Dermatol. 2024 Jan 26;17:229-235. doi: 10.2147/CCID.S443542. eCollection 2024. PMID: 38292322

Structure-Guided Approach for the Development of MUC1-Glycopeptide-Based Cancer Vaccines with Predictable Responses.
Bermejo IA, Guerreiro A, Eguskiza A, Martínez-Sáez N, Lazaris FS, Asín A, Somovilla VJ, Compañón I, Raju TK, Tadic S, Garrido P, García-Sanmartín J, Mangini V, Grosso AS, Marcelo F, Avenoza A, Busto JH, García-Martín F, Hurtado-Guerrero R, Peregrina JM, Bernardes GJL, Martínez A, Fiammengo R, Corzana F. JACS Au. 2023 Nov 21;4(1):150-163. doi: 10.1021/jacsau.3c00587. eCollection 2024 Jan 22. PMID: 38274250

Effect of Echinacea purpurea (L.) Moench and its extracts on the immunization outcome of avian influenza vaccine in broilers.
Wang X, Chen J, Chan Y, Li S, Li M, Lin F, Mehmood K, Idrees A, Lin R, Su Y, Wang C, Shi D. J Ethnopharmacol. 2024 Jan 30;319(Pt 3):117306. doi: 10.1016/j.jep.2023.117306. Epub 2023 Oct 13. PMID: 37839770

Prevalence and characteristics of long COVID-19 in Jordan: A cross sectional survey.
Obeidat M, Abu Zahra A, Alsattari F. PLoS One. 2024 Jan 26;19(1):e0295969. doi: 10.1371/journal.pone.0295969. eCollection 2024. PMID: 38277361

Impact of the 'Health on Wheels' (HoW) strategy on COVID-19 vaccination coverage in hard-to-reach communities in Alta Verapaz, Guatemala, 2022.
Balsells E, Vicente M, Reyes S, Figueroa M, Sum K, López Lacán MA, Escalante A, Campos D, Montenegro M, Alvarado G, Quezada LF, Jarquin C, Montufar E, Rondy M. Vaccine. 2024 Jan 27:S0264-410X(24)00033-1. doi: 10.1016/j.vaccine.2024.01.033. Online ahead of print. PMID: 38281901

RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T, Qi X, Yan H, Chang Y. ACS Nano. 2024 Jan 25. doi: 10.1021/acsnano.3c07284. Online ahead of print. PMID: 38270089

rWTC-MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells.
Wang H, Medina R, Ye J, Zhang Y, Chakraborty S, Valenzuela A, Uher O, Hadrava Vanova K, Sun M, Sang X, Park DM, Zenka J, Gilbert MR, Pacak K, Zhuang Z. Adv Sci (Weinh). 2024 Jan 31:e2308280. doi: 10.1002/advs.202308280. Online ahead of print. PMID: 38298111

Are COVID-19 vaccination mandates for healthcare workers effective? A systematic review of the impact of mandates on increasing vaccination, alleviating staff shortages and decreasing staff illness.
Okpani AI, Adu P, Paetkau T, Lockhart K, Yassi A. Vaccine. 2024 Jan 27:S0264-410X(24)00052-5. doi: 10.1016/j.vaccine.2024.01.041. Online ahead of print. PMID: 38281897

Myeloid Cell-Triggered in Situ Cell Engineering for Robust Vaccine-Based Cancer Treatment.
Li WH, Su JY, Zhang BD, Zhao L, Zhuo SH, Wang TY, Hu HG, Li YM. Adv Mater. 2024 Jan 31:e2308155. doi: 10.1002/adma.202308155. Online ahead of print. PMID: 38295870

A review on medical waste treatment in COVID-19 pandemics: Technologies, managements and future strategies.
Sanito RC, Mujiyanti DR, You SJ, Wang YF. J Air Waste Manag Assoc. 2024 Feb;74(2):72-99. doi: 10.1080/10962247.2023.2282011. Epub 2024 Jan 30. PMID: 37955449

One HA stalk topping multiple heads as a novel influenza vaccine.
Zhou P, Qiu T, Wang X, Yang X, Shi H, Zhu C, Dai W, Xing M, Zhang X, Xu J, Zhou D. Emerg Microbes Infect. 2024 Dec;13(1):2290838. doi: 10.1080/22221751.2023.2290838. Epub 2024 Jan 22. PMID: 38044872

Capsular gene distribution and RAPD typing of Streptococcus agalactiae isolated from pregnant women.
Zakerifar M, Goli HR, Kaboosi H, Rahmani Z, Peyravii Ghadikolaii F. AMB Express. 2024 Jan 28;14(1):13. doi: 10.1186/s13568-024-01671-x. PMID: 38282173

Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer.
Lin X, Tang S, Guo Y, Tang R, Li Z, Pan X, Chen G, Qiu L, Dong X, Zhang L, Liu X, Cai Z, Xie B. Cancer Immunol Immunother. 2024 Jan 27;73(2):26. doi: 10.1007/s00262-023-03598-x. PMID: 38280084

Safety signal detection with control of latent factors.
Tan X, Wang W, Zeng D, Liu GF, Diao G, Jafari N, Alt EM, Ibrahim JG. Stat Med. 2024 Jan 31. doi: 10.1002/sim.10015. Online ahead of print. PMID: 38297431

Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.
Soni M, Tulsian K, Barot P, K Vyas V. Recent Adv Antiinfect Drug Discov. 2024 Jan 25. doi: 10.2174/0127724344267452231206061944. Online ahead of print. PMID: 38279760

An electronic health record alert for inpatient COVID-19 vaccinations increases vaccination ordering and uncovers workflow inefficiencies.
Black KC, Snyder NA, Zhou M, Zhu Z, Uptegraft C, Chintalapani A, Orwoll B. Appl Clin Inform. 2024 Jan 22. doi: 10.1055/a-2250-6305. Online ahead of print. PMID: 38253337

Are COVID-19 vaccination mandates for healthcare workers effective? A systematic review of the impact of mandates on increasing vaccination, alleviating staff shortages and decreasing staff illness.
Okpani AI, Adu P, Paetkau T, Lockhart K, Yassi A. Vaccine. 2024 Jan 27:S0264-410X(24)00052-5. doi: 10.1016/j.vaccine.2024.01.041. Online ahead of print. PMID: 38281897

Travel and tourism to the Kingdom of Saudi Arabia: what are the health risks?
Memish ZA, Memish TZ, Kattan RF. J Travel Med. 2024 Jan 28;31(1):taad145. doi: 10.1093/jtm/taad145. PMID: 37975906

The Underlying Structure of Preventive Behaviors and Related Factors During the COVID-19 Pandemic: A Comprehensive Network Analysis.
Liang Y, Zhu Q, Yang Y, Gu X, Yan Y, Gu J, Huang J. Ann Behav Med. 2024 Jan 29:kaad073. doi: 10.1093/abm/kaad073. Online ahead of print. PMID: 38284623

Non-invasive transdermal delivery of biomacromolecules with fluorocarbon-modified chitosan for melanoma immunotherapy and viral vaccines.
Zhu W, Wei T, Xu Y, Jin Q, Chao Y, Lu J, Xu J, Zhu J, Yan X, Chen M, Chen Q, Liu Z. Nat Commun. 2024 Jan 27;15(1):820. doi: 10.1038/s41467-024-45158-6. PMID: 38280876

Descriptive analysis to assess seasonal patterns of COVID-19 and influenza in low-income and middle-income countries in Asia, the Middle East and Latin America.
Kyaw MH, Spinardi JR, Jagun O, Franco Villalobos C, Kapetanakis V, Sharf-Williams R, Yarnoff B. BMJ Open. 2024 Jan 31;14(1):e081019. doi: 10.1136/bmjopen-2023-081019. PMID: 38296298

Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan.
Lee CY, Kuo HW, Liu YL, Chuang JH, Chou JH. Emerg Infect Dis. 2024 Jan 31;30(3). doi: 10.3201/eid3003.230893. Online ahead of print. PMID: 38295401

Risedronate-functionalized manganese-hydroxyapatite amorphous particles: A potent adjuvant for subunit vaccines and cancer immunotherapy.
Zhang X, Wei M, Zhang Z, Zeng Y, Zou F, Zhang S, Wang Z, Chen F, Xiong H, Li Y, Zhou L, Li T, Zheng Q, Yu H, Zhang J, Gu Y, Zhao Q, Li S, Xia N. J Control Release. 2024 Jan 23;367:13-26. doi: 10.1016/j.jconrel.2024.01.033. Online ahead of print. PMID: 38244843

CIC2022: An Informatics-Driven Strategy for Improving Immunization Healthcare Data Quality using 2D Barcoding and Barcode Scanning Practices.
Reza F, Jones C, Reed JH. Appl Clin Inform. 2024 Jan 29. doi: 10.1055/a-2255-9749. Online ahead of print. PMID: 38286429

An In silico Study on B-cell Epitope Mapping of Acinetobacter baumannii Outer Membrane Protein K.
Heidarinia H, Ghadiri K, Zargaran FN, Lorestani RC, Rostamian M. Curr Comput Aided Drug Des. 2024 Jan 29. doi: 10.2174/0115734099281401240118054834. Online ahead of print. PMID: 38288827

Strengthening the WHO Regional Office for Africa (WHO AFRO) COVID-19 vaccination information system.
Shragai T, Bukhari A, Atagbaza AO, Oyaole DR, Shah R, Volkmann K, Kamau L, Sheillah N, Farham B, Wong MK, Lam E, Mboussou F, Impouma B. BMJ Glob Health. 2024 Jan 30;9(1):e014097. doi: 10.1136/bmjgh-2023-014097. PMID: 38290787

Multi-epitopes vaccine design for surface glycoprotein against SARS-CoV-2 using immunoinformatic approach.
Arshad SF, Rehana R, Saleem MA, Usman M, Arshad HJ, Rizwana R, Shakeela S, Rukh AS, Khan IA, Hayssam MA, Anwar M. Heliyon. 2024 Jan 10;10(2):e24186. doi: 10.1016/j.heliyon.2024.e24186. eCollection 2024 Jan 30. PMID: 38298616

Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
Niu L, Miao Y, Cao Z, Wei T, Zhu J, Li M, Bai B, Chen L, Liu N, Pan F, Zhu J, Wang C, Yang Y, Chen Q. ACS Nano. 2024 Jan 30;18(4):3349-3361. doi: 10.1021/acsnano.3c10174. Epub 2024 Jan 17. PMID: 38230639

Detection and complete genome sequence analysis of human adenovirus in children with acute diarrhea in Yunnan, China, 2015-2021.
Cao Y, Yang J, Li N, Zhang R, Jiang L, Zhou X, Xiang Y, Cun J, Qiao E. Arch Virol. 2024 Jan 23;169(2):34. doi: 10.1007/s00705-023-05950-z. PMID: 38263334

Identification of specific neutralizing antibodies for highly pathogenic avian influenza H5 2.3.4.4b clades to facilitate vaccine design and therapeutics.
Tuan Duong B, Ju Yeo S, Park H. Emerg Microbes Infect. 2024 Dec;13(1):2302106. doi: 10.1080/22221751.2024.2302106. Epub 2024 Jan 22. PMID: 38170506

The Impact of Social and Broadcast Media on Public Health Initiatives: Study of the COVID-19 Infodemics.
Upadhyay U, Dhar E, Bomrah S, Huang Y, Uddin M, Kabir MA, Syed-Abdul S. Stud Health Technol Inform. 2024 Jan 25;310:469-473. doi: 10.3233/SHTI231009. PMID: 38269847

Associations of five blood heavy metals with hepatitis B virus infection and immunity in adults: a cross-sectional study.
Li X, Bi L, Han L. BMC Public Health. 2024 Jan 23;24(1):266. doi: 10.1186/s12889-024-17799-1. PMID: 38262984

In Utero Exposure to Maternal COVID-19 Vaccination and Offspring Neurodevelopment at 12 and 18 Months.
Jaswa EG, Cedars MI, Lindquist KJ, Bishop SL, Kim YS, Kaing A, Prahl M, Gaw SL, Corley J, Hoskin E, Cho YJ, Rogers E, Huddleston HG. JAMA Pediatr. 2024 Jan 22:e235743. doi: 10.1001/jamapediatrics.2023.5743. Online ahead of print. PMID: 38252445

Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection.
Huang Y, Shi H, Forgacs D, Ross TM. Vaccine. 2024 Jan 30:S0264-410X(23)01543-8. doi: 10.1016/j.vaccine.2023.12.084. Online ahead of print. PMID: 38296701

Molecular characteristics and antimicrobial resistance of invasive pneumococcal isolates from children in the post-13-valent pneumococcal conjugate vaccine era in Shenzhen, China.
Huang L, Bao Y, Yi Q, Yu D, Wang H, Wang H, Liu Z, Zhu C, Meng Q, Chen Y, Wang W, Deng J, Liu G, Zheng Y, Yang Y. J Glob Antimicrob Resist. 2024 Jan 22:S2213-7165(24)00016-X. doi: 10.1016/j.jgar.2024.01.013. Online ahead of print. PMID: 38266961

Understanding the factors affecting global political priority for controlling sexually transmitted infections: a qualitative policy analysis.
Wu D, Low N, Hawkes SJ. BMJ Glob Health. 2024 Jan 23;9(1):e014237. doi: 10.1136/bmjgh-2023-014237. PMID: 38262682

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future.
Parums DV. Med Sci Monit. 2024 Jan 28;30:e943912. doi: 10.12659/MSM.943912. PMID: 38281080

Differential interferon responses to influenza A and B viruses in primary ferret respiratory epithelial cells.
Rowe T, Davis W, Wentworth DE, Ross T. J Virol. 2024 Jan 31:e0149423. doi: 10.1128/jvi.01494-23. Online ahead of print. PMID: 38294251

Trends of risk factors associated with childhood stunting and anaemia in Ghana: evidence from the Demographic Health Survey and Multiple Indicator Cluster Survey (2003-2017).
Sewor C, Jayalakshmi R. Public Health Nutr. 2024 Jan 23;27(1):e29. doi: 10.1017/S1368980023002951. PMID: 38253537

Hydrophobization of Ribonucleic Acids for Facile Systemic Delivery and Multifaceted Cancer Immunotherapy.
Zhang Y, Chen C, Su M, Wang J, Li C, Yang X. Nano Lett. 2024 Jan 31;24(4):1376-1384. doi: 10.1021/acs.nanolett.3c04507. Epub 2024 Jan 17. PMID: 38232332

The Astonishing Accomplishment of Biological Drug Delivery using Lipid Nanoparticles: An Ubiquitous Review.
Kapoor D, Chilkapalli SC, Prajapati BG, Rodriques P, Patel R, Singh S, Bhattacharya S. Curr Pharm Biotechnol. 2024 Jan 23. doi: 10.2174/0113892010268824231122041237. Online ahead of print. PMID: 38265380

Interplay between vaccines and treatment for dengue control: An epidemic model.
Sow A, Diallo C, Cherifi H. PLoS One. 2024 Jan 25;19(1):e0295025. doi: 10.1371/journal.pone.0295025. eCollection 2024. PMID: 38271384

A universal design of restructured dimer antigens: Development of a superior vaccine against the paramyxovirus in transgenic rice.
Ma F, Xu Q, Wang A, Yang D, Li Q, Guo J, Zhang L, Ou J, Li R, Yin H, Li K, Wang L, Wang Y, Zhao X, Niu X, Zhang S, Li X, Chai S, Zhang E, Rao Z, Zhang G. Proc Natl Acad Sci U S A. 2024 Jan 23;121(4):e2305745121. doi: 10.1073/pnas.2305745121. Epub 2024 Jan 18. PMID: 38236731

Comparison of geological clusters between influenza and COVID-19 in Thailand with unsupervised clustering analysis.
Methiyothin T, Ahn I. PLoS One. 2024 Jan 22;19(1):e0296888. doi: 10.1371/journal.pone.0296888. eCollection 2024. PMID: 38252644

Impact of innovative immunization strategy on PCV13 vaccination coverage among children under 5 years in Weifang city, China: A retrospective study.
Wang CP, Lin YT, Du YZ, Zhang T, Wang YY, Wang YJ, Wang JC, Xu RY, Wang ZS, Wang Y, Feng LZ. Vaccine. 2024 Jan 23:S0264-410X(24)00030-6. doi: 10.1016/j.vaccine.2024.01.030. Online ahead of print. PMID: 38267332

Canadians' knowledge of cancer risk factors and belief in cancer myths.
E R, J T, Ek Q, Ss F, E H, G P, Ce P. BMC Public Health. 2024 Jan 30;24(1):329. doi: 10.1186/s12889-024-17832-3. PMID: 38291409

Clinical Characteristics of Children Infected with SARS-CoV-2 Omicron (B.1.1.529) in China's Shanghai.
Shu J, Jia L, Zhang P, Wang R, Wang M, Sun X, Peng Y, Wang P, Li X, Tang Z, Han T, Ju T, Wei Y, Pang W, Gao C, Xia Z. Int J Gen Med. 2024 Jan 23;17:245-251. doi: 10.2147/IJGM.S429870. eCollection 2024. PMID: 38283077

Comparative genomics of Leishmania donovani progeny from genetic crosses in two sand fly species and impact on the diversity of diagnostic and vaccine candidates.
Sádlová J, Yeo M, Mateus DS, Phelan J, Hai LA, Bhattacharyya T, Kurtev S, Sebesta O, Myskova J, Seblova V, Andersson B, Florez de Sessions P, Volf P, Miles MA. PLoS Negl Trop Dis. 2024 Jan 31;18(1):e0011920. doi: 10.1371/journal.pntd.0011920. eCollection 2024 Jan. PMID: 38295092

Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma.
Zhang J, Joshua AM, Yue L, O'Meara CH, Morris MJ, Khachigian LM. Cancer Lett. 2024 Jan 26:216633. doi: 10.1016/j.canlet.2024.216633. Online ahead of print. PMID: 38281663

Correction to: Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?
Surma S, Sahebkar A, Banach M. Curr Atheroscler Rep. 2024 Jan 22. doi: 10.1007/s11883-024-01189-4. Online ahead of print. PMID: 38252373

Bladder sparing by short-course radiotherapy combined with toripalimab in high-risk/extremely high-risk non-muscle invasive bladder cancer (HOPE-04): study protocol for a single-arm, prospective, phase II trial.
Wen F, Lin T, Zhang P, Zeng H, Wei Q, Shen Y. BMJ Open. 2024 Jan 22;14(1):e076663. doi: 10.1136/bmjopen-2023-076663. PMID: 38262639

Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India.
Selvavinayagam TS, Somasundaram A, Selvam JM, Sampath P, Vijayalakshmi V, Kumar CAB, Subramaniam S, Kumarasamy P, Raju S, Avudaiselvi R, Prakash V, Yogananth N, Subramanian G, Roshini A, Dhiliban DN, Imad S, Tandel V, Parasa R, Sachdeva S, Ramachandran S, Malani A. Sci Rep. 2024 Jan 24;14(1):2091. doi: 10.1038/s41598-023-50338-3. PMID: 38267448

Spatial epidemiology of human anthrax in Son La province, Vietnam, 2003-2022.
Luong T, Nguyen TD, Lu VT, Metrailer MC, Pham VK, Hoang TTH, Hung Tran TM, Pham TH, Pham TL, Pham QT, Blackburn JK. Zoonoses Public Health. 2024 Jan 28. doi: 10.1111/zph.13112. Online ahead of print. PMID: 38282103

Severe symptomatic late onset dermographism after mRNA COVID-19 vaccine.
Patruno C, Fabbrocini G, Napolitano M. Ital J Dermatol Venerol. 2024 Jan 23. doi: 10.23736/S2784-8671.23.07454-6. Online ahead of print. PMID: 38261308

HCMV IE1/IE1mut Therapeutic Vaccine Induces Tumor Regression via Intratumoral Tertiary Lymphoid Structure Formation and Peripheral Immunity Activation in Glioblastoma Multiforme.
Yang X, Jiang S, Liu F, Li Z, Liu W, Zhang X, Nan F, Li J, Yu M, Wang Y, Wang B. Mol Neurobiol. 2024 Jan 23. doi: 10.1007/s12035-024-03937-8. Online ahead of print. PMID: 38261253

Nanoparticle-Conjugated Toll-Like Receptor 9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines.
Ou BS, Baillet J, Picece VCTM, Gale EC, Powell AE, Saouaf OM, Yan J, Nejatfard A, Lopez Hernandez H, Appel EA. ACS Nano. 2024 Jan 30;18(4):3214-3233. doi: 10.1021/acsnano.3c09700. Epub 2024 Jan 12. PMID: 38215338

Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
Campanella A, Capasso A, Heltai S, Taccetti C, Albi E, Herishanu Y, Haggenburg S, Chatzikonstantinou T, Doubek M, Kättström M, Giannopoulos K, Simkovic M, Moreno C, Massaia M, Bumbea H, Alshemmari S, Ranghetti P, Perotta E, Martini F, Sant'Antonio E, Colia M, Combi C, Levi S, Kater AP, Hazenberg M, Nijhof IS, Hofsink Q, Demosthenous C, Kotaskova J, Zaleska J, Vrbacky F, Raya AM, Bisogno D, Tripoli IE, Popov VM, Roman V, Stavroyianni N, Karypidou M, Scarano E, Locatelli M, Frenquelli M, Scarfò L, Stamatopoulos K, Ghia P. Am J Hematol. 2024 Jan 24. doi: 10.1002/ajh.27218. Online ahead of print. PMID: 38264829

Insights for enhancing resilience in prolonged crises: impact of COVID-19 pandemic on nurses' quality of life.
Salimi S, Özel S. BMJ Lead. 2024 Jan 22:leader-2023-000886. doi: 10.1136/leader-2023-000886. Online ahead of print. PMID: 38071578

Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Masuda S, Osawa R, Hosokawa N, Nakashima K, Kamura H, Imura H, Inoue H, Matsuzaka S, Sugimoto Y, Kuwamitsu O, Motohashi I, Morikawa T, Oda R, Hoshina Y, Matono T, Teshigahara O, Sando E, Asami S, Kudo S, Akizuki N, Muto Y, Hayakawa T, Kishaba T, Ohara Y, Kubo Y, Suzuki M, Morimoto K. Expert Rev Vaccines. 2024 Jan 30. doi: 10.1080/14760584.2024.2310807. Online ahead of print. PMID: 38288980

Long-Term Hepatitis B Vaccine Immunity in Ethiopian Children That Received a Pentavalent Vaccine Series: A Retrospective Cohort Study.
Alemayehu T, Daba MD, Buonsenso D. Children (Basel). 2024 Jan 22;11(1):136. doi: 10.3390/children11010136. PMID: 38275446

Rhipicephalus microplus thyropin-like protein: Structural and immunologic analyzes.
Dedavid E Silva LA, Parizi LF, Molossi FA, Driemeier D, da Silva Vaz Junior I. Vet Parasitol. 2024 Jan 26;327:110136. doi: 10.1016/j.vetpar.2024.110136. Online ahead of print. PMID: 38290194

Political polarization may affect attitudes towards vaccination. An analysis based on the European Social Survey data from 23 countries.
Wróblewski M, Meler A. Eur J Public Health. 2024 Jan 26:ckae002. doi: 10.1093/eurpub/ckae002. Online ahead of print. PMID: 38276887

Patterns of Animal Rabies Prevalence in Northern South Africa between 1998 and 2022.
Mogano K, Sabeta CT, Suzuki T, Makita K, Chirima GJ. Trop Med Infect Dis. 2024 Jan 22;9(1):27. doi: 10.3390/tropicalmed9010027. PMID: 38276638

Longitudinal analysis of antibody responses to Plasmodium vivax sporozoite antigens following natural infection.
Thawornpan P, Nicholas J, Malee C, Kochayoo P, Wangriatisak K, Tianpothong P, Ntumngia FB, J Barnes S, H Adams J, Chootong P. PLoS Negl Trop Dis. 2024 Jan 26;18(1):e0011907. doi: 10.1371/journal.pntd.0011907. eCollection 2024 Jan. PMID: 38277340

Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
Patel PD, Liang Y, Meiring JE, Chasweka N, Patel P, Misiri T, Mwakiseghile F, Wachepa R, Banda HC, Shumba F, Kawalazira G, Dube Q, Nampota-Nkomba N, Nyirenda OM, Girmay T, Datta S, Jamka LP, Tracy JK, Laurens MB, Heyderman RS, Neuzil KM, Gordon MA; TyVAC team. Lancet. 2024 Jan 25:S0140-6736(23)02031-7. doi: 10.1016/S0140-6736(23)02031-7. Online ahead of print. PMID: 38281499

INTRANASAL DELIVERY OF LaAg VACCINE IMPROVES IMMUNITY OF AGED MICE AGAINST VISCERAL LEISHMANIASIS.
Salgado CL, Corea AFM, Covre LP, Fonseca-Martins AM, Falqueto A, Guedes HLM, Rossi-Bergmann B, Gomes DCO. Acta Trop. 2024 Jan 25:107125. doi: 10.1016/j.actatropica.2024.107125. Online ahead of print. PMID: 38280636

The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
El-Ashwah S, Salmanton-García J, Bilgin YM, Itri F, Žák P, Weinbergerová B, Verga L, Omrani AS, Silva MGD, Szotkowski T, Marchetti M, Buquicchio C, Nucci M, Schönlein M, Farina F, Besson C, Prezioso L, Nizamuddin S, Dávila-Valls J, Martín-Pérez S, Bonuomo V, Van Doesum J, Tisi MC, Passamonti F, Méndez GA, Meers S, Maertens J, López-García A, Glenthøj A, Bonnani M, Rinaldi I, Ormazabal-Vélez I, Labrador J, Kulasekararaj A, Espigado I, Demirkan F, De Jonge N, Collins GP, Calbacho M, Blennow O, Al-Khabori M, Adžić-Vukičević T, Arellano E, Mišković B, Mladenović M, Nordlander A, Ráčil Z, Ammatuna E, Cordoba R, Hersby DS, Gräfe S, Emarah Z, Hanakova M, Sacchi MV, Ijaz M, Rahimli L, Nunes Rodrigues R, Zambrotta GPM, Marchesi F, Cornely OA, Pagano L. Leuk Lymphoma. 2024 Feb;65(2):199-208. doi: 10.1080/10428194.2023.2280886. Epub 2024 Jan 24. PMID: 37966980

Genomic and phenotypic analysis of invasive Streptococcus suis isolated in Spain reveals genetic diversification and associated virulence traits.
Uruén C, Fernandez A, Arnal JL, Del Pozo M, Amoribieta MC, de Blas I, Jurado P, Calvo JH, Gottschalk M, González-Vázquez LD, Arenas M, Marín CM, Arenas J. Vet Res. 2024 Jan 24;55(1):11. doi: 10.1186/s13567-024-01267-0. PMID: 38268053

Aminopyrimidine Derivatives as Multiflavivirus Antiviral Compounds Identified from a Consensus Virtual Screening Approach.
Serafim MSM, Kronenberger T, Rocha REO, Rosa ADRA, Mello TLG, Poso A, Ferreira RS, Abrahão JS, Kroon EG, Mota BEF, Maltarollo VG. J Chem Inf Model. 2024 Jan 22;64(2):393-411. doi: 10.1021/acs.jcim.3c01505. Epub 2024 Jan 9. PMID: 38194508

Erratum to "Examining vaccine hesitancy among a diverse sample of Canadian adults" [Vaccine 42(2) (2024) 129-135].
Burns KE, Dubé È, Nascimento HG, Meyer SB. Vaccine. 2024 Jan 30:S0264-410X(24)00061-6. doi: 10.1016/j.vaccine.2024.01.049. Online ahead of print. PMID: 38296702

A New-fangled COVID-19 Variant, Eris, Might be the One to Lookout in 2023 or far from Over.
Ray SK, Mukherjee S. Infect Disord Drug Targets. 2024 Jan 22. doi: 10.2174/0118715265276833240105110046. Online ahead of print. PMID: 38258765

Contact tracing in Austria, Georgia, Kyrgyzstan, Ukraine, and Kosovo† during the COVID-19 pandemic: response review and good practices.
Aboushady AT, Blackmore C, Nagel A, Janashvili L, Gexha D, Otorbaeva D, Bugaienko N, Pebody R, Hegermann-Lindencrone M. Eur J Public Health. 2024 Jan 22:ckad217. doi: 10.1093/eurpub/ckad217. Online ahead of print. PMID: 38261364

A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants.
Johnson M, Chelysheva I, Öner D, McGinley J, Lin GL, O'Connor D, Robinson H, Drysdale SB, Gammin E, Vernon S, Muller J, Wolfenden H, Westcar S, Anguvaa L, Thwaites RS, Bont L, Wildenbeest J, Martinón-

Torres F, Aerssens J, Openshaw PJM, Pollard AJ. J Infect Dis. 2024 Jan 25:jiae029. doi: 10.1093/infdis/jiae029. Online ahead of print. PMID: 38271230

Impact of the COVID-19 Pandemic on Health Care Utilization in the Vaccine Safety Datalink: Retrospective Cohort Study.
Qian L, Sy LS, Hong V, Glenn SC, Ryan DS, Nelson JC, Hambidge SJ, Crane B, Zerbo O, DeSilva MB, Glanz JM, Donahue JG, Liles E, Duffy J, Xu S. JMIR Public Health Surveill. 2024 Jan 23;10:e48159. doi: 10.2196/48159. PMID: 38091476

An engineered Accum-E7 protein-based vaccine with dual anti-cervical cancer activity.
Bikorimana JP, Abusarah J, Gonçalves M, Farah R, Saad W, Talbot S, Stanga D, Beaudoin S, Plouffe S, Rafei M. Cancer Sci. 2024 Jan 29. doi: 10.1111/cas.16096. Online ahead of print. PMID: 38287511

Recombinant BCG vaccine expressing multistage antigens of *Mycobacterium tuberculosis* provides long-term immunity against tuberculosis in BALB/c mice.
Fang D, Wang R, Fan X, Li M, Qian C, Cao B, Yu J, Liu H, Lou Y, Wan K. Hum Vaccin Immunother. 2024 Dec 31;20(1):2299607. doi: 10.1080/21645515.2023.2299607. Epub 2024 Jan 23. PMID: 38258510

Women Health Literacy and Associated Factors on Women and Child Health Care in Ilu Ababor Public Health Facilities, Ethiopia.
Jiregna B, Amare M, Dinku M, Nigatu D, Desalegn D. Int J Womens Health. 2024 Jan 26;16:143-152. doi: 10.2147/IJWH.S443198. eCollection 2024. PMID: 38292301

In Situ Stability Test for mRNA Vaccines Based on Deep-UV Resonance Raman Spectroscopy.
Almehmadi LM, Reverdatto SV, Ermolenkov VV, Shekhtman A, Lednev IK. Anal Chem. 2024 Jan 23;96(3):1003-1008. doi: 10.1021/acs.analchem.3c01761. Epub 2023 Dec 5. PMID: 38052070

Comparison design and evaluation power in cohort and self-controlled case series designs for post-authorization vaccine safety studies.
Sato S, Kawazoe Y, Katsuta T, Fukuda H. PeerJ. 2024 Jan 23;12:e16780. doi: 10.7717/peerj.16780. eCollection 2024. PMID: 38282861

Artificial intelligence models for pre-travel consultation and advice: yea or nay?
Ngiam JN, Koh MCY, Lye P, Liong TS, Salada BMA, Tambyah PA, Oon JEL. J Travel Med. 2024 Jan 28;31(1):taad124. doi: 10.1093/jtm/taad124. PMID: 37788080

Serological monitoring of Enterococcus cecorum specific antibodies in chickens.
Silberborth A, Schnug J, Rautenschlein S, Jung A. Vet Immunol Immunopathol. 2024 Jan 22;269:110714. doi: 10.1016/j.vetimm.2023.110714. Online ahead of print. PMID: 38280311

Respiratory distress in SARS-CoV-2 exposed uninfected neonates followed in the COVID Outcomes in Mother-Infant Pairs (COMP) Study.
Man OM, Azamor T, Cambou MC, Fuller TL, Kerin T, Paiola SG, Cranston JS, Mok T, Rao R, Chen W, Jung JU, Martinez VF, Foo SS, Nielsen-Saines K. Nat Commun. 2024 Jan 24;15(1):399. doi: 10.1038/s41467-023-44549-5. PMID: 38267411

Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 - Veterans Health Administration, March-September 2022.
Monach PA, Anand ST, Fillmore NR, La J, Branch-Elliman W. MMWR Morb Mortal Wkly Rep. 2024 Jan 25;73(3):57-61. doi: 10.15585/mmwr.mm7303a2. PMID: 38271286

Seasonal trends in lysogeny in an Appalachian oak-hickory forest soil.
Jacoby ML, Hogg GD, Assaad MR, Williamson KE. Appl Environ Microbiol. 2024 Jan 24;90(1):e0140823. doi: 10.1128/aem.01408-23. Epub 2023 Dec 12. PMID: 38084945

Prevalence and genetic evolution of porcine reproductive and respiratory syndrome virus in commercial fattening pig farms in China.
Li C, Zhao J, Li W, Xu H, Gong B, Sun Q, Guo Z, Li J, Xiang L, Tang YD, Leng C, Wang Q, Peng J, Zhou G, Liu H, An T, Cai X, Tian ZJ, Zhang H. Porcine Health Manag. 2024 Jan 22;10(1):5. doi: 10.1186/s40813-024-00356-y. PMID: 38254191

Is health literacy of adolescent athletes' parents whose children belonged to sports clubs related to their children's intention to receive medications, vaccines, supplements, and energy drinks? A cross-sectional study.
Nakajima R, Komoriya M, Watanabe F. BMC Public Health. 2024 Jan 22;24(1):257. doi: 10.1186/s12889-024-17746-0. PMID: 38254028

Burden of child mortality from malaria in high endemic areas: results from the CHAMPS Network using minimally invasive tissue sampling.
Ogbuanu IU, Otieno K, Varo R, Sow SO, Ojulong J, Duduyemi B, Kowuor D, Cain CJ, Rogena EA, Onyango D, Akelo V, Tippett Barr BA, terKuile F, Kotloff KL, Tapia MD, Keita AM, Juma J, Assefa N, Assegid N, Acham Y, Madrid L, Scott JAG, Arifeen SE, Gurley ES, Mahtab S, Dangor Z, Wadula J, Dutoit J, Madhi SA, Mandomando I, Torres-Fernandez D, Kincardett M, Mabunda R, Mutevedzi P, Madewell ZJ, Blau DM, Whitney CG, Samuels AM, Bassat Q; CHAMPS consortium. J Infect. 2024 Jan 28:S0163-4453(24)00025-2. doi: 10.1016/j.jinf.2024.01.006. Online ahead of print. PMID: 38290664

Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination.
Nziza N, Deng Y, Wood L, Dhanoa N, Dulit-Greenberg N, Chen T, Kane AS, Swank Z, Davis JP, Demokritou M, Chitnis AP, Fasano A, Edlow AG, Jain N, Horwitz BH, McNamara RP, Walt DR, Lauffenburger DA, Julg B, Shreffler WG, Alter G, Yonker LM. Nat Commun. 2024 Jan 30;15(1):905. doi: 10.1038/s41467-024-45181-7. PMID: 38291080

Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine: Comment.
Daungsupawong H, Wiwanitkit V. Hum Vaccin Immunother. 2024 Dec 31;20(1):2306032. doi: 10.1080/21645515.2024.2306032. Epub 2024 Jan 23. PMID: 38258525

Improving large language models for clinical named entity recognition via prompt engineering.
Hu Y, Chen Q, Du J, Peng X, Keloth VK, Zuo X, Zhou Y, Li Z, Jiang X, Lu Z, Roberts K, Xu H. J Am Med Inform Assoc. 2024 Jan 27:ocad259. doi: 10.1093/jamia/ocad259. Online ahead of print. PMID: 38281112

Capsular gene distribution and RAPD typing of Streptococcus agalactiae isolated from pregnant women.
Zakerifar M, Goli HR, Kaboosi H, Rahmani Z, Peyravii Ghadikolaii F. AMB Express. 2024 Jan 28;14(1):13. doi: 10.1186/s13568-024-01671-x. PMID: 38282173

Current status and future of cancer vaccines: A bibliographic study.
Yu R, Zhao F, Xu Z, Zhang G, Du B, Shu Q. Heliyon. 2024 Jan 11;10(2):e24404. doi: 10.1016/j.heliyon.2024.e24404. eCollection 2024 Jan 30. PMID: 38293405

Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study).
Molnár GA, Vokó Z, Sütő G, Rokszin G, Nagy D, Surján G, Surján O, Nagy P, Kenessey I, Wéber A, Pálosi M, Müller C, Kásler M, Wittmann I, Kiss Z. BMJ Open Diabetes Res Care. 2024 Jan 24;12(1):e003777. doi: 10.1136/bmjdrc-2023-003777. PMID: 38267204

Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States.
La EM, Bunniran S, Garbinsky D, Reynolds M, Schwab P, Poston S, Harrington L. Hum Vaccin Immunother. 2024 Dec 31;20(1):2303796. doi: 10.1080/21645515.2024.2303796. Epub 2024 Jan 31. PMID: 38297921

Attitudes Toward Routine Vaccines and COVID-19 Vaccines Among Parents of Infants and Toddlers in an Urban Safety-Net Setting.
Zimmerman M, Zapata LP, Bachiller K, Devera JL, Hall TA, Casey SM, Perkins RB, Pierre-Joseph N. Clin Pediatr (Phila). 2024 Jan 27:99228231224168. doi: 10.1177/00099228231224168. Online ahead of print. PMID: 38279858

Establishment of serological neutralizing tests using pseudotyped viruses for comprehensive detection of antibodies against all 18 lyssaviruses.
Inoue Y, Kaku Y, Harada M, Ishijima K, Kuroda Y, Tatemoto K, Virhuez-Mendoza M, Nishino A, Yamamoto T, Park ES, Inoue S, Matsuu A, Maeda K. J Vet Med Sci. 2024 Jan 26;86(1):128-134. doi: 10.1292/jvms.23-0463. Epub 2023 Dec 12. PMID: 38092389

Cathepsin B Responsive Peptide-Purpurin Conjugates Assembly-Initiated in Situ Self-Aggregation for Cancer Sonotheranostics.
Dai Q, Xie L, Ren E, Liu G. Nano Lett. 2024 Jan 24;24(3):950-957. doi: 10.1021/acs.nanolett.3c04371. Epub 2024 Jan 10. PMID: 38198622

In silico Identification of MHC Displayed Tumor Associated Peptides in Ovarian Cancer for Multi-Epitope Vaccine Construct.
Dobhal S, Chauhan K, Kumar S, Shikha S, Jogi M, Kumar D, Kumar A, Jaiswal V, Kumar P. Endocr Metab Immune Disord Drug Targets. 2024 Jan 24. doi: 10.2174/0118715303169428231205173914. Online ahead of print. PMID: 38275062

Difference in the Dynamics of Antibody Titers between COVID-19 Vaccination and SARS-CoV-2 Infection in Healthcare Workers - A Case Study Based on Long-Term and Densely Repeated Measurements of Antibody Titers.
Tanaka H, Sawatari H, Ando SI. Jpn J Infect Dis. 2024 Jan 24;77(1):51-54. doi: 10.7883/yoken.JJID.2023.175. Epub 2023 Sep 29. PMID: 37779029

Construction and expression of Mycobacterium tuberculosis fusion protein SHR3 and its immunogenicity analysis in combination with various adjuvants.

Zhang Z, Xu L, Wang X, Kong L, Shi Z, Zhong Q, Xu Y, Wang J. Tuberculosis (Edinb). 2024 Jan 23;145:102480. doi: 10.1016/j.tube.2024.102480. Online ahead of print. PMID: 38278100

Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines.
Vukovich MJ, Raju N, Kgagudi P, Manamela NP, Abu-Shmais AA, Gripenstraw KR, Wasdin PT, Shen X, Dwyer B, Akoad J, Lynch RM, Montefiori DC, Richardson SI, Moore PL, Georgiev IS. J Virol. 2024 Jan 23;98(1):e0147823. doi: 10.1128/jvi.01478-23. Epub 2023 Dec 12. PMID: 38085509

Neutralizing Immunity Against Antigenically Advanced Omicron BA.5 in Children After SARS-CoV-2 Infection.
Belongia EA, Petrie JG, Feldstein LR, Guan L, Halfmann PJ, King JP, Neumann G, Pattinson D, Rolfes MA, McLean HQ, Kawaoka Y. J Pediatric Infect Dis Soc. 2024 Jan 29;13(1):100-104. doi: 10.1093/jpids/piad109. PMID: 38142128

European priority review vouchers for neglected disease product development.
Ridley DB, Lasanta AM, Storer Jones F, Ridley SK. BMJ Glob Health. 2024 Jan 30;9(1):e013686. doi: 10.1136/bmjgh-2023-013686. PMID: 38290786

Maternal pertussis immunization and the blunting of routine vaccine effectiveness: a meta-analysis and modeling study.
Briga M, Goult E, Brett TS, Rohani P, Domenech de Cellès M. Nat Commun. 2024 Jan 31;15(1):921. doi: 10.1038/s41467-024-44943-7. PMID: 38297003

Individual predictors of vaccine hesitancy in the Italian post COVID-19 pandemic era.
Vicario CM, Mucciardi M, Faraone G, Lucifora C, Schade HM, Falzone A, Salehinejad MA, Craparo G, Nitsche MA. Hum Vaccin Immunother. 2024 Dec 31;20(1):2306677. doi: 10.1080/21645515.2024.2306677. Epub 2024 Jan 30. PMID: 38289323

Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.
Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 study group. Clin Infect Dis. 2024 Jan 22:ciae010. doi: 10.1093/cid/ciae010. Online ahead of print. PMID: 38253338

Vaccination protects against acute respiratory distress syndrome (ARDS) in hospitalized patients with COVID-19.
Madrid J, Agarwal P, Müller-Peltzer K, Askani M, Benning L, Selig M, Diehl P, Kalbhenn J, Trummer G, Utzolino S, Wengenmayer T, Busch HJ, Stolz D, Rieg S, Panning M, Schlett CL, Bamberg F, Askani E. Clin Exp Med. 2024 Jan 27;24(1):21. doi: 10.1007/s10238-023-01293-w. PMID: 38280024

The cholera outbreak during the Balkan Wars in Greece and the anticholeric vaccine as a force multiplier of the Greek army.
Diamantis A, Velisariou I, Magiorkinis E. BMJ Mil Health. 2024 Jan 25;170(1):85-86. doi: 10.1136/bmjmilitary-2022-002094. PMID: 35292505

Prevalence and factors associated with the death of older people hospitalized due to Covid-19 in the state of Paraná.
Inoue LH, Baccon WC, Pesce GB, Pereira ND, Silva IVTC, Salci MA, Vissoci JRN, Facchini LA, Carreira L. Rev Esc Enferm USP. 2024 Jan 22;57:e20230036. doi: 10.1590/1980-220X-REEUSP-2023-0036en. eCollection 2024. PMID: 38265117

A Versatile Nanovaccine Enhancement Strategy Based on Suction-Inspired Physical Therapy.
Wu J, Feng Y, Guo X, Meng M, Li H, Fang H, Li Z, Lin L, Guo Z, Chen J, Tian H, Chen X. ACS Nano. 2024 Jan 30. doi: 10.1021/acsnano.3c10623. Online ahead of print. PMID: 38288709

Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.
Shapiro Ben David S, Baruch Gez S, Adler L, Kovatch R, Rahamim-Cohen D, Shamir-Stein N, Shahar A, Mizrhi-Reuveni M. Vaccine. 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024.01.055. Online ahead of print. PMID: 38281902

AI-driven covalent drug design strategies targeting main protease (m^{pro}) against SARS-CoV-2: structural insights and molecular mechanisms.
Haghir Ebrahim Abadi MH, Ghasemlou A, Bayani F, Sefidbakht Y, Vosough M, Mozaffari-Jovin S, Uversky VN. J Biomol Struct Dyn. 2024 Jan 29:1-29. doi: 10.1080/07391102.2024.2308769. Online ahead of print. PMID: 38287509

Tpgen: a language model for stable protein design with a specific topology structure.
Min X, Yang C, Xie J, Huang Y, Liu N, Jin X, Wang T, Kong Z, Lu X, Ge S, Zhang J, Xia N. BMC Bioinformatics. 2024 Jan 23;25(1):35. doi: 10.1186/s12859-024-05637-5. PMID: 38254030

The Long-Term Serological Profile of CoronaVac Vaccine Based on Comorbidities and History of SARS-CoV-2 Infection in Indonesia.
Chilmi S, Kesuma TA, Wibawa PA, Susianti H, Iskandar A, Wulanda IA, Wahono CS, Handono K. Jpn J Infect Dis. 2024 Jan 24;77(1):40-46. doi: 10.7883/yoken.JJID.2023.061. Epub 2023 Oct 31. PMID: 37914294

High vaccination coverage and infection rate result in a robust SARS-CoV-2-specific immunity in the majority of liver cirrhosis and transplant patients: A single-center cross-sectional study.
von der Schulenburg P, Herting A, Harberts A, Lütgehetmann M, Jahnke-Triankowski J, Pischke S, Piecha F, Drolz A, Jörg V, Hübener P, Wehmeyer M, Addo MM, Fischer L, Lohse AW, Schulze Zur Wiesch J, Sterneck M. United European Gastroenterol J. 2024 Jan 27. doi: 10.1002/ueg2.12528. Online ahead of print. PMID: 38279837

Initial Health Outcomes of a Community-Based Collaboration for Children in Foster Care.
Espeleta HC, Schelbe L, Ruggiero KJ, Klika JB. Health Soc Work. 2024 Jan 30;49(1):25-33. doi: 10.1093/hsw/hlad038. PMID: 38148103

Rapid and high throughput assessment of cellular immunity against SARS-CoV-2 based on the ex vivo activation of genes in leukocyte assay with whole blood.

Saito T, Couzinet A, Murakami T, Shimomura M, Suzuki T, Katayama Y, Nakatsura T. Biochem Biophys Res Commun. 2024 Jan 29;694:149398. doi: 10.1016/j.bbrc.2023.149398. Epub 2023 Dec 16. PMID: 38134475

Maternal singing reduced pain indexes in 2-month-old infants and increased proximity during vaccinations.
Monaci MG, Caruzzo CM, Raso R, Spagnuolo C, Benedetti MC, Grandjean D, Filippa M. Acta Paediatr. 2024 Jan 24. doi: 10.1111/apa.17121. Online ahead of print. PMID: 38264948

MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma.
Chen D, Zhang R, Huang X, Ji C, Xia W, Qi Y, Yang X, Lin L, Wang J, Cheng H, Tang W, Yu J, Hoon DSB, Zhang J, Gao X, Yao Y. Biomark Res. 2024 Jan 31;12(1):14. doi: 10.1186/s40364-024-00560-6. PMID: 38291499

Efficacy of novel staphylococcal surface associated protein vaccines against Staphylococcus aureus and non-aureus staphylococcal mastitis in dairy cows.
Vidlund J, Gelalcha BD, Gillespie BE, Agga GE, Schneider L, Swanson SM, Frady KD, Kerro Dego O. Vaccine. 2024 Jan 27:S0264-410X(24)00079-3. doi: 10.1016/j.vaccine.2024.01.067. Online ahead of print. PMID: 38281900

Type 2 diabetes and its genetic susceptibility are associated with increased severity and mortality of COVID-19 in UK Biobank.
Lee A, Seo J, Park S, Cho Y, Kim G, Li J, Liang L, Park T, Chung W. Commun Biol. 2024 Jan 24;7(1):122. doi: 10.1038/s42003-024-05799-1. PMID: 38267566

Enhancing cell-scale performance *via* sustained release of the varicella-zoster virus antigen from a microneedle patch under simulated microgravity.
Yin Y, Yang J, Gao G, Zhou H, Chi B, Yang HY, Li J, Wang Y. Biomater Sci. 2024 Jan 30;12(3):763-775. doi: 10.1039/d3bm01440a. PMID: 38164004

Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis.
Manak M, Gagnon L, Phay-Tran S, Levesque-Damphousse P, Fabie A, Daugan M, Khan ST, Proud P, Hussey B, Knott D, Charlton S, Hallis B, Medigeshi GK, Garg N, Anantharaj A, Raqib R, Sarker P, Alam MM, Rahman M, Murreddu M, Balgobind A, Hofman R, Grappi S, Coluccio R, Calandro P, Montomoli E, Mattiuzzo G, Prior S, Le Duff Y, Page M, Mitchell J, Schwartz LM, Bartsch YC, Azizi A, Bernasconi V; CEPI CLN Study Group. Lancet Microbe. 2024 Jan 23:S2666-5247(23)00324-5. doi: 10.1016/S2666-5247(23)00324-5. Online ahead of print. PMID: 38278167

Comparison of Omicron Breakthrough Infection Versus Monovalent SARS-CoV-2 Intramuscular Booster Reveals Differences in Mucosal and Systemic Humoral Immunity.
Nantel S, Sheikh-Mohamed S, Y C Chao G, Kurtesi A, Hu Q, Wood H, Colwill K, Li Z, Liu Y, Seifried L, Bourdin B, McGeer A, Hardy WR, Rojas OL, Al-Aubodah TA, Liu Z, Ostrowski MA, Brockman MA, Piccirillo CA, Quach C, Rini JM, Gingras AC, Decaluwe H, Gommerman JL. Mucosal Immunol. 2024 Jan 24:S1933-0219(24)00004-7. doi: 10.1016/j.mucimm.2024.01.004. Online ahead of print. PMID: 38278415

Availability of antimalarial medicines and inventory management at the community level: a case study of Bugesera district in Rwanda.
Gakinahe GU, Rutungwa E, Mbonyinshuti F, Kayitare E. BMC Health Serv Res. 2024 Jan 24;24(1):136. doi: 10.1186/s12913-024-10605-z. PMID: 38267916

Clinical presentation and antimicrobial resistance of invasive Escherichia coli disease in hospitalized older adults: a prospective multinational observational study.
Doua J, Rodríguez-Baño J, Froget R, Puranam P, Go O, Geurtsen J, van Rooij S, Vilken T, Minoru I, Yasumori I, Spiessens B, Tacconelli E, Biehl LM, Thaden JT, Sarnecki M, Goossens H, Poolman J, Bonten M, Ekkelenkamp M; COMBACTE-NET Consortium/EXPECT Study Group. Infection. 2024 Jan 25. doi: 10.1007/s15010-023-02163-z. Online ahead of print. PMID: 38267801

Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization.
Jiang W, Maldeney AR, Yuan X, Richer MJ, Renshaw SE, Luo W. Cell Rep. 2024 Jan 23;43(1):113665. doi: 10.1016/j.celrep.2023.113665. Epub 2024 Jan 8. PMID: 38194344

Mitochondrial disturbance related to increased caspase-1 of $CD4^+$T cells in HIV-1 infection.
Yu F, Ma C, Jin X, Zhao H, Xiao J, Li L, Song S, Xie X, Yang S, Tang Y, Wang L, Zhang F. BMC Infect Dis. 2024 Jan 24;24(1):129. doi: 10.1186/s12879-023-08485-5. PMID: 38267841

What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety.
Clothier HJ, Shetty AN, Mesfin Y, Mackie M, Pearce C, Buttery JP. Vaccine. 2024 Jan 22:S0264-410X(24)00025-2. doi: 10.1016/j.vaccine.2024.01.025. Online ahead of print. PMID: 38262811

Identification of differentially recognized T cell epitopes in the spectrum of tuberculosis infection.
Panda S, Morgan J, Cheng C, Saito M, Gilman RH, Ciobanu N, Crudu V, Catanzaro DG, Catanzaro A, Rodwell T, Perera JSB, Chathuranga T, Gunasena B, DeSilva AD, Peters B, Sette A, Lindestam Arlehamn CS. Nat Commun. 2024 Jan 26;15(1):765. doi: 10.1038/s41467-024-45058-9. PMID: 38278794

Development of reverse genetics system for Guanarito virus: substitution of E1497K in the L protein of Guanarito virus S-26764 strain changes plaque phenotype and growth kinetics.
Taniguchi S, Maruyama J, Saito T, Littlefield K, Reyna RA, Manning JT, Huang C, Saijo M, Paessler S. J Virol. 2024 Jan 30:e0196423. doi: 10.1128/jvi.01964-23. Online ahead of print. PMID: 38289100

Comparison of HVT-ND recombinant and convection-based Newcastle disease vaccination programs in the protection against the genotype VII NDV challenges: an experimental study.
Rajab MK, Fard MHB, Ghalyanchilangeroudi A, Hosseini H, Charkhkar S. Virus Genes. 2024 Jan 30. doi: 10.1007/s11262-023-02038-3. Online ahead of print. PMID: 38289523

Clinical features and outcomes of influenza and RSV coinfections: a report from Canadian immunization research network serious outcomes surveillance network.
Pott H, J LeBlanc J, S ElSherif M, Hatchette TF, McNeil SA, Andrew MK; Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN). BMC Infect Dis. 2024 Jan 30;24(1):147. doi: 10.1186/s12879-024-09033-5. PMID: 38291361

Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.
Agarwal G, Moore S, Sadler R, Varghese S, Turner A, Chen LY, Larham J, Gray N, Carty O, Barrett J, Koshiaris C, Kothari J, Bowcock S, Oppermann U, Gamble V, Cook G, Kyriakou C, Drayson M, Basu S, McDonald S, McKinley S, Gooding S, Javaid MK, Ramasamy K. Haematologica. 2024 Jan 25. doi: 10.3324/haematol.2023.284286. Online ahead of print. PMID: 38268439

Humoral Response Following 3 Doses of mRNA COVID-19 Vaccines in Patients With Non-Dialysis-Dependent CKD: An Observational Study.
Enilama O, Yau K, Er L, Atiquzzaman M, Oliver MJ, Romney MG, Leis JA, Abe KT, Qi F, Colwill K, Gingras AC, Hladunewich MA, Levin A. Can J Kidney Health Dis. 2024 Jan 29;11:20543581231224127. doi: 10.1177/20543581231224127. eCollection 2024. PMID: 38292817

The spike protein of the apathogenic Beaudette strain of avian coronavirus can elicit a protective immune response against a virulent M41 challenge.
Keep S, Stevenson-Leggett P, Webb I, Fones A, Kirk J, Britton P, Bickerton E. PLoS One. 2024 Jan 24;19(1):e0297516. doi: 10.1371/journal.pone.0297516. eCollection 2024. PMID: 38265985

Transmission-reducing and -enhancing monoclonal antibodies against *Plasmodium vivax* gamete surface protein Pvs48/45.
Bansal GP, Araujo MdS, Cao Y, Shaffer E, Araujo JE, Medeiros JF, Hayashi C, Vinetz J, Kumar N. Infect Immun. 2024 Jan 30:e0037423. doi: 10.1128/iai.00374-23. Online ahead of print. PMID: 38289124

Short term Outcomes of COVID-19 Vaccines Among Lactating Mother and Child Dyads in Bangladesh: A Multi-centre, Cross-sectional Study.
Low JM, Afroze S, Al Mamun MA, Afroze S, Tisha S, Hossain MA, Mannan MA, Dey SK, Amin Z, Shahidullah M. Matern Child Health J. 2024 Jan 22. doi: 10.1007/s10995-023-03881-4. Online ahead of print. PMID: 38252330

Impact of vitamin D supplementation as COVID-19 vaccine adjuvant on sperm parameters and sex hormones in men with idiopathic infertility: Two separate pre-post studies.
Zarepoor M, Nazari A, Pourmasumi S. Clin Exp Reprod Med. 2024 Jan 24. doi: 10.5653/cerm.2023.06464. Online ahead of print. PMID: 38263587

Empowering Riverine Communities in the Amazon: Strategies for Preventing Rabies.
Silva JGN, Silva SS, Gomes TCM, Nascimento GDS, Valentim LA, Quaresma TC, Fernandes FP, Oliveira SMS, Moraes WP. Int J Environ Res Public Health. 2024 Jan 22;21(1):117. doi: 10.3390/ijerph21010117. PMID: 38276811

Long-term immunity following yellow fever vaccination: a systematic review and meta-analysis.
Schnyder JL, de Jong HK, Bache BE, Schaumburg F, Grobusch MP. Lancet Glob Health. 2024 Jan 22:S2214-109X(23)00556-9. doi: 10.1016/S2214-109X(23)00556-9. Online ahead of print. PMID: 38272044

The Chinese Hamster Ovary Cell-Based H9 HA Subunit Avian Influenza Vaccine Provides Complete Protection against the H9N2 Virus Challenge in Chickens.

Zhu S, Nie Z, Che Y, Shu J, Wu S, He Y, Wu Y, Qian H, Feng H, Zhang Q. Viruses. 2024 Jan 22;16(1):163. doi: 10.3390/v16010163. PMID: 38275973

Fertility-Related Conversations in the Context of COVID-19 and Vaccinations.
Palmer C, Khademi S, Javed M, Dimaguila GL, Buttery J. Stud Health Technol Inform. 2024 Jan 25;310:644-648. doi: 10.3233/SHTI231044. PMID: 38269888

Does the Duty of Rescue support a moral obligation to vaccinate? Seasonal influenza and the Institutional Duty of Rescue.
Harmer AS. J Med Ethics. 2024 Jan 22:jme-2023-109545. doi: 10.1136/jme-2023-109545. Online ahead of print. PMID: 38041664

The impact of preoperative coronavirus disease 19 infection on early postoperative mortality during the vaccination era: a nationwide retrospective cohort study.
Ju JW, Kim T, Yoon SH, Kim WH, Lee HJ. Korean J Anesthesiol. 2024 Jan 26. doi: 10.4097/kja.23761. Online ahead of print. PMID: 38273737

Myocarditis and pericarditis risk with mRNA COVID-19 vaccination compared to unvaccinated individuals: A retrospective cohort study in a Spanish Tertiary Hospital.
Elizalde MU, Eguinoa FJG, de Las Huertas AGL, Jiménez-González M, Ramírez E. Biomed Pharmacother. 2024 Jan 22;171:116181. doi: 10.1016/j.biopha.2024.116181. Online ahead of print. PMID: 38262150

rWTC-MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells.
Wang H, Medina R, Ye J, Zhang Y, Chakraborty S, Valenzuela A, Uher O, Hadrava Vanova K, Sun M, Sang X, Park DM, Zenka J, Gilbert MR, Pacak K, Zhuang Z. Adv Sci (Weinh). 2024 Jan 31:e2308280. doi: 10.1002/advs.202308280. Online ahead of print. PMID: 38298111

High prevalence of hepatitis B virus susceptibility among persons undergoing community-based hepatitis C virus treatment.
Campusano C, Kanner R, McDonell C, Morris M, Duarte M, Price JC. Harm Reduct J. 2024 Jan 29;21(1):25. doi: 10.1186/s12954-024-00942-x. PMID: 38281942

Pandemic lifeworlds: A segmentation analysis of public responsiveness to official communication about Covid-19 in England.
Coleman S, Slater MD, Wright P, Wright O, Skardon L, Hayes G. PLoS One. 2024 Jan 31;19(1):e0296049. doi: 10.1371/journal.pone.0296049. eCollection 2024. PMID: 38295034

Fertility Declines Near the End of the COVID-19 Pandemic: Evidence of the 2022 Birth Declines in Germany and Sweden.
Bujard M, Andersson G. Eur J Popul. 2024 Jan 22;40(1):4. doi: 10.1007/s10680-023-09689-w. PMID: 38252183

Zika virus precursor membrane peptides induce immune response in peripheral blood mononuclear cells.
Gupta Y, Baranwal M, Chudasama B. Hum Immunol. 2024 Jan 24:110761. doi: 10.1016/j.humimm.2024.110761. Online ahead of print. PMID: 38272735

Cardiac Magnetic Resonance Imaging Findings and Clinical Features of COVID-19 Vaccine-Associated Myocarditis, Compared With Those of Other Types of Myocarditis.
Kim SG, Lee JY, Jeong WG, Lee JE, Kim YH. J Korean Med Sci. 2024 Jan 29;39(4):e42. doi: 10.3346/jkms.2024.39.e42. PMID: 38288542

Epidemiology of group A rotavirus in children under five years of age with gastroenteritis in N'Djamena, Chad.
Djikoloum B, Abakar MF, Ndze VN, Nkandi RG, Enjeh CN, Kimala P, Assam JPA, Boda M. BMC Infect Dis. 2024 Jan 22;24(1):111. doi: 10.1186/s12879-023-08647-5. PMID: 38254036

Identification of a novel linear B-cell epitope on the p30 protein of African swine fever virus using monoclonal antibodies.
Tian P, Sun Z, Wang M, Song J, Sun J, Zhou L, Jiang D, Zhang A, Wu Y, Zhang G. Virus Res. 2024 Jan 27;341:199328. doi: 10.1016/j.virusres.2024.199328. Online ahead of print. PMID: 38262569

Understanding the impact of chronic diseases on COVID-19 vaccine hesitancy using propensity score matching: Internet-based cross-sectional study.
Miao Y, Shen Z, Li Q, Ma M, Xu D, Tarimo CS, Gu J, Wei W, Zhou X, Zhao L, Feng Y, Wu J, Wang M. J Clin Nurs. 2024 Jan 30. doi: 10.1111/jocn.16958. Online ahead of print. PMID: 38291345

A prospective cohort study of SARS-CoV-2 infection-induced seroconversion and disease incidence in German healthcare workers before and during the rollout of COVID-19 vaccines.
Gehring S, Kowalzik F, Okasha O, Engelmann T, Schreiner D, Jensen C, Mähringer-Kunz A, Hartig-Merkel W, Mai Phuong Tran T, Oostvogels C, Verstraeten T. PLoS One. 2024 Jan 30;19(1):e0294025. doi: 10.1371/journal.pone.0294025. eCollection 2024. PMID: 38289913

The role of local health officers in advancing public health and primary care integration: lessons from the ongoing Universal Health Coverage reforms in the Philippines.
de Claro V, Lava JB, Bondoc C, Stan L. BMJ Glob Health. 2024 Jan 22;9(1):e014118. doi: 10.1136/bmjgh-2023-014118. PMID: 38262684

Miscarriage after SARS-CoV-2 vaccination: A request to report more details of the regression models and analyses.
Levi R, Schurr E. BJOG. 2024 Jan 22. doi: 10.1111/1471-0528.17767. Online ahead of print. PMID: 38247342

Chemical Synthesis Creates Single Glycoforms of the Ectodomain of Herpes Simplex Virus-1 Glycoprotein D.
Zhao J, Liu X, Liu J, Ye F, Wei B, Deng M, Li T, Huang P, Wang P. J Am Chem Soc. 2024 Jan 31;146(4):2615-2623. doi: 10.1021/jacs.3c11543. Epub 2023 Dec 20. PMID: 38117537

Application of elastic net regression for modeling COVID-19 sociodemographic risk factors.
Moxley TA, Johnson-Leung J, Seamon E, Williams C, Ridenhour BJ. PLoS One. 2024 Jan 26;19(1):e0297065. doi: 10.1371/journal.pone.0297065. eCollection 2024. PMID: 38277346

Dog Bite Injury: Rusk Became a Risk - A Case Report.
Nehru S, Thangaraju P, Cibee N, Velmurugan H. Infect Disord Drug Targets. 2024 Jan 25. doi: 10.2174/0118715265277314231211045515. Online ahead of print. PMID: 38279737

Neurotoxicity profiling of aluminum salt-based nanoparticles as adjuvants for therapeutic cancer vaccine.
Chen C, Xue C, Jiang J, Bi S, Hu Z, Yu G, Sun B, Mao C. J Pharmacol Exp Ther. 2024 Jan 25:JPET-AR-2023-002031. doi: 10.1124/jpet.123.002031. Online ahead of print. PMID: 38272670

Pseudouridine-modified RNA probe for label-free electrochemical detection of nucleic acids on 2D MoS_2 nanosheets.
Das PK, Adil O, DeGregorio AP, Sumita M, Shamsi MH. Analyst. 2024 Jan 22. doi: 10.1039/d3an01832f. Online ahead of print. PMID: 38247383

Immune-mediated diseases after vaccinations with AZD1222, BNT-162b2, &/or mRNA-1273: An observational investigation of 78 patients.
Ou TS, Sun YS, Lai CC, Chen WS, Tsai HC, Chen MH, Chou CT, Chang FP, Peng YC, Tsai CC, Liao HT, Tsai CY. Int Immunopharmacol. 2024 Jan 25;127:111455. doi: 10.1016/j.intimp.2023.111455. Epub 2023 Dec 28. PMID: 38157699

Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study.
Puthanakit T, Prompetchara E, Gatechompol S, Ketloy C, Thitithanyanont A, Jongkaewwattana A, Buranapraditkun S, Ubolyam S, Kerr SJ, Sophonphan J, Apornpong T, Kittanamongkolchai W, Siwamogsatham S, Sriplienchan S, Patarakul K, Theerawit T, Promsena P, Nantanee R, Manomaisantiphap S, Chokyakorn S, Hong L, Samija M, Montefiori DC, Gao H, Eaton A, Wijagkanalan W, Alameh MG, Weissman D, Ruxrungtham K; ChulaVac001-Phase 2 study team. Sci Rep. 2024 Jan 29;14(1):2373. doi: 10.1038/s41598-023-49653-6. PMID: 38287068

Current Development of Data Resources and Bioinformatics Tools for Anticoronavirus Peptide.
Li B, Li M, Lu C, Wu Y, Chen H, He B. Curr Med Chem. 2024 Jan 22. doi: 10.2174/0109298673264218231121104407. Online ahead of print. PMID: 38265399

Can adverse cardiac events of the COVID-19 vaccine exacerbate preexisting diseases?
Razzaque MS. Expert Rev Anti Infect Ther. 2024 Jan 29. doi: 10.1080/14787210.2024.2311837. Online ahead of print. PMID: 38284355

Analysis of seroconversion following COVID-19 vaccination among multiple sclerosis patients treated with disease-modifying therapies in Poland.
Podlecka-Piętowska A, Sierdziński J, Nojszewska M, Stawicki J, Bartosik-Psujek H, Lech B, Popiel M, Perenc A, Kułakowska A, Czarnowska A, Kulikowska J, Kapica-Topczewska K, Jamróz-Wiśniewska A, Rejdak K, Zaborski J, Kubicka-Bączyk K, Niedziela N, Wierzbicki K, Adamczyk-Sowa M, Zwiernik J, Zwiernik B, Milewska-Jędrzejczak M, Głąbiński A, Jasińska E, Puz P, Krzystanek E, Stęposz A, Karuga A, Lasek-Bal A, Siuda J, Kściuk B, Walawska-Hrycek A, Patalong-Ogiewa M, Kaczmarczyk A, Siutka K, Brola W, Zakrzewska-Pniewska B. Neurol Neurochir Pol. 2024 Jan 22. doi: 10.5603/pjnns.96425. Online ahead of print. PMID: 38251955

A novel lateral flow immunochromatographic assay using a recombinant VP2 antigen for total antibody detection of canine parvovirus-2.
Salmanli E, Tezcan T, Karaoglu T. Anal Methods. 2024 Jan 25;16(4):551-557. doi: 10.1039/d3ay01870a. PMID: 38186287

Vaccine efficacy against the SARS-CoV-2 Delta variant during a COVID-19 outbreak aboard a military ship.
Maugey N, Lefebvre T, Tournier JN, Neulat-Ripoll F, Chapus C, Grandperret V, Raynaud F, Letois F, Dutasta F, Janvier F, Wolf A, de Laval F. BMJ Mil Health. 2024 Jan 25;170(1):91-92. doi: 10.1136/bmjmilitary-2022-002082. PMID: 35487589

Hepatitis C virus E1 recruits high-density lipoprotein to support infectivity and evade antibody recognition.
Casiano Matos J, Harichandran K, Tang J, Sviridov DO, Sidoti Migliore G, Suzuki M, Olano LR, Hobbs A, Kumar A, Paskel MU, Bonsignori M, Dearborn AD, Remaley AT, Marcotrigiano J. J Virol. 2024 Jan 23;98(1):e0084923. doi: 10.1128/jvi.00849-23. Epub 2024 Jan 4. PMID: 38174935

Comparative study of acetalated-dextran microparticle fabrication methods for a clinically translatable subunit-based influenza vaccine.
Pena ES, Batty CJ, Hendy DA, Yang S, Ontiveros-Padilla L, Stiepel RT, Ting JP, Ainslie KM, Bachelder EM. Int J Pharm. 2024 Jan 22;652:123836. doi: 10.1016/j.ijpharm.2024.123836. Online ahead of print. PMID: 38266940

Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-serotype community acquired pneumococcal diseases among children in China: A test-negative case-control study.
Xiaofei L, Yudan LI, Qinghui C, Jiaming S, Benfeng Z, Youyi Z, Biying W, Lijun Y, Jun Z, Jianmei T, Lin L, Xuejun S, Genming Z, Tao Z. Vaccine. 2024 Jan 30:S0264-410X(24)00080-X. doi: 10.1016/j.vaccine.2024.01.068. Online ahead of print. PMID: 38296700

Evidence of concerning decline of COVID-19 vaccination in older persons.
Mattiuzzi C, Lippi G. Immunol Res. 2024 Jan 26. doi: 10.1007/s12026-024-09460-1. Online ahead of print. PMID: 38277057

Recurrent Acute Disseminated Encephalomyelitis Presenting as Conus Medullaris Syndrome: A Case Report.
Lee DW, Kang S, Kim N. Medicina (Kaunas). 2024 Jan 22;60(1):188. doi: 10.3390/medicina60010188. PMID: 38276067

Hypocretin mRNA loss in Pandemrix vaccinated mice.
Luo G. Sleep. 2024 Jan 30:zsae029. doi: 10.1093/sleep/zsae029. Online ahead of print. PMID: 38289980

Imagination and idealism after the COVID-19 pandemic: the science of healthy ageing.
Farrelly C. R Soc Open Sci. 2024 Jan 31;11(1):231102. doi: 10.1098/rsos.231102. eCollection 2024 Jan. PMID: 38298401

Biogenic Selenium Nanoparticles Synthesized by L. brevis 23017 Enhance Aluminum Adjuvanticity and Make Up for its Disadvantage in Mice.

Zhang Z, De X, Sun W, Liu R, Li Y, Yang Z, Liu N, Wu J, Miao Y, Wang J, Wang F, Ge J. Biol Trace Elem Res. 2024 Jan 26. doi: 10.1007/s12011-023-04042-y. Online ahead of print. PMID: 38273184

Myeloid Cell-Triggered in Situ Cell Engineering for Robust Vaccine-Based Cancer Treatment.
Li WH, Su JY, Zhang BD, Zhao L, Zhuo SH, Wang TY, Hu HG, Li YM. Adv Mater. 2024 Jan 31:e2308155. doi: 10.1002/adma.202308155. Online ahead of print. PMID: 38295870

Compartmentalized SARS-CoV-2 replication in upper versus lower respiratory tract after intranasal inoculation or aerosol exposure.
Fischer RJ, Bushmaker T, Williamson BN, Pérez-Pérez L, Feldmann F, Lovaglio J, Scott D, Saturday G, Feldmann H, Munster VJ, de Wit E, van Doremalen N. J Infect Dis. 2024 Jan 23:jiae018. doi: 10.1093/infdis/jiae018. Online ahead of print. PMID: 38261786

Enzymatic isolation and microfluidic electrophoresis analysis of residual dsRNA impurities in mRNA vaccines and therapeutics.
Coll De Peña A, Vaduva M, Li NS, Shah S, Ben Frej M, Tripathi A. Analyst. 2024 Jan 24. doi: 10.1039/d3an02157b. Online ahead of print. PMID: 38265070

Effects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profile.
New J, Cham J, Smith L, Puglisi L, Huynh T, Kurian S, Bagsic S, Fielding R, Hong L, Reddy P, Eum KS, Martin A, Barrick B, Marsh C, Quigley M, Nicholson LJ, Pandey AC. J Immunother Cancer. 2024 Jan 31;12(1):e008233. doi: 10.1136/jitc-2023-008233. PMID: 38296596

Alcaligenes lipid A functions as a superior mucosal adjuvant to monophosphoryl lipid A via the recruitment and activation of CD11b+ dendritic cells in nasal tissue.
Sun X, Hosomi K, Shimoyama A, Yoshii K, Saika A, Yamaura H, Nagatake T, Kiyono H, Fukase K, Kunisawa J. Int Immunol. 2024 Jan 29;36(1):33-43. doi: 10.1093/intimm/dxad045. PMID: 38006376

Post-mortem investigation of deaths due to pneumonia in children aged 1-59 months in sub-Saharan Africa and South Asia from 2016 to 2022: an observational study.
Mahtab S, Blau DM, Madewell ZJ, Ogbuanu I, Ojulong J, Lako S, Legesse H, Bangura JS, Bassat Q, Mandomando I, Xerinda E, Fernandes F, Varo R, Sow SO, Kotloff KL, Tapia MD, Keita AM, Sidibe D, Onyango D, Akelo V, Gethi D, Verani JR, Revathi G, Scott JAG, Assefa N, Madrid L, Bizuayehu H, Tirfe TT, El Arifeen S, Gurley ES, Islam KM, Alam M, Zahid Hossain M, Dangor Z, Baillie VL, Hale M, Mutevedzi P, Breiman RF, Whitney CG, Madhi SA; CHAMPS Consortium. Lancet Child Adolesc Health. 2024 Jan 25:S2352-4642(23)00328-0. doi: 10.1016/S2352-4642(23)00328-0. Online ahead of print. PMID: 38281495

A randomized first-in-human Phase 1 trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults.
Tiono BA, Plieskatt JL, Ouedraogo A, Soulama BI, Miura K, Bougouma EC, Naghizadeh M, Barry A, Yaro JBB, Ezinmegnon S, Henry NB, Ofori E, Adu B, Singh SK, Konkobo A, Lövgren Bengtsson K, Diarra A, Carnrot C, Reimer JM, Ouedraogo AZ, Tienta M, Long CA, Nebie IN, Sagara I, Sirima SB, Theisen M. J Clin Invest. 2024 Jan 30:e175707. doi: 10.1172/JCI175707. Online ahead of print. PMID: 38290009

Effect of glycosylation on the affinity of the MTB protein Ag85B for specific antibodies: towards the design of a dual-acting vaccine against tuberculosis.
Bernardini R, Tengattini S, Li Z, Piubelli L, Bavaro T, Modolea AB, Mattei M, Conti P, Marini S, Zhang Y, Pollegioni L, Temporini C, Terreni M. Biol Direct. 2024 Jan 25;19(1):11. doi: 10.1186/s13062-024-00454-5. PMID: 38268026

Ocular inflammatory events following COVID-19 vaccination: reporting of suspected adverse drug reactions to regulatory authorities in the UK.
Testi I, Soomro T, Pavesio C, Solebo AL. Br J Ophthalmol. 2024 Jan 22:bjo-2023-324503. doi: 10.1136/bjo-2023-324503. Online ahead of print. PMID: 38041661

Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants.
Russell TW, Townsley H, Abbott S, Hellewell J, Carr EJ, Chapman LAC, Pung R, Quilty BJ, Hodgson D, Fowler AS, Adams L, Bailey C, Mears HV, Harvey R, Clayton B, O'Reilly N, Ngai Y, Nicod J, Gamblin S, Williams B, Gandhi S, Swanton C, Beale R, Bauer DLV, Wall EC, Kucharski AJ. PLoS Biol. 2024 Jan 30;22(1):e3002463. doi: 10.1371/journal.pbio.3002463. eCollection 2024 Jan. PMID: 38289907

Interdisciplinary Learning Health System Response to Public Vaccine Concerns.
Dimaguila GL, Javed M, Clothier HJ, Hickman J, Petrovic D, Machingaifa F, Kaufman J, Habibabadi SK, Palmer C, Buttery J. Stud Health Technol Inform. 2024 Jan 25;310:1146-1150. doi: 10.3233/SHTI231144. PMID: 38269994

Measles surge causes alarm: what scientists think.
Wong C. Nature. 2024 Jan 31. doi: 10.1038/d41586-024-00265-8. Online ahead of print. PMID: 38297056

SARS-CoV-2 vaccination in inflammatory bowel disease patients is not associated with flares: a retrospective single-centre Swiss study.
Rossier LN, Décosterd NP, Matter CB, Staudenmann DA, Moser A, Egger B, Seibold FW. Ann Med. 2024 Dec;56(1):2295979. doi: 10.1080/07853890.2023.2295979. Epub 2024 Jan 30. PMID: 38289017

Effectiveness of mRNA BNT162b2 and inactivated CoronaVac vaccines against severe COVID-19 outcomes among non-hospitalized children aged 1-3 years with SARS-CoV-2 Omicron infection.
Wong CKH, Lau KTK, Au ICH, Lau EHY, Cowling BJ. Int J Antimicrob Agents. 2024 Jan 23:107094. doi: 10.1016/j.ijantimicag.2024.107094. Online ahead of print. PMID: 38272281

Evaluation of Asymptomatic Bordetella Carriage in a Convenience Sample of Children and Adolescents in Atlanta, Georgia, United States.
Acosta AM, Simon A, Thomas S, Tunali A, Satola S, Jain S, Farley MM, Tondella ML, Skoff TH. J Pediatric Infect Dis Soc. 2024 Jan 29;13(1):105-109. doi: 10.1093/jpids/piad104. PMID: 37974480

COVID-19: incidence and mortality in Sweden comparing all foreign-born to all Swedish-born individuals in different occupations in an unvaccinated cohort of year 2020.
Tondel M, Nordquist T, Helgesson M, Svartengren M. Occup Environ Med. 2024 Jan 24:oemed-2023-108952. doi: 10.1136/oemed-2023-108952. Online ahead of print. PMID: 38267211

Geographic distribution and genetic diversity of Newcastle disease virus in pigeons from Pakistan.
Wajid A, Maqsood Q, Ben Said M, Sherzada S, Nooruzzaman M, Batool A, Yin R, Sabra M, Hanif A, Azam Kakar M, Hussain T, Ahmed N. Avian Pathol. 2024 Apr;53(2):134-145. doi: 10.1080/03079457.2023.2291107. Epub 2024 Jan 25. PMID: 38037737

Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2.
Göritzer K, Groppelli E, Grünwald-Gruber C, Figl R, Ni F, Hu H, Li Y, Liu Y, Hu Q, Puligedda RD, Jung JW, Strasser R, Dessain S, K-C Ma J. Mol Ther. 2024 Jan 23:S1525-0016(24)00025-X. doi: 10.1016/j.ymthe.2024.01.025. Online ahead of print. PMID: 38268188

Non-biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases.
Kanatoula DD, Bodner E, Ghoreschi K, Meier K, Solimani F. J Dtsch Dermatol Ges. 2024 Jan 23. doi: 10.1111/ddg.15270. Online ahead of print. PMID: 38259085

Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts.
Chittrakarn S, Siripaitoon P, Chusri S, Kanchanasuwan S, Charoenmak B, Hortiwakul T, Kantikit P, Kositpantawong N. Hum Vaccin Immunother. 2024 Dec 31;20(1):2309734. doi: 10.1080/21645515.2024.2309734. Epub 2024 Jan 31. PMID: 38297904

On-column refolding and off-column assembly of parvovirus B19 virus-like particles from bacteria-expressed protein.
Sánchez-Moguel I, Coffeen CF, Bustos-Jaimes I. Appl Microbiol Biotechnol. 2024 Jan 22;108(1):160. doi: 10.1007/s00253-024-13004-w. PMID: 38252281

COVID-19 vaccination during pregnancy and adverse perinatal outcomes: a systematic review and meta-analysis.
Wang J, Deng Y, Wang W. Trans R Soc Trop Med Hyg. 2024 Jan 31:trad093. doi: 10.1093/trstmh/trad093. Online ahead of print. PMID: 38291854

Evaluation of a multi-component early warning system for pastoralist populations in Doolo zone, Ethiopia: mixed-methods study.
Baertlein L, Dubad BA, Sahelie B, Damulak IC, Osman M, Stringer B, Bestman A, Kuehne A, van Boetzelaer E, Keating P. Confl Health. 2024 Jan 30;18(1):13. doi: 10.1186/s13031-024-00571-y. PMID: 38291440

Evaluation of possible cytotoxic, genotoxic and epigenotoxic effects of titanium dioxide nanoparticles and possible protective effect of melatonin.
Balci-Ozyurt A, Yirün A, Cakır DA, Zeybek ND, Oral D, Sabuncuoğlu S, Erkekoğlu P. Toxicol Mech Methods. 2024 Feb;34(2):109-121. doi: 10.1080/15376516.2023.2259980. Epub 2024 Jan 29. PMID: 37794599

Wastewater-based epidemiology for COVID-19 using dynamic artificial neuronal networks.
Zamarreño JM, Torres AF, Gonçalves J, Muñoz R, Rodriguez E, Eiros JM, Garcia-Encina P. Sci Total Environ. 2024 Jan 24:170367. doi: 10.1016/j.scitotenv.2024.170367. Online ahead of print. PMID: 38278261

Association between regular physical activity and pneumonia-related hospitalization according to pneumococcal vaccination status: The VENUS study.
Murata F, Maeda M, Ono R, Fukuda H. Vaccine. 2024 Jan 27:S0264-410X(24)00072-0. doi: 10.1016/j.vaccine.2024.01.060. Online ahead of print. PMID: 38281899

Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge.
Grunst MW, Gil HM, Grandea AG 3rd, Snow BJ, Andrabi R, Nedellec R, Burton I, Clark NM, Janaka SK, Keles NK, Moriarty RV, Weiler AM, Capuano S 3rd, Fennessey CM, Friedrich TC, O'Connor SL, O'Connor DH, Broman AT, Keele BF, Lifson JD, Hangartner L, Burton DR, Evans DT. PLoS Pathog. 2024 Jan 22;20(1):e1011819. doi: 10.1371/journal.ppat.1011819. Online ahead of print. PMID: 38252675

Is it time to reconsider universal SARS-CoV-2 PCR screening for asymptomatic potential non-lung solid organ transplant donors?
Natori Y, Anjan S, Hand J. Am J Transplant. 2024 Jan 22:S1600-6135(24)00089-3. doi: 10.1016/j.ajt.2024.01.021. Online ahead of print. PMID: 38266710

The vaccination changed the profile of rotavirus infection with the increase of non-rotavirus A species diagnosis in one-week-old diarrheic piglets.
Dall Agnol AM, Guimarães NS, Leme RA, da Costa AR, Alfieri AF, Alfieri AA. Braz J Microbiol. 2024 Jan 27. doi: 10.1007/s42770-024-01262-9. Online ahead of print. PMID: 38280092

Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates.
Woolsey C, Cross RW, Prasad AN, Agans KN, Borisevich V, Deer DJ, Dobias NS, Fears AC, Harrison MB, Heinrich ML, Fenton KA, Garry RF, Branco LM, Geisbert TW. Emerg Microbes Infect. 2024 Dec;13(1):2301061. doi: 10.1080/22221751.2023.2301061. Epub 2024 Jan 22. PMID: 38164768

Diverse immune responses in vaccinated individuals with and without symptoms after omicron exposure during the recent outbreak in Guangzhou, China.
Gao M, Xing X, Hao W, Zhang X, Zhong K, Lu C, Deng X, Yu L. Heliyon. 2024 Jan 10;10(2):e24030. doi: 10.1016/j.heliyon.2024.e24030. eCollection 2024 Jan 30. PMID: 38293451

Consanguineous marriages increase the incidence of recurrent tuberculosis: Evidence from whole exome sequencing.
Akbar NU, Ahmad S, Khan TA, Tayyeb M, Akhter N, Shafiq L, Khan SN, Alam MM, Abdullah AM, Rehman MFU, Bajaber MA, Akram MS. Infect Genet Evol. 2024 Jan 23;118:105559. doi: 10.1016/j.meegid.2024.105559. Online ahead of print. PMID: 38266757

Neurological disorders throughout acute SARS-CoV2 infection: A comparative study between vaccinated and non-vaccinated patients.

Cristillo V, Pilotto A, Piccinelli SC, Libri I, Locatelli M, Giunta M, Mazzoleni V, Pezzini D, Arici D, Gipponi S, di Cola FS, Cottini E, Gamba M, Magoni M, Padovani A. J Neurol Sci. 2024 Jan 23;457:122898. doi: 10.1016/j.jns.2024.122898. Online ahead of print. PMID: 38281402

Layering vaccination with antibiotic therapy results in protection and clearance of *Burkholderia pseudomallei* in Balb/c mice.
Barnes KB, Brett P, Burtnick M, Vente A, Bentley C, Richards MI, Flick-Smith HC, Burgess G, Thwaite JE, Laws TR, Maishman TC, Nelson M, Harding SV. Infect Immun. 2024 Jan 30:e0045523. doi: 10.1128/iai.00455-23. Online ahead of print. PMID: 38289122

Missed Vaccine Doses Tied to Worse COVID-19 Outcomes.
Harris E. JAMA. 2024 Jan 31. doi: 10.1001/jama.2023.28340. Online ahead of print. PMID: 38294786

pH-Dependent Lyotropic Liquid Crystalline Mesophase and Ionization Behavior of Phytantriol-Based Ionizable Lipid Nanoparticles.
Yu H, Dyett B, Kirby N, Cai X, Mohamad ME, Bozinovski S, Drummond CJ, Zhai J. Small. 2024 Jan 31:e2309200. doi: 10.1002/smll.202309200. Online ahead of print. PMID: 38295089

Author Correction: Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany.
Nygren TM, Pilic A, Böhmer MM, Wagner-Wiening C, Wichmann O, Harder T, Hellenbrand W. Sci Rep. 2024 Jan 30;14(1):2504. doi: 10.1038/s41598-024-53031-1. PMID: 38291240

Infant ustekinumab Clearance, Risk of Infection, and Development after exposure during pregnancy.
Julsgaard M, Wieringa JW, Baunwall SMD, Bibby BM, Driessen GJA, Kievit L, Brodersen JB, Poulsen A, Kjeldsen J, Hansen MM, Tang HQ, Balmer CL, Glerup H, Seidelin JB, Haderslev KV, Svenningsen L, Wildt S, Juel MA, Neumann A, Fuglsang J, Jess T, Hasse AM, Hvas CL, Kelsen J, Janneke van der Woude C; NEXUS Collaborator Group. Clin Gastroenterol Hepatol. 2024 Jan 24:S1542-3565(24)00083-1. doi: 10.1016/j.cgh.2024.01.008. Online ahead of print. PMID: 38278191

COVID-19 mRNA vaccination during pregnancy does not harm syncytiotrophoblast development.
Voorden AJV, Groot CJM, Ris-Stalpers C, Afink GB, Leeuwen EV. Int J Infect Dis. 2024 Jan 25:S1201-9712(24)00015-8. doi: 10.1016/j.ijid.2024.01.014. Online ahead of print. PMID: 38280665

Attenuation of hepatitis A antibody after immunization with hepatitis A vaccine (Aimmugen) in people living with HIV.
Koga M, Saito M, Kubota M, Senkoji T, Adachi E, Ikeuchi K, Kikuchi T, Otani A, Takahashi K, Tsutsumi T, Yotsuyanagi H. Hepatol Res. 2024 Jan 24. doi: 10.1111/hepr.14012. Online ahead of print. PMID: 38263905

"There's a little bit of mistrust": Red River Métis experiences of the H1N1 and COVID-19 pandemics.
Driedger SM, Maier R, Capurro G, Jardine C, Tustin J, Chartrand F, Sanguins J, Kloss O. Risk Anal. 2024 Jan 29. doi: 10.1111/risa.14274. Online ahead of print. PMID: 38286593

Bilateral central retinal vein occlusion following COVID-19 vaccination: Cause or coincidence?
Matri KE, Werda S, Chebbi Z, Saidane R, Doukh M, Choura R, Falfoul Y, Limaiem R, Matri LE. Eur J Ophthalmol. 2024 Jan 30:11206721241229109. doi: 10.1177/11206721241229109. Online ahead of print. PMID: 38291623

WHO Strategic Advisory Group of Experts on Immunization recommendations for use of a novel pentavalent meningococcal ACWXY vaccine: a critical step towards ending meningococcal epidemics in Africa.
McNamara LA, Neatherlin J. J Travel Med. 2024 Jan 28;31(1):taae002. doi: 10.1093/jtm/taae002. PMID: 38195714

Comparative analysis and prediction of avian influenza in Shangrao city, China from 2016 to 2022.
Fang K, Song W, Zhang Y, Zheng Y, You C, Hu J, Liu L, Feng L, Zhao Z, Zhao Y, Wang J, Wang X, Zhu L, Chen T. Virology. 2024 Jan 24;592:109995. doi: 10.1016/j.virol.2024.109995. Online ahead of print. PMID: 38290415

How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations.
Ring KL, Duska LR. Gynecol Oncol. 2024 Jan 24;184:8-15. doi: 10.1016/j.ygyno.2024.01.008. Online ahead of print. PMID: 38271774

Effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine against recurrent hospitalisations and mortality in relation to influenza circulation: a post-hoc analysis of the DANFLU-1 randomised clinical trial.
Johansen ND, Modin D, Skaarup KG, Nealon J, Samson S, Dufournet M, Loiacono MM, Harris RC, Larsen CS, Reimer Jensen AM, Landler NE, Claggett BL, Solomon PSD, Landray PMJ, Gislason PGH, Køber PL, Stæhr Jensen PJU, Sivapalan P, Vestergaard LS, Valentiner-Branth P, Krause TG, Biering-Sørensen PT. Clin Microbiol Infect. 2024 Jan 27:S1198-743X(24)00039-9. doi: 10.1016/j.cmi.2024.01.017. Online ahead of print. PMID: 38286177

Double-layered N-S1 protein nanoparticle immunization elicits robust cellular immune and broad antibody responses against SARS-CoV-2.
Li R, Chang Z, Liu H, Wang Y, Li M, Chen Y, Fan L, Wang S, Sun X, Liu S, Cheng A, Ding P, Zhang G. J Nanobiotechnology. 2024 Jan 30;22(1):44. doi: 10.1186/s12951-024-02293-y. PMID: 38291444

Hypermetabolic Axillary Lymphadenopathy After Shingrix Vaccination for Varicella Zoster Virus.
Eshet Y, Eifer M, Domachevsky L, Tau N. Clin Nucl Med. 2024 Jan 25. doi: 10.1097/RLU.0000000000005039. Online ahead of print. PMID: 38271246

High Prevalence of Novel Sequence Types in *Streptococcus pneumoniae* That Caused Invasive Diseases in Kuwait in 2018.
Mokaddas E, Asadzadeh M, Syed S, Albert MJ. Microorganisms. 2024 Jan 22;12(1):225. doi: 10.3390/microorganisms12010225. PMID: 38276209

Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study.
van Boven M, van Dorp CH, Westerhof I, Jaddoe V, Heuvelman V, Duijts L, Fourie E, Sluiter-Post J, van Houten MA, Badoux P, Euser S, Herpers B, Eggink D, de Hoog M, Boom T, Wildenbeest J, Bont L, Rozhnova G, Bonten MJ, Kretzschmar ME, Bruijning-Verhagen P. PLoS Comput Biol. 2024 Jan 29;20(1):e1011832. doi: 10.1371/journal.pcbi.1011832. Online ahead of print. PMID: 38285727

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia.

Roberts T, Uwenedi G, Bruton R, McIlroy G, Damery S, Sylla P, Logan N, Scott S, Lau M, Elzaidi A, Plass S, Mallick S, Spencer K, Stephens C, Bentley C, Pratt G, Zuo J, Paneesha S, Willett B, Moss P, Parry H. Blood Cancer J. 2024 Jan 25;14(1):22. doi: 10.1038/s41408-023-00940-5. PMID: 38272915

A Model for Monitoring Spontaneously Reported Medication Errors Using the Adjuvanted Recombinant Zoster Vaccine as an Example.
Dessart C, Tavares-Da-Silva F, Van Holle L, Mahaux O, Stegmann JU. Adv Pharmacol Pharm Sci. 2024 Jan 24;2024:6435993. doi: 10.1155/2024/6435993. eCollection 2024. PMID: 38298461

COVID-19 Testing and Vaccination Among US Older Adults with Vision Impairment: The National Health and Aging Trends Study 2021.
Almidani L, Swenor BK, Ehrlich JR, Varadaraj V. Ophthalmic Epidemiol. 2024 Jan 24:1-6. doi: 10.1080/09286586.2023.2301587. Online ahead of print. PMID: 38265038

Immunogenicity of BNT162b2 vaccine after two and three doses: Correspondence.
Daungsupawong H, Wiwanitkit V. Semergen. 2024 Jan 30;50(4):102132. doi: 10.1016/j.semerg.2023.102132. Online ahead of print. PMID: 38295632

Human coronavirus OC43-elicited $CD4^+$ T cells protect against SARS-CoV-2 in HLA transgenic mice.
Dos Santos Alves RP, Timis J, Miller R, Valentine K, Pinto PBA, Gonzalez A, Regla-Nava JA, Maule E, Nguyen MN, Shafee N, Landeras-Bueno S, Olmedillas E, Laffey B, Dobaczewska K, Mikulski Z, McArdle S, Leist SR, Kim K, Baric RS, Ollmann Saphire E, Elong Ngono A, Shresta S. Nat Commun. 2024 Jan 26;15(1):787. doi: 10.1038/s41467-024-45043-2. PMID: 38278784

Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue.
Shi G, Li T, Lai KK, Johnson RF, Yewdell JW, Compton AA. Nat Commun. 2024 Jan 30;15(1):889. doi: 10.1038/s41467-024-45075-8. PMID: 38291024

Ensuring Continuity of Tuberculosis Care during Social Distancing through Integrated Active Case Finding at COVID-19 Vaccination Events in Vietnam: A Cohort Study.
Dinh LV, Vo LNQ, Wiemers AMC, Nguyen HB, Vu HQ, Mo HTL, Nguyen LP, Nguyen NTT, Dong TTT, Tran KT, Dang TMH, Nguyen LH, Pham AT, Codlin AJ, Forse RJ. Trop Med Infect Dis. 2024 Jan 22;9(1):26. doi: 10.3390/tropicalmed9010026. PMID: 38276637

Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis.
Martínez-Fleta P, Vicente-Rabaneda EF, Triguero-Martínez A, Roy-Vallejo E, Uriarte-Ecenarro M, Gutiérrez-Rodríguez F, Quiroga-Colina P, Romero-Robles A, Montes N, García-Castañeda N, Mejía-Abril GP, García-Vadillo JA, Llorente-Cubas I, Villagrasa JR, Serra López-Matencio JM, Ancochea J, Urzainqui A, Esparcia-Pinedo L, Alfranca A, de la Fuente H, García-Vicuña R, Sánchez-Madrid F, González-Álvaro I, Castañeda S. NPJ Vaccines. 2024 Jan 30;9(1):21. doi: 10.1038/s41541-024-00805-3. PMID: 38291047

Case Report: Fecal Microbiota Transplantation for the Treatment of Generalized Eczema Occurring After COVID-19 Vaccination.
Huang T, Lv Y, Wang W, Chen Y, Fan L, Teng Z, Zhou X, Shen H, Fu G. Clin Cosmet Investig Dermatol. 2024 Jan 26;17:229-235. doi: 10.2147/CCID.S443542. eCollection 2024. PMID: 38292322

Immunoinformatics-driven approach for development of potential multi-epitope vaccine against the secreted protein FlaC of *Campylobacter jejuni*.
Saravanan D, Mohan M. J Biomol Struct Dyn. 2024 Jan 29:1-12. doi: 10.1080/07391102.2024.2308766. Online ahead of print. PMID: 38287490

An Analysis of Various Factors Underlying Covid-19 Prevention Practice and Strategy in Jigjiga Town, Northeast Ethiopia.
Marine BT, Mengistie DT. Infect Drug Resist. 2024 Jan 22;17:187-206. doi: 10.2147/IDR.S441538. eCollection 2024. PMID: 38283111

Characterization of reverse-engineered anti-PF4 stereotypic antibodies derived from serum of patients with VITT.
Wang JJ, van der Neut Kolfschoten M, Rutten L, Armour B, Tan CW, Chataway T, Bos R, Koornneef A, Abeywickrema P, Kapur R, Porcelijn L, Khalifa M, Sadi A, Bouchier P, Kourkouta E, Perkasa A, Kwaks T, Zahn R, Solforosi L, Gordon TP. Blood. 2024 Jan 25;143(4):370-374. doi: 10.1182/blood.2023021307. PMID: 37976451

Ally, adversary, or arbitrator? The context-dependent role of eosinophils in vaccination for respiratory viruses and subsequent breakthrough infections.
Chang LA, Schotsaert M. J Leukoc Biol. 2024 Jan 30:qiae010. doi: 10.1093/jleuko/qiae010. Online ahead of print. PMID: 38289826

Dynamic action of an intrinsically disordered protein in DNA compaction that induces mycobacterial dormancy.
Nishiyama A, Shimizu M, Narita T, Kodera N, Ozeki Y, Yokoyama A, Mayanagi K, Yamaguchi T, Hakamata M, Shaban AK, Tateishi Y, Ito K, Matsumoto S. Nucleic Acids Res. 2024 Jan 25;52(2):816-830. doi: 10.1093/nar/gkad1149. PMID: 38048321

Virological characteristics of the SARS-CoV-2 BA.2.86 variant.
Tamura T, Mizuma K, Nasser H, Deguchi S, Padilla-Blanco M, Oda Y, Uriu K, Tolentino JEM, Tsujino S, Suzuki R, Kojima I, Nao N, Shimizu R, Wang L, Tsuda M, Jonathan M, Kosugi Y, Guo Z, Hinay AA Jr, Putri O, Kim Y, Tanaka YL, Asakura H, Nagashima M, Sadamasu K, Yoshimura K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Saito A, Ito J, Irie T, Tanaka S, Zahradnik J, Ikeda T, Takayama K, Matsuno K, Fukuhara T, Sato K. Cell Host Microbe. 2024 Jan 22:S1931-3128(24)00005-2. doi: 10.1016/j.chom.2024.01.001. Online ahead of print. PMID: 38280382

Human metapneumovirus infection of organoid-derived human bronchial epithelium represents cell tropism and cytopathology as observed in *in vivo* models.
Ribó-Molina P, van Nieuwkoop S, Mykytyn AZ, van Run P, Lamers MM, Haagmans BL, Fouchier RAM, van den Hoogen BG. mSphere. 2024 Jan 24:e0074323. doi: 10.1128/msphere.00743-23. Online ahead of print. PMID: 38265200

Lung microvascular occlusion by platelet-rich neutrophil-platelet aggregates promotes cigarette smoke-induced severe flu.
Kaminski TW, Brzoska T, Li X, Vats R, Katoch O, Dubey RK, Bagale K, Watkins SC, McVerry BJ, Pradhan-Sundd T, Zhang L, Robinson KM, Nyunoya T, Sundd P. JCI Insight. 2024 Jan 23;9(2):e167299. doi: 10.1172/jci.insight.167299. PMID: 38060312

On the indirect link between virus anthropomorphism and health behavior: Evidence from the pandemic.
Valtorta RR, Orabona N, Paladino MP. Acta Psychol (Amst). 2024 Jan 29;243:104155. doi: 10.1016/j.actpsy.2024.104155. Online ahead of print. PMID: 38290185

Identification of a druggable site on GRP78 at the GRP78-SARS-CoV-2 interface and virtual screening of compounds to disrupt that interface.
Lazou M, Hutton JR, Chakravarty A, Joseph-McCarthy D. J Comput Aided Mol Des. 2024 Jan 24;38(1):6. doi: 10.1007/s10822-023-00546-w. PMID: 38263499

Genetic engineering employing MPB70 and its promoter enables efficient secretion and expression of foreign antigen in bacillus Calmette Guérin (BCG) Tokyo.
Takeishi A, Shaban AK, Kakihana T, Takihara H, Okuda S, Osada H, Suameitria Dewi DNS, Ozeki Y, Yoshida Y, Nishiyama A, Tateishi Y, Aizu Y, Chuma Y, Onishi K, Hayashi D, Yamamoto S, Mukai T, Ato M, Thai DH, Nhi HTT, Shirai T, Shibata S, Obata F, Fujii J, Yamayoshi S, Kiso M, Matsumoto S. Microbiol Immunol. 2024 Jan 31. doi: 10.1111/1348-0421.13116. Online ahead of print. PMID: 38294180

Evolving Interoperability Across a State Public Health Immunization Registry and Electronic Health Records.
Rajamani S, Jiter N, Leeds M, Muscoplat M, White K, Bieringer A, Melton GB. Stud Health Technol Inform. 2024 Jan 25;310:23-27. doi: 10.3233/SHTI230920. PMID: 38269758

Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds.
Wamhoff EC, Ronsard L, Feldman J, Knappe GA, Hauser BM, Romanov A, Case JB, Sanapala S, Lam EC, Denis KJS, Boucau J, Barczak AK, Balazs AB, Diamond MS, Schmidt AG, Lingwood D, Bathe M. Nat Commun. 2024 Jan 30;15(1):795. doi: 10.1038/s41467-024-44869-0. PMID: 38291019

Adjuvant activity of cordycepin, a natural derivative of adenosine from *Cordyceps militaris*, on an inactivated rabies vaccine in an animal model.
Chen X, Liao B, Ren T, Liao Z, Huang Z, Lin Y, Zhong S, Li J, Wen S, Li Y, Lin X, Du X, Yang Y, Guo J, Zhu X, Lin H, Liu R, Wang J. Heliyon. 2024 Jan 12;10(2):e24612. doi: 10.1016/j.heliyon.2024.e24612. eCollection 2024 Jan 30. PMID: 38293396

A large-scale study of peptide features defining immunogenicity of cancer neo-epitopes.
Wan YR, Koşaloğlu-Yalçın Z, Peters B, Nielsen M. NAR Cancer. 2024 Jan 29;6(1):zcae002. doi: 10.1093/narcan/zcae002. eCollection 2024 Mar. PMID: 38288446

MMR vaccination induces trained immunity via functional and metabolic reprogramming of γδ T cells.
Röring RJ, Debisarun PA, Botey-Bataller J, Suen TK, Bulut O, Kilic G, Koeken VA, Sarlea A, Bahrar H, Dijkstra H, Lemmers H, Gössling KL, Rüchel N, Ostermann PN, Müller L, Schaal H, Adams O, Borkhardt A, Ariyurek Y, de Meijer EJ, Kloet SL, Ten Oever J, Placek K, Li Y, Netea MG. J Clin Invest. 2024 Jan 30:e170848. doi: 10.1172/JCI170848. Online ahead of print. PMID: 38290093

Comparison of mouse models of microbial experience reveals differences in microbial diversity and response to vaccination.

Sanders AE, Arnesen H, Shepherd FK, Putri DS, Fiege JK, Pierson MJ, Roach SN, Carlsen H, Masopust D, Boysen P, Langlois RA. mSphere. 2024 Jan 29:e0065423. doi: 10.1128/msphere.00654-23. Online ahead of print. PMID: 38286428

Enhancing Antigenic Peptide Discovery: Improved MHC-I Binding Prediction and Methodology.
Giziński S, Preibisch G, Kucharski P, Tyrolski M, Rembalski M, Grzegorczyk P, Gambin A. Methods. 2024 Jan 29:S1046-2023(24)00030-6. doi: 10.1016/j.ymeth.2024.01.016. Online ahead of print. PMID: 38295891

AutoTransOP: translating omics signatures without orthologue requirements using deep learning.
Meimetis N, Pullen KM, Zhu DY, Nilsson A, Hoang TN, Magliacane S, Lauffenburger DA. NPJ Syst Biol Appl. 2024 Jan 29;10(1):13. doi: 10.1038/s41540-024-00341-9. PMID: 38287079

Allogeneic "Zombie Cell" as Off-The-Shelf Vaccine for Postsurgical Cancer Immunotherapy.
Li B, Zhang P, Li J, Zhou R, Zhou M, Liu C, Liu X, Chen L, Li L. Adv Sci (Weinh). 2024 Jan 26:e2307030. doi: 10.1002/advs.202307030. Online ahead of print. PMID: 38279587

Pharmacokinetic Analyses of a Lipid Nanoparticle-Encapsulated mRNA-Encoded Antibody against Rift Valley Fever Virus.
Wang S, Zhu Z, Li J. Mol Pharm. 2024 Jan 31. doi: 10.1021/acs.molpharmaceut.3c01016. Online ahead of print. PMID: 38295278

Plasmid co-expressing siRNA-PD-1 and Endostatin carried by attenuated Salmonella enhanced the anti-melanoma effect via inhibiting the expression of PD-1 and VEGF on tumor-bearing mice.
Wei T, Li Y, Li B, Xie Q, Huang Y, Wu Z, Chen H, Meng Y, Liang L, Wang M, Geng J, Lei M, Shang J, Guo S, Yang Z, Jia H, Ren F, Zhao T. Int Immunopharmacol. 2024 Jan 25;127:111362. doi: 10.1016/j.intimp.2023.111362. Epub 2023 Dec 15. PMID: 38103411

Upregulated Selenoprotein I during LPS-induced B cell activation promotes lipidomic changes and is required for effective differentiation into IgM secreting plasma B cells.
Ma C, Hoffmann FW, Shay AE, Koo I, Green KA, Green WR, Hoffmann PR. J Leukoc Biol. 2024 Jan 30:qiae024. doi: 10.1093/jleuko/qiae024. Online ahead of print. PMID: 38289835

Differences in lethality and diffusion of Covid-19 and different kinds of vaccines: Correspondence.
Daungsupawong H, Wiwanitkit V. J Public Health Res. 2024 Jan 25;13(1):22799036241227787. doi: 10.1177/22799036241227787. eCollection 2024 Jan. PMID: 38282689

An ensemble docking-based virtual screening and molecular dynamics simulation of phytochemical compounds from Malaysian Kelulut Honey (KH) against SARS-CoV-2 target enzyme, human angiotensin-converting enzyme 2 (ACE-2).
Ismail CMKH, Abdul Hamid AA, Abdul Rashid NN, Lestari W, Mokhtar KI, Mustafa Alahmad BE, Abd Razak MRM, Ismail A. J Biomol Struct Dyn. 2024 Jan 27:1-30. doi: 10.1080/07391102.2024.2308762. Online ahead of print. PMID: 38279932

Navigating the infodemic: A qualitative study of university students' information strategies during the COVID-19 pandemic.

Gies L, Gogoi M, Bayliss CD, Pareek M, Webb A. Digit Health. 2024 Jan 30;10:20552076241228695. doi: 10.1177/20552076241228695. eCollection 2024 Jan-Dec. PMID: 38298526

Campesterol and dithymoquinone as a potent inhibitors of SARS cov-2 main proteases-promising drug candidates for targeting its novel variants.
Algaissi A, Khan E, Tabassum H, Samreen S, Khamjan NA, Lohani M, Khan S, Kameli N, Madkhali F, Ahmad IZ. J Biomol Struct Dyn. 2024 Jan 30:1-15. doi: 10.1080/07391102.2023.2301684. Online ahead of print. PMID: 38288958

Exploring Hollow Mesoporous Silica Nanoparticles as a Nanocarrier in the Delivery of Foot-And-Mouth Disease Virus-like Particle Vaccines.
Ru J, Chen Y, Tao S, Du S, Liang C, Teng Z, Gao Y. ACS Appl Bio Mater. 2024 Jan 29. doi: 10.1021/acsabm.3c01015. Online ahead of print. PMID: 38286026

Plant stanol consumption increases anti-COVID-19 antibody responses, independent of changes in serum cholesterol concentrations: a randomized controlled trial.
van Brakel L, Mensink RP, Lütjohann D, Plat J. Am J Clin Nutr. 2024 Jan 24:S0002-9165(24)00050-9. doi: 10.1016/j.ajcnut.2024.01.017. Online ahead of print. PMID: 38278364

Bivalent mRNA vaccine effectiveness against COVID-19 among older adults in Japan: a test-negative study from the VENUS study.
Tamada Y, Takeuchi K, Kusama T, Maeda M, Murata F, Osaka K, Fukuda H. BMC Infect Dis. 2024 Jan 29;24(1):135. doi: 10.1186/s12879-024-09035-3. PMID: 38287337

Safety, Tolerability and Immunogenicity of a mRNA-based RSV Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial.
Shaw CA, Mithani R, Kapoor A, Dhar R, Wilson L, El Asmar L, Schnyder-Ghamloush S, Schaefers K, August A, Stoszek SK, Chen GL. J Infect Dis. 2024 Jan 31:jiae035. doi: 10.1093/infdis/jiae035. Online ahead of print. PMID: 38298125

Drug use during the second year of the COVID-19 pandemic: observations from repeated cross-sectional surveys of sexual minority men in the US active on social networking applications.
Starks TJ, Hillesheim JR, Castiblanco J, Cain D, Stephenson R. AIDS Care. 2024 Jan 30:1-9. doi: 10.1080/09540121.2024.2308738. Online ahead of print. PMID: 38289592

In vivo antiviral efficacy of LCTG-002, a pooled, purified human milk secretory IgA product, against SARS-CoV-2 in a murine model of COVID-19.
Mane V, Mehta R, Alvarez N, Sharma V, Park S, Fox A, DeCarlo C, Yang X, Perlin DS, Powell RLR. Hum Vaccin Immunother. 2024 Dec 31;20(1):2303226. doi: 10.1080/21645515.2024.2303226. Epub 2024 Jan 22. PMID: 38251677

RSV vaccines administered in error to infants and pregnant people, CDC reports.
Boytchev H. BMJ. 2024 Jan 29;384:q236. doi: 10.1136/bmj.q236. PMID: 38286481

Prediction of linear B-cell epitopes based on protein sequence features and BERT embeddings.
Liu F, Yuan C, Chen H, Yang F. Sci Rep. 2024 Jan 30;14(1):2464. doi: 10.1038/s41598-024-53028-w. PMID: 38291341

DEEPOMICS FFPE, a deep neural network model, identifies DNA sequencing artifacts from formalin fixed paraffin embedded tissue with high accuracy.
Heo DH, Kim I, Seo H, Kim SG, Kim M, Park J, Park H, Kang S, Kim J, Paik S, Hong SE. Sci Rep. 2024 Jan 31;14(1):2559. doi: 10.1038/s41598-024-53167-0. PMID: 38297116

A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient.
Schober GB, Story S, Arya DP. Sci Rep. 2024 Jan 29;14(1):2403. doi: 10.1038/s41598-024-52685-1. PMID: 38287070

The U.S. COVID-19 vaccination program: A look back and future directions.
Hall E, Mahon BE, Peacock G. Vaccine. 2024 Jan 26:S0264-410X(24)00065-3. doi: 10.1016/j.vaccine.2024.01.053. Online ahead of print. PMID: 38280828

IL-17 and IFN-γ-producing respiratory tissue resident memory CD4 T cells persist for decades in adults immunized as children with whole cell pertussis vaccines.
McCarthy KN, Hone S, McLoughlin RM, Mills KHG. J Infect Dis. 2024 Jan 30:jiae034. doi: 10.1093/infdis/jiae034. Online ahead of print. PMID: 38290045

The life-long protective immunity of yellow fever vaccination: time to review?
Juan-Giner A, Hombach J. Lancet Glob Health. 2024 Jan 22:S2214-109X(23)00594-6. doi: 10.1016/S2214-109X(23)00594-6. Online ahead of print. PMID: 38272045

Long-term protection conferred by typhoid conjugate vaccines: a step towards typhoid elimination?
Tadesse BT, Cardona RSB, Marks F. Lancet. 2024 Jan 25:S0140-6736(23)02350-4. doi: 10.1016/S0140-6736(23)02350-4. Online ahead of print. PMID: 38281498

Global-PPS targets for antimicrobial stewardship in paediatric patients at hospitals in Sanandaj, western Iran, benchmarked with South-East Asian and European hospitals.
Soltani J, Behzadi S, Pauwels I, Goossens H, Versporten A; Global-PPS Group Members. J Glob Antimicrob Resist. 2024 Jan 25:S2213-7165(24)00018-3. doi: 10.1016/j.jgar.2024.01.011. Online ahead of print. PMID: 38280720

The memory B cell response to influenza vaccination is impaired in older persons.
Burton AR, Guillaume SM, Foster WS, Wheatley AK, Hill DL, Carr EJ, Linterman MA. Cell Rep. 2024 Jan 27;43(2):113745. doi: 10.1016/j.celrep.2024.113745. Online ahead of print. PMID: 38281131

Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells.
Yang XY, Liu T, Jiang SC, Zhang ZW, Fu YF, Li ZL, Hu J, Yuan S. Vaccine. 2024 Jan 27:S0264-410X(24)00099-9. doi: 10.1016/j.vaccine.2024.01.074. Online ahead of print. PMID: 38281898

A digital image colorimetry system based on smart devices for immediate and simultaneous determination of enzyme-linked immunosorbent assays.
Mirhosseini S, Nasiri AF, Khatami F, Mirzaei A, Aghamir SMK, Kolahdouz M. Sci Rep. 2024 Jan 31;14(1):2587. doi: 10.1038/s41598-024-52931-6. PMID: 38297148

Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
Takalani A, Robinson M, Jonas P, Bodenstein A, Sambo V, Jacobson B, Louw V, Opie J, Peter J, Rowji P, Seocharan I, Reddy T, Yende-Zuma N, Khutho K, Sanne I, Bekker LG, Gray G, Garrett N, Goga A; Sisonke Study Team. Vaccine. 2024 Jan 25:S0264-410X(24)00078-1. doi: 10.1016/j.vaccine.2024.01.066. Online ahead of print. PMID: 38278629

Booster vaccination: host preparation against Omicron challenge by innate immunity training.
Bai L, Zhou F, Zhang L. MedComm (2020). 2024 Jan 30;5(2):e477. doi: 10.1002/mco2.477. eCollection 2024 Feb. PMID: 38292329

Less is more: uptake of recommended vaccines in a UK Travel Clinic.
Harrison T, Clark J, Darton TC. J Infect. 2024 Jan 25:S0163-4453(24)00027-6. doi: 10.1016/j.jinf.2024.01.008. Online ahead of print. PMID: 38280681

Household environment associated with anaemia among children aged 6-59 months in Ethiopia: a multilevel analysis of Ethiopia demographic and health survey (2005-2016).
Sahiledengle B, Mwanri L, Agho KE. BMC Public Health. 2024 Jan 29;24(1):315. doi: 10.1186/s12889-024-17780-y. PMID: 38287295

Vector-Control Potential of Unani Medicines: A Review of Classical Unani Texts and Contemporary Scientific Literature.
Shahabuddin F, Itrat M, Kumar S. J Vector Borne Dis. 2024 Jan 29. doi: 10.4103/JVBD.JVBD_173_23. Online ahead of print. PMID: 38287745

De Novo Vitiligo Following Covid-19 Infection and Vaccination: A Door Open to Future Events?
Mormile R. Arch Med Res. 2024 Jan 30;55(2):102961. doi: 10.1016/j.arcmed.2024.102961. Online ahead of print. PMID: 38295468

Measles outbreaks: Investing in patient relationships through GP continuity will be key to boosting MMR confidence.
Wilkinson E. BMJ. 2024 Jan 29;384:q221. doi: 10.1136/bmj.q221. PMID: 38286475

Revealing Propolis Potential Activity on Inhibiting Estrogen Receptor and Heat Shock Protein 90 Overexpressed in Breast Cancer by Bioinformatics Approaches.
Simanjuntak MV, Jauhar MM, Syaifie PH, Arda AG, Mardliyati E, Shalannanda W, Hermanto BR, Anshori I. Bioinform Biol Insights. 2024 Jan 24;18:11779322231224187. doi: 10.1177/11779322231224187. eCollection 2024. PMID: 38274992

"Everything has changed since COVID": Ongoing challenges faced by Canadian adults with intellectual disabilities during waves 2 and 3 of the COVID-19 pandemic.
Safar Y, Formuli F, Volpe T, St John L, Lunsky Y. J Intellect Disabil. 2024 Jan 24:17446295241229364. doi: 10.1177/17446295241229364. Online ahead of print. PMID: 38266144

Should Patients be Required to Receive COVID Vaccine to be Listed for Kidney Transplant?: COMMENTARY.

Joachim E, Djamali A. Kidney360. 2024 Jan 26. doi: 10.34067/KID.0000000000000329. Online ahead of print. PMID: 38279676

Should Patients Be Required to Receive COVID Vaccine to Be Listed for Kidney Transplant?: PRO.
Smith L. Kidney360. 2024 Jan 26. doi: 10.34067/KID.0000000000000324. Online ahead of print. PMID: 38279678

Should Patients be Required to Receive COVID Vaccine to be Listed for Kidney Transplant?: CON.
Warfield C. Kidney360. 2024 Jan 26. doi: 10.34067/KID.0000000000000378. Online ahead of print. PMID: 38277242

Author Correction: Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice.
Homma T, Nagata N, Hashimoto M, Iwata-Yoshikawa N, Seki NM, Shiwa-Sudo N, Ainai A, Dohi K, Nikaido E, Mukai A, Ukai Y, Nakagawa T, Shimo Y, Maeda H, Shirai S, Aoki M, Sonoyama T, Sato M, Fumoto M, Nagira M, Nakata F, Hashiguchi T, Suzuki T, Omoto S, Hasegawa H. Sci Rep. 2024 Jan 31;14(1):2599. doi: 10.1038/s41598-024-52772-3. PMID: 38297027

Aged AG129 mice support the generation of highly virulent novel mouse-adapted DENV (1-4) viruses exhibiting neuropathogenesis and high lethality.
Siddqui G, Vishwakarma P, Saxena S, Kumar V, Bajpai S, Kumar A, Kumar S, Khatri R, Kaur J, Bhattacharya S, Ahmed S, Syed GH, Kumar Y, Samal S. Virus Res. 2024 Jan 30;341:199331. doi: 10.1016/j.virusres.2024.199331. Online ahead of print. PMID: 38280436

Correction to: Minimal effects from injunctive norm and contentiousness treatments on COVID-19 vaccine intentions: evidence from 3 countries.
[No authors listed] PNAS Nexus. 2024 Jan 30;3(1):pgad458. doi: 10.1093/pnasnexus/pgad458. eCollection 2024 Jan. PMID: 38292543

Structure-aware deep model for MHC-II peptide binding affinity prediction.
Yu Y, Zu L, Jiang J, Wu Y, Wang Y, Xu M, Liu Q. BMC Genomics. 2024 Jan 30;25(1):127. doi: 10.1186/s12864-023-09900-6. PMID: 38291350

Outcomes of SARS-CoV-2 Omicron infection in vaccinated children with asthma versus matched controls: A nationwide population-based study.
Wee LE, Tan JYJ, Chiew CJ, Lye DCB, Tan KB. Pediatr Pulmonol. 2024 Jan 30. doi: 10.1002/ppul.26893. Online ahead of print. PMID: 38289098

Author Correction: Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Qβ virus-like particles.
Carboni F, Cozzi R, Romagnoli G, Tuscano G, Balocchi C, Buffi G, Bodini M, Brettoni C, Giusti F, Marchi S, Brogioni G, Brogioni B, Cinelli P, Cappelli L, Nocciolini C, Senesi S, Facciotti C, Frigimelica E, Fabbrini M, Stranges D, Savino S, Maione D, Adamo R, Wizel B, Margarit I, Romano MR. NPJ Vaccines. 2024 Jan 25;9(1):19. doi: 10.1038/s41541-024-00808-0. PMID: 38272903

Distinct transcriptomic signatures define febrile malaria depending on initial infective states, asymptomatic or uninfected.

Kimenyi KM, Akinyi MY, Mwikali K, Gilmore T, Mwangi S, Omer E, Gichuki B, Wambua J, Njunge J, Obiero G, Bejon P, Langhorne J, Abdi A, Ochola-Oyier LI. BMC Infect Dis. 2024 Jan 29;24(1):140. doi: 10.1186/s12879-024-08973-2. PMID: 38287287

Analysis of related factors of plasma antibody levels in patients with severe and critical COVID-19.
Xie Y, Xia Y, Xu H, Wang J, Zhang W, Li L, Liu Z. Sci Rep. 2024 Jan 31;14(1):2581. doi: 10.1038/s41598-024-52572-9. PMID: 38297067

Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study.
Lo CKL, Lo CKF, Komorowski AS, Leung V, Matic N, McKenna S, Perez-Patrigeon S, Sheth PM, Lowe CF, Chagla Z, Bai AD. BMC Res Notes. 2024 Jan 24;17(1):37. doi: 10.1186/s13104-024-06695-x. PMID: 38267971

Urgent need for lived experience in hepatitis B guideline development.
Freeland C, Lo W, Kabagambe K, Wang S, Adda D, Graham CS, Gish R, Cohen C. Lancet Gastroenterol Hepatol. 2024 Jan 22:S2468-1253(23)00455-7. doi: 10.1016/S2468-1253(23)00455-7. Online ahead of print. PMID: 38272054

Correction to: Social media behavior is associated with vaccine hesitancy.
[No authors listed] PNAS Nexus. 2024 Jan 30;3(1):pgad471. doi: 10.1093/pnasnexus/pgad471. eCollection 2024 Jan. PMID: 38292558

Hybrid immunity to SARS-CoV-2 during pregnancy provides more durable infant antibody responses compared to natural infection or vaccination alone.
LaCourse SM, Wetzler EA, Aurelio MC, Escudero JN, Selke SS, Greninger AL, Goecker EA, Barnes SR, Arnould IS, Pérez-Osorio AC, Richardson BA, Kachikis A, Englund JA, Drake AL. J Infect Dis. 2024 Jan 29:jiae046. doi: 10.1093/infdis/jiae046. Online ahead of print. PMID: 38285008

Development of a potent recombinant scFv antibody against the SARS-CoV-2 by in-depth bioinformatics study: Paving the way for vaccine/diagnostics development.
Yaghoobizadeh F, Roayaei Ardakani M, Ranjbar MM, Khosravi M, Galehdari H. Comput Biol Med. 2024 Jan 28;170:108091. doi: 10.1016/j.compbiomed.2024.108091. Online ahead of print. PMID: 38295473

Mycoplasma mycoides subspecies capri, an uncommon mastitis and respiratory pathogen isolated in a German flock of goats.
Wagner H, Heller M, Fawzy A, Schnee C, Nesseler A, Kaim U, Ewers C, Semmler T, Spergser J, Schultze T, Eisenberg T. Vet Microbiol. 2024 Jan 24;290:109996. doi: 10.1016/j.vetmic.2024.109996. Online ahead of print. PMID: 38295490

Correction: A conformational epitope in placental malaria vaccine antigen VAR2CSA: What does it teach us?
Doritchamou JYA, Renn JP, Hviid L, Duffy PE. PLoS Pathog. 2024 Jan 29;20(1):e1011503. doi: 10.1371/journal.ppat.1011503. eCollection 2024 Jan. PMID: 38285967

Identification of four genes responsible for antimicrobial resistance of MEL-B against S. aureus.
Yamauchi S, Shimoda S, Kawahara A, Sugahara T, Yamamoto S, Kitabayashi M, Sogabe A, Jansen CA, Tobe R, Hirakawa R, Islam J, Furukawa M, Yoneyama H, Nochi T. Biochem Biophys Res Commun. 2024 Jan 23;699:149566. doi: 10.1016/j.bbrc.2024.149566. Online ahead of print. PMID: 38290176

Author Correction: Developing a prediction model to estimate the true burden of respiratory syncytial virus (RSV) in hospitalised children in Western Australia.
Gebremedhin AT, Hogan AB, Blyth CC, Glass K, Moore HC. Sci Rep. 2024 Jan 29;14(1):2411. doi: 10.1038/s41598-024-52791-0. PMID: 38286849

Surgical Resection Delays among Patients with Stage 1 Lung Cancer: A Study with Disaggregated Ethnic Groups.
Kazzi B, Mankuzhy NP, Swami N, Jain B, Patel TA, Chan JSK, Lam MB, Tian S, Dee EC. Ann Surg Oncol. 2024 Jan 28. doi: 10.1245/s10434-024-14952-3. Online ahead of print. PMID: 38282026

Correction: Evaluating adherence to government recommendations for post-exposure rabies vaccine among animal-bite victims: A hospital-based study in Bangladesh.
Tamanna S, Yasmin D, Ghosh S, Rahaman MM, Dey AK, Das TK, Chowdhury S. PLOS Glob Public Health. 2024 Jan 31;4(1):e0002909. doi: 10.1371/journal.pgph.0002909. eCollection 2024. PMID: 38295037

Corrigendum to "3C^{pro} of FMDV inhibits type II interferon-stimulated JAK-STAT signaling pathway by blocking STAT1 nuclear translocation" [Virol Sin 38 (2023) 387-397].
Wu X, Chen L, Sui C, Hu Y, Jiang D, Yang F, Miller LC, Li J, Cong X, Hrabchenko N, Lee C, Du Y, Qi J. Virol Sin. 2024 Jan 27:S1995-820X(23)00160-8. doi: 10.1016/j.virs.2023.12.007. Online ahead of print. PMID: 38281821

Recent Advances in Photoinduced Modification of Amino Acids, Peptides, and Proteins.
De Jesus IS, Vélez JAC, Pissinati EF, Correia JTM, Rivera DG, Paixao MW. Chem Rec. 2024 Jan 26:e202300322. doi: 10.1002/tcr.202300322. Online ahead of print. PMID: 38279622

PRRSV degrades MDA5 via dual autophagy receptors P62 and CCT2 to evade antiviral innate immunity.
Sun R, Guo Y, Zhang L, Zhang H, Yin B, Li X, L C, Yang L, Zhang L, Li Z, Huang J. Virol Sin. 2024 Jan 23:S1995-820X(24)00005-1. doi: 10.1016/j.virs.2024.01.005. Online ahead of print. PMID: 38272236

Laparoscopic partial splenectomy in distal pancreatectomy may preserve splenic function.
Bell-Allen N, McNamara A, Bull N, Lewin J, O'Rourke N. ANZ J Surg. 2024 Jan 22. doi: 10.1111/ans.18880. Online ahead of print. PMID: 38251818

The Reasoning through Evidence versus Advice (EvA) Scale: Scale Development and Validation.
Shin H, Shah P, Preston SD. J Pers Assess. 2024 Jan 25:1-15. doi: 10.1080/00223891.2023.2297266. Online ahead of print. PMID: 38271474

Epidemiology of Pertussis and Pertussis-Related Complications in Adults: A German Claims Data Analysis.

Surmann B, Witte J, Batram M, Criée CP, Hermann C, Leischker A, Schelling J, Steinmüller M, Wahle K, Heiseke AF, Marijic P. Infect Dis Ther. 2024 Jan 31. doi: 10.1007/s40121-023-00912-z. Online ahead of print. PMID: 38294623

Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus.
Cross RW, Fenton KA, Woolsey C, Prasad AN, Borisevich V, Agans KN, Deer DJ, Dobias NS, Fears AC, Heinrich ML, Geisbert JB, Garry RF, Branco LM, Geisbert TW. Cell Rep Med. 2024 Jan 23:101392. doi: 10.1016/j.xcrm.2024.101392. Online ahead of print. PMID: 38280377

Implementation strategies of cervical cancer screening in South Asia: A systematic review.
Sabeena S, Ravishankar N, Kalpana MM. Int J Gynaecol Obstet. 2024 Jan 24. doi: 10.1002/ijgo.15366. Online ahead of print. PMID: 38268412

Novel 2-indolinone derivatives as promising agents against respiratory syncytial and yellow fever viruses.
Apaydın ÇB, Göktaş F, Naesens L, Karalı N. Future Med Chem. 2024 Jan 30. doi: 10.4155/fmc-2023-0179. Online ahead of print. PMID: 38288568

Social care data in the UK; current landscape, challenges, and future recommendations.
Mendes D, Wood R, Seif M, Collings SL. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb;24(2):303-314. doi: 10.1080/14737167.2023.2274843. Epub 2024 Jan 25. PMID: 38272069

In vivo functional phenotypes from a computational epistatic model of evolution.
Alvarez S, Nartey CM, Mercado N, de la Paz JA, Huseinbegovic T, Morcos F. Proc Natl Acad Sci U S A. 2024 Feb 6;121(6):e2308895121. doi: 10.1073/pnas.2308895121. Epub 2024 Jan 29. PMID: 38285950

Prevalence of Influenza Viruses A and B, Adenovirus, Respiratory Syncytial Virus, and Human Metapneumonia Viruses among Children with Acute Respiratory Tract Infection.
Farzi R, Pirbonyeh N, Kadivar MR, Moattari A. Adv Virol. 2024 Jan 22;2024:7613948. doi: 10.1155/2024/7613948. eCollection 2024. PMID: 38292215

Implementation of an Awareness Level Training to Prepare the Workforce for Future Infectious Disease Outbreaks.
Workman B, Fulk F, Carreón T, Nabors L. Disaster Med Public Health Prep. 2024 Jan 30;18:e9. doi: 10.1017/dmp.2024.10. PMID: 38287864

Profile of hospitalised maltreated children aged 0 to 3 years and their families.
Kwan R, Abraham S, Low WCJ, Lim JCY, Chong WH, Mun SBS, Oh JY, Chay OM, Yeleswarapu SP. Singapore Med J. 2024 Jan 23. doi: 10.4103/singaporemedj.SMJ-2022-052. Online ahead of print. PMID: 38263550

Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs.
Zhao Q, Zong H, Zhu P, Su C, Tang W, Chen Z, Jin S. Exp Hematol Oncol. 2024 Jan 22;13(1):6. doi: 10.1186/s40164-024-00474-x. PMID: 38254219

Clinical profile and outcomes of tetanus patients in a tertiary hospital in the Philippines: a ten-year retrospective study.

Lanuza PDT, Garcia JJB, Turalde CWR, Prado MJB. BMC Infect Dis. 2024 Jan 29;24(1):142. doi: 10.1186/s12879-024-09037-1. PMID: 38287272

Family Medicine Team Perspectives on Screening for Health-Related Social Needs.
Porterfield L, Jan QH, Jones F, Cao T, Davis L, Guillot-Wright S, Walcher CM. J Am Board Fam Med. 2024 Jan 25:jabfm.2023.230167R3. doi: 10.3122/jabfm.2023.230167R3. Online ahead of print. PMID: 38272534

ppmFixer: a mass error adjustment for pGlyco3.0 to correct near-isobaric mismatches.
Adams TM, Zhao P, Kong R, Wells L. Glycobiology. 2024 Jan 23:cwae006. doi: 10.1093/glycob/cwae006. Online ahead of print. PMID: 38263491

MicroRNA-22-3p displaces critical host factors from the 5' UTR and inhibits the translation of Coxsackievirus B3 RNA.
Rani P, George B, V S, Biswas S, V M, Pal A, Rajmani RS, Das S. J Virol. 2024 Jan 30:e0150423. doi: 10.1128/jvi.01504-23. Online ahead of print. PMID: 38289119

Anti-COVID-19 Potential of Withaferin-A and Caffeic Acid Phenethyl Ester.
Kumar V, Sari AN, Gupta D, Ishida Y, Terao K, Kaul SC, Vrati S, Sundar D, Wadhwa R. Curr Top Med Chem. 2024 Jan 24. doi: 10.2174/0115680266280720231221100004. Online ahead of print. PMID: 38279743

Unveiling the role of host kinases at different steps of influenza A virus life cycle.
Dey S, Mondal A. J Virol. 2024 Jan 23;98(1):e0119223. doi: 10.1128/jvi.01192-23. Epub 2024 Jan 4. PMID: 38174932

Comparison of Different Vascular Biomarkers for Predicting In-Hospital Mortality in Severe SARS-CoV-2 Infection.
Sütő R, Pócsi M, Fagyas M, Kalina E, Fejes Z, Szentkereszty Z, Kappelmayer J, Nagy B Jr. Microorganisms. 2024 Jan 22;12(1):229. doi: 10.3390/microorganisms12010229. PMID: 38276214

Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
Bogacheva MS, Kuivanen S, Potdar S, Hassinen A, Huuskonen S, Pöhner I, Luck TJ, Turunen L, Feodoroff M, Szirovicza L, Savijoki K, Saarela J, Tammela P, Paavolainen L, Poso A, Varjosalo M, Kallioniemi O, Pietiäinen V, Vapalahti O. Antiviral Res. 2024 Jan 23:105813. doi: 10.1016/j.antiviral.2024.105813. Online ahead of print. PMID: 38272320

Clinical characteristics and outcomes of patients admitted with COVID-19 at a public-sector hospital over the first two waves of SARS-CoV-2 infection in Harare, Zimbabwe: A prospective cohort study.
Fryatt A, Chivandire T, Simms V, Chikide P, Munorwa T, Simon E, Sigwadhi LN, Kranzer K, Magure TM, Maunganidze A, Katsidzira L, Ferrand RA. PLOS Glob Public Health. 2024 Jan 25;4(1):e0001100. doi: 10.1371/journal.pgph.0001100. eCollection 2024. PMID: 38271476

Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus.

Salem GM, Galula JU, Wu SR, Liu JH, Chen YH, Wang WH, Wang SF, Song CS, Chen FC, Abarientos AB, Chen GW, Wang CY, Chao DY. Commun Biol. 2024 Jan 24;7(1):15. doi: 10.1038/s42003-023-05661-w. PMID: 38267569

Decidual-tissue-resident memory T cells protect against nonprimary human cytomegalovirus infection at the maternal-fetal interface.
Alfi O, Cohen M, Bar-On S, Hashimshony T, Levitt L, Raz Y, Blecher Y, Chaudhry MZ, Cicin-Sain L, Ben-El R, Oiknine-Djian E, Lahav T, Vorontsov O, Cohen A, Zakay-Rones Z, Daniel L, Berger M, Mandel-Gutfreund Y, Panet A, Wolf DG. Cell Rep. 2024 Jan 23;43(2):113698. doi: 10.1016/j.celrep.2024.113698. Online ahead of print. PMID: 38265934

COVID-19 Reinfection Has Better Outcomes Than the First Infection in Solid Organ Transplant Recipients.
Solera JT, Árbol BG, Mittal A, Hall VG, Marinelli T, Bahinskaya I, Humar A, Kumar D. Transplantation. 2024 Jan 31. doi: 10.1097/TP.0000000000004902. Online ahead of print. PMID: 38291585

All-cause excess mortality among end-stage renal disease (ESRD) patients during the COVID-19 pandemic in Thailand: a cross-sectional study from a national-level claims database.
Jirapanakorn S, Witthayapipopsakul W, Kusreesakul K, Lakhotia D, Tangcharoensathien V, Suphanchaimat R. BMJ Open. 2024 Jan 25;14(1):e081383. doi: 10.1136/bmjopen-2023-081383. PMID: 38272543

Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.
Gaballa SA, Shimizu T, Takata H, Ando H, Ibrahim M, Emam SE, Amorim Matsuo NC, Kim Y, Naguib YW, Mady FM, Khaled KA, Ishida T. Mol Pharm. 2024 Jan 25. doi: 10.1021/acs.molpharmaceut.3c00774. Online ahead of print. PMID: 38273445

Artificial Intelligence Approach for Severe Dengue Early Warning System.
Anggraini Ningrum DN, Li YJ, Hsu CY, Solihuddin Muhtar M, Pandu Suhito H. Stud Health Technol Inform. 2024 Jan 25;310:881-885. doi: 10.3233/SHTI231091. PMID: 38269935

Ivermectin antiviral activity against Varicellovirus bovinealpha 1: assessment of intracellular drug accumulation in virus-infected cells.
Pérez S, Miró MV, Verna A, Altamiranda EG, Barcos O, Lanusse C, Lifschitz A. Arch Microbiol. 2024 Jan 26;206(2):78. doi: 10.1007/s00203-023-03806-3. PMID: 38277061

Impact of Ebola and COVID-19 on maternal, neonatal, and child health care among populations affected by conflicts: a scoping review exploring demand and supply-side barriers and solutions.
Shafiq Y, Rubini E, Fazal ZZ, Bukhari MM, Zakaria M, Zeeshan NUH, Muhammad A, Ragazzoni L, Barone-Adesi F, Valente M. Confl Health. 2024 Jan 30;18(1):12. doi: 10.1186/s13031-024-00572-x. PMID: 38291492

Culturable yeast diversity in urban topsoil influenced by various anthropogenic impacts.
Glushakova A, Tepeeva A, Prokof'eva T, Kachalkin A. Int Microbiol. 2024 Jan 23. doi: 10.1007/s10123-024-00482-1. Online ahead of print. PMID: 38263536

Impact of Invasive Escherichia Coli Disease on Clinical Outcomes and Medical Resource Utilization Among Asian Patients in the United States.
Zhuo C, Zheng B, Wattanakamolkul K, Nakayama Y, Cloutier M, Gauthier-Loiselle M, Feng J, Wu D, Neary MP, Geurtsen J, El Khoury AC, Gu Y. Infect Dis Ther. 2024 Jan 24. doi: 10.1007/s40121-023-00911-0. Online ahead of print. PMID: 38265627

Porcine epidemic diarrhea virus strain CH/HLJ/18 isolated in China: characterization and phylogenetic analysis.
Guo Y, Sui L, Kong D, Liu D, Gao Y, Jiang Y, Cui W, Li J, Li Y, Wang L. Virol J. 2024 Jan 24;21(1):28. doi: 10.1186/s12985-023-02233-6. PMID: 38268010

Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications.
Dhayalan M, Wang W, Riyaz SUM, Dinesh RA, Shanmugam J, Irudayaraj SS, Stalin A, Giri J, Mallik S, Hu R. 3 Biotech. 2024 Feb;14(2):57. doi: 10.1007/s13205-023-03901-8. Epub 2024 Jan 29. PMID: 38298556

Risk factor associations for severe COVID-19, influenza and pneumonia in people with diabetes to inform future pandemic preparations: UK population-based cohort study.
Hopkins R, Young KG, Thomas NJ, Godwin J, Raja D, Mateen BA, Challen RJ, Vollmer SJ, Shields BM, McGovern AP, Dennis JM. BMJ Open. 2024 Jan 31;14(1):e078135. doi: 10.1136/bmjopen-2023-078135. PMID: 38296292

Yellow fever virus infection in human hepatocyte cells triggers an imbalance in redox homeostasis with increased reactive oxygen species production, oxidative stress, and decreased antioxidant enzymes.
Coelho Ferraz A, Bueno da Silva Menegatto M, Lameira Souza Lima R, Samuel Ola-Olub O, Caldeira Costa D, Carlos de Magalhães J, Maurício Rezende I, Desiree LaBeaud A, P Monath T, Augusto Alves P, Teixeira de Carvalho A, Assis Martins-Filho O, P Drumond B, Magalhães CLB. Free Radic Biol Med. 2024 Jan 24;213:266-273. doi: 10.1016/j.freeradbiomed.2024.01.042. Online ahead of print. PMID: 38278309

What is next for BCG revaccination to prevent tuberculosis?
White RG, Fiore-Gartland AJ, Hanekom WA, Vekemans J, Garcia-Basteiro AL, Churchyard G, Rangaka MX, Frick M, Behr MA, Hill PC, Mave V. Lancet Respir Med. 2024 Jan 22:S2213-2600(24)00009-2. doi: 10.1016/S2213-2600(24)00009-2. Online ahead of print. PMID: 38272048

From obscurity to urgency: a comprehensive analysis of the rising threat of duck circovirus.
Lei X, Wang A, Zhu S, Wu S. Vet Res. 2024 Jan 26;55(1):12. doi: 10.1186/s13567-024-01265-2. PMID: 38279181

Clinical human metapneumovirus isolates show distinct pathogenesis and inflammatory profiles but similar CD8$^+$ T cell impairment.
Sojati J, Zhang Y, Williams JV. mSphere. 2024 Jan 30;9(1):e0057023. doi: 10.1128/msphere.00570-23. Epub 2024 Jan 10. PMID: 38197640

A 6-month exercise intervention clinical trial in women: effects of physical activity on multi-omics biomarkers and health during the first wave of COVID-19 in Korea.
Park J, Kim J, Kang J, Choi J, Kim JE, Min KJ, Choi SW, Cho JY, Lee M, Choi JY. BMC Sports Sci Med Rehabil. 2024 Jan 29;16(1):30. doi: 10.1186/s13102-024-00824-6. PMID: 38287431

Global health concern on the rising dengue and chikungunya cases in the American regions: Countermeasures and preparedness.
Mohapatra RK, Bhattacharjee P, Desai DN, Kandi V, Sarangi AK, Mishra S, Sah R, Ibrahim AAA, Rabaan AA, Zahan KE. Health Sci Rep. 2024 Jan 24;7(1):e1831. doi: 10.1002/hsr2.1831. eCollection 2024 Jan. PMID: 38274135

Deep immunoglobulin repertoire sequencing depicts a comprehensive atlas of spike-specific antibody lineages shared among COVID-19 convalescents.
Yan Q, Zhang Y, Hou R, Pan W, Liang H, Gao X, Deng W, Huang X, Qu L, Tang C, He P, Liu B, Wang Q, Zhao X, Lin Z, Chen Z, Li P, Han J, Xiong X, Zhao J, Li S, Niu X, Chen L. Emerg Microbes Infect. 2024 Dec;13(1):2290841. doi: 10.1080/22221751.2023.2290841. Epub 2024 Jan 24. PMID: 38044868

Gardnerella Species and their Association with Bacterial Vaginosis.
Munch MM, Strenk SM, Srinivasan S, Fiedler TL, Proll S, Fredricks DN. J Infect Dis. 2024 Jan 24:jiae026. doi: 10.1093/infdis/jiae026. Online ahead of print. PMID: 38268121

Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics.
Yang H, Zeng X, Liu J, Wen X, Liu H, Liang Y, Wang X, Fang J, Zhang Q, Li J, Zhang X, Guo Z. Eur J Nucl Med Mol Imaging. 2024 Jan 22. doi: 10.1007/s00259-024-06610-3. Online ahead of print. PMID: 38246910

The spatial and single-cell analysis reveals remodeled immune microenvironment induced by synthetic oncolytic adenovirus treatment.
Liu G, Hu Q, Peng S, Ning H, Mai J, Chen X, Tao M, Liu Q, Huang H, Jiang Y, Ding Y, Zhang X, Gu J, Xie Z. Cancer Lett. 2024 Jan 28;581:216485. doi: 10.1016/j.canlet.2023.216485. Epub 2023 Nov 24. PMID: 38008394

Host factor MxA restricts Dabie bandavirus infection by targeting the viral NP protein to inhibit NP-RdRp interaction and ribonucleoprotein activity.
Chang M, Min Y-Q, Xu Z, Deng F, Wang H, Ning Y-J. J Virol. 2024 Jan 23;98(1):e0156823. doi: 10.1128/jvi.01568-23. Epub 2023 Dec 6. PMID: 38054738

Pseudorabies virus upregulates low-density lipoprotein receptors to facilitate viral entry.
Ma Y-X, Chai Y-J, Han Y-Q, Zhao S-B, Yang G-Y, Wang J, Ming S-L, Chu B-B. J Virol. 2024 Jan 23;98(1):e0166423. doi: 10.1128/jvi.01664-23. Epub 2023 Dec 6. PMID: 38054618

^{68}Ga-Labeled TMTP1 Modified with d-Amino Acid for Positron Emission Tomography Diagnosis of Highly Metastatic Hepatocellular Carcinoma.
Wang Y, Sun Y, Zeng X, Zhuang R, Huang J, Zhang X, Guo Z, Li Y. J Med Chem. 2024 Jan 25. doi: 10.1021/acs.jmedchem.3c02090. Online ahead of print. PMID: 38270637

Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants.
Clegg L, Freshwater E, Leach A, Villafana T, Hamrén UW. J Clin Pharmacol. 2024 Jan 31. doi: 10.1002/jcph.2401. Online ahead of print. PMID: 38294353

Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants.
Wang Y, Yan A, Song D, Duan M, Dong C, Chen J, Jiang Z, Gao Y, Rao M, Feng J, Zhang Z, Qi R, Ma X, Liu H, Yu B, Wang Q, Zong M, Jiao J, Xing P, Pan R, Li D, Xiao J, Sun J, Li Y, Zhang L, Shen Z, Sun B, Zhao Y, Zhang L, Dai J, Zhao J, Wang L, Dou C, Liu Z, Zhao J. Nat Commun. 2024 Jan 29;15(1):842. doi: 10.1038/s41467-024-45050-3. PMID: 38287016

Monitoring of hepatitis E virus in wastewater can identify clinically relevant variants.
Rau F, Elsner C, Meister TL, Gömer A, Kallies R, Dittmer U, Steinmann E, Todt D. Liver Int. 2024 Jan 30. doi: 10.1111/liv.15842. Online ahead of print. PMID: 38291853

Prevalence and Burden of Human Adenovirus-Associated Acute Respiratory Illness in the Republic of Korea Military, 2013 to 2022.
Kim D, Lee E, Eom J, Kim Y, Kwon SH, Oh HS, Huh K, Park H, Jung J, Park B. J Korean Med Sci. 2024 Jan 29;39(4):e38. doi: 10.3346/jkms.2024.39.e38. PMID: 38288539

Vitellin/Vitellogenin Is an Important Allergen in German Cockroach.
Hadiwinarta C, Blank A, Somers J, Schal C, Bronzert C, Sharma K, Strader MB, Hamilton RG, Slater JE. Int Arch Allergy Immunol. 2024 Jan 22:1-6. doi: 10.1159/000535935. Online ahead of print. PMID: 38253039

Identification of a broad sarbecovirus neutralizing antibody targeting a conserved epitope on the receptor-binding domain.
Wang Y, Zhang Z, Yang M, Xiong X, Yan Q, Cao L, Wei P, Zhang Y, Zhang L, Lv K, Chen J, Liu X, Zhao X, Xiao J, Zhang S, Zhu A, Gan M, Zhang J, Cai R, Zhuo J, Zhang Y, Rao H, Qu B, Zhang Y, Chen L, Dai J, Cheng L, Hu Q, Chen Y, Lv H, So RTY, Peiris M, Zhao J, Liu X, Mok CKP, Wang X, Zhao J. Cell Rep. 2024 Jan 23;43(1):113653. doi: 10.1016/j.celrep.2023.113653. Epub 2024 Jan 3. PMID: 38175758

Analysis of tweets discussing the risk of Mpox among children and young people in school (May-October 2022): a retrospective observational study.
Knudsen B, Høeg TB, Prasad V. BMJ Paediatr Open. 2024 Jan 31;8(1):e002236. doi: 10.1136/bmjpo-2023-002236. PMID: 38296602

Synthesis and biological activity of imidazole phenazine derivatives as potential inhibitors for NS2B-NS3 dengue protease.
Khalili NSD, Khawory MH, Salin NH, Zakaria II, Hariono M, Mikhaylov AA, Kamarulzaman EE, A Wahab H, Supratman U, Nurul Azmi M. Heliyon. 2024 Jan 8;10(2):e24202. doi: 10.1016/j.heliyon.2024.e24202. eCollection 2024 Jan 30. PMID: 38293469

Serine-rich repeat proteins: well-known yet little-understood bacterial adhesins.
Cinar MS, Niyas A, Avci FY. J Bacteriol. 2024 Jan 25;206(1):e0024123. doi: 10.1128/jb.00241-23. Epub 2023 Nov 17. PMID: 37975670

Purified diet affects intestinal epithelial proliferation and barrier functions through gut microbial alterations.
Shiratori H, Hattori KM, Nakata K, Okawa T, Komiyama S, Kinashi Y, Kabumoto Y, Kaneko Y, Nagai M, Shindo T, Moritoki N, Kawamura YI, Dohi T, Takahashi D, Kimura S, Hase K. Int Immunol. 2024 Jan 23:dxae003. doi: 10.1093/intimm/dxae003. Online ahead of print. PMID: 38262747

Comprehensive review of melatonin as a promising nutritional and nutraceutical supplement.
Kamfar WW, Khraiwesh HM, Ibrahim MO, Qadhi AH, Azhar WF, Ghafouri KJ, Alhussain MH, Aldairi AF, AlShahrani AM, Alghannam AF, Abdulal RH, Al-Slaihat AH, Qutob MS, Elrggal ME, Ghaith MM, Azzeh FS. Heliyon. 2024 Jan 8;10(2):e24266. doi: 10.1016/j.heliyon.2024.e24266. eCollection 2024 Jan 30. PMID: 38293391

Systems immunology of transcriptional responses to viral infection identifies conserved antiviral pathways across macaques and humans.
Ratnasiri K, Zheng H, Toh J, Yao Z, Duran V, Donato M, Roederer M, Kamath M, Todd JM, Gagne M, Foulds KE, Francica JR, Corbett KS, Douek DC, Seder RA, Einav S, Blish CA, Khatri P. Cell Rep. 2024 Jan 30;43(2):113706. doi: 10.1016/j.celrep.2024.113706. Online ahead of print. PMID: 38294906

Denonvilliers' fascia as a potential nerve-course marker for the female urinary bladder.
Chikazawa K, Muro S, Yamaguchi K, Imai K, Kuwata T, Konno R, Akita K. Gynecol Oncol. 2024 Jan 24;184:1-7. doi: 10.1016/j.ygyno.2024.01.025. Online ahead of print. PMID: 38271772

Exploring virulence factors of Helicobacter pylori isolated from gastric biopsy.
Javanbakhat P, Peeridogaheh H, Nemati R, Yazdanbod A, Teimourpour A, Sadeghnezhad M, Esmaelizad M, Teimourpour R. Mol Biol Rep. 2024 Jan 25;51(1):192. doi: 10.1007/s11033-023-09075-z. PMID: 38270789

Extensively Drug-Resistant Klebsiella pneumoniae Associated with Complicated Urinary Tract Infection in Northern India.
Kaza P, Xavier BB, Mahindroo J, Singh N, Baker S, Nguyen TNT, Mavuduru RS, Mohan B, Taneja N. Jpn J Infect Dis. 2024 Jan 24;77(1):7-15. doi: 10.7883/yoken.JJID.2023.009. Epub 2023 Aug 31. PMID: 37648492

The influence of fixation and cryopreservation of cerebrospinal fluid on antigen expression and cell percentages by flow cytometric analysis.
Singh G, van Laarhoven A, Adams R, Reid TD, Combrinck J, van Dorp S, Riou C, Thango N, Enslin J, Kruger S, Figaji AA, Rohlwink UK. Sci Rep. 2024 Jan 30;14(1):2463. doi: 10.1038/s41598-024-52669-1. PMID: 38291295

TiO_2 nanorod arrays@PDA/Ag with biomimetic polydopamine as binary mediators for duplex SERS detection of illegal food dyes.
Tan L, Cao Y, Yan J, Mao K, Liu L, Wang X, Ye W, Harris RA, Zhang H. Anal Chim Acta. 2024 Jan 25;1287:342047. doi: 10.1016/j.aca.2023.342047. Epub 2023 Nov 25. PMID: 38182363

Assessing the Redox Toxicity of 2D Nanosheets Based on Their Redox Effect on Cytochrome *c* in Microchannels.
Zhao L, Wang Q, Cui X, Li H, Zhao L, Wang Z, Zhou X, Wang X, Ma Z, Pu Q. Anal Chem. 2024 Jan 24. doi: 10.1021/acs.analchem.3c04062. Online ahead of print. PMID: 38266028

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group. Lancet Child Adolesc Health. 2024 Jan 22:S2352-4642(23)00316-4. doi: 10.1016/S2352-4642(23)00316-4. Online ahead of print. PMID: 38272046

International travel increases risk of urinary tract infection caused by extended-spectrum beta-lactamase-producing Enterobacterales-three-arm case-control study.
Patjas A, Martelius A, Ollgren J, Kantele A. J Travel Med. 2024 Jan 28;31(1):taad155. doi: 10.1093/jtm/taad155. PMID: 38123504

Two-step evolution of HIV-1 budding system leading to pandemic in the human population.
Konno Y, Uriu K, Chikata T, Takada T, Kurita JI, Ueda MT, Islam S, Yang Tan BJ, Ito J, Aso H, Kumata R, Williamson C, Iwami S, Takiguchi M, Nishimura Y, Morita E, Satou Y, Nakagawa S, Koyanagi Y, Sato K. Cell Rep. 2024 Jan 30;43(2):113697. doi: 10.1016/j.celrep.2024.113697. Online ahead of print. PMID: 38294901

Multidimensional Response Surface Methodology for the Development of a Gene Editing Protocol for p67^{phox}-Deficient Chronic Granulomatous Disease.
Whittaker TE, Moula SE, Bahal S, Bakri FG, Hayajneh WA, Daoud AK, Naseem A, Cavazza A, Thrasher AJ, Santilli G. Hum Gene Ther. 2024 Jan 24. doi: 10.1089/hum.2023.114. Online ahead of print. PMID: 38062734

Structural determination of *Rickettsia* lipid A without chemical extraction confirms shorter acyl chains in later-evolving spotted fever group pathogens.
Yang H, Verhoeve VI, Chandler CE, Nallar S, Snyder GA, Ernst RK, Gillespie JJ. mSphere. 2024 Jan 23:e0060923. doi: 10.1128/msphere.00609-23. Online ahead of print. PMID: 38259062

Implementation of bubble continuous positive airway pressure for children with severe pneumonia and hypoxemia in intensive care unit of Dhaka Hospital, Bangladesh-Effect on pneumonia mortality.
Chisti MJ, Clemens JD, K M S, Shahid ASMSB, Sarmin M, Afroze F, Shaly NJ, Kabir F, Rahman AE, El Arifeen S, Ahmed T, Duke T. Pediatr Pulmonol. 2024 Jan 24. doi: 10.1002/ppul.26881. Online ahead of print. PMID: 38265176

Individualized Antibiotic Plans as a Quality Improvement Initiative to Reduce Carbapenem Use for Hematopoietic Cell Transplant Patients at a Freestanding Pediatric Hospital.
Brothers AW, Pak DJ, Poole NM, Kronman MP, Bettinger B, Wilkes JJ, Carpenter PA, Englund JA, Weissman SJ. Clin Infect Dis. 2024 Jan 25;78(1):15-23. doi: 10.1093/cid/ciad518. PMID: 37647637

γδ T cell antigen receptor polyspecificity enables T cell responses to a broad range of immune challenges.
Guo J, Chowdhury RR, Mallajosyula V, Xie J, Dubey M, Liu Y, Li J, Wei YL, Palanski BA, Wang C, Qiu L, Ohanyan M, Kask O, Sola E, Kamalyan L, Lewis DB, Scriba TJ, Davis MM, Dodd D, Zeng X, Chien YH. Proc Natl Acad Sci U S A. 2024 Jan 23;121(4):e2315592121. doi: 10.1073/pnas.2315592121. Epub 2024 Jan 16. PMID: 38227652

Anti-rheumatic colchicine phytochemical exhibits potent antiviral activities against avian and seasonal Influenza A viruses (IAVs) via targeting different stages of IAV replication cycle.
Hegazy A, Soltane R, Alasiri A, Mostafa I, Metwaly AM, Eissa IH, Mahmoud SH, Allayeh AK, Shama NMA, Khalil AA, Barre RS, El-Shazly AM, Ali MA, Martinez-Sobrido L, Mostafa A. BMC Complement Med Ther. 2024 Jan 22;24(1):49. doi: 10.1186/s12906-023-04303-2. PMID: 38254071

Reported antibiotic use among patients in the multicenter ANDEMIA infectious diseases surveillance study in sub-saharan Africa.
Wieters I, Johnstone S, Makiala-Mandanda S, Poda A, Akoua-Koffi C, Abu Sin M, Eckmanns T, Galeone V, Kaboré FN, Kahwata F, Leendertz FH, Mputu B, Ouedraogo AS, Page N, Schink SB, Touré FS, Traoré A, Venter M, Vietor AC, Schubert G, Tomczyk S. Antimicrob Resist Infect Control. 2024 Jan 25;13(1):9. doi: 10.1186/s13756-024-01365-w. PMID: 38273333

Disparities in Stage at Presentation Among Hispanic and Latinx Patients With Non-Small-Cell Lung Cancer in the United States.
Dee EC, Swami N, Kazzi B, Lapen K, Franco I, Jain B, Patel TA, Mahal BA, Rimner A, Wu A, Iyengar P, Li B, Florez N, Gomez DR. JCO Oncol Pract. 2024 Jan 22:OP2300474. doi: 10.1200/OP.23.00474. Online ahead of print. PMID: 38252900

Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer.
Kashiro A, Kobayashi M, Oh T, Miyamoto M, Atsumi J, Nagashima K, Takeuchi K, Nara S, Hijioka S, Morizane C, Kikuchi S, Kato S, Kato K, Ochiai H, Obata D, Shizume Y, Konishi H, Nomura Y, Matsuyama K, Xie C, Wong C, Huang Y, Jung G, Srivastava S, Kutsumi H, Honda K. J Gastroenterol. 2024 Jan 23. doi: 10.1007/s00535-023-02072-w. Online ahead of print. PMID: 38261000

DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial.
Nampota-Nkomba N, Nyirenda OM, Mallewa J, Chimalizeni Y, Dzabala N, Fay MP, Gopalakrishnan M, Laurens MB, O'Brien NF, Miller LH, Pierce SK, Riggle BA, Postels DG. Trials. 2024 Jan 26;25(1):87. doi: 10.1186/s13063-023-07808-w. PMID: 38279124

Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features.
Juraska M, Bai H, deCamp AC, Magaret CA, Li L, Gillespie K, Carpp LN, Giorgi EE, Ludwig J, Molitor C, Hudson A, Williamson BD, Espy N, Simpkins B, Rudnicki E, Shao D, Rossenkhan R, Edlefsen PT, Westfall DH, Deng W, Chen L, Zhao H, Bhattacharya T, Pankow A, Murrell B, Yssel A, Matten D, York T, Beaume N, Gwashu-Nyangiwe A, Ndabambi N, Thebus R, Karuna ST, Morris L, Montefiori DC, Hural JA, Cohen MS, Corey L, Rolland M, Gilbert PB, Williamson C, Mullins JI. Proc Natl Acad Sci U S A. 2024 Jan 23;121(4):e2308942121. doi: 10.1073/pnas.2308942121. Epub 2024 Jan 19. PMID: 38241441

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20240122:20240131 as the publication date 39 records*

1.WO/2024/020545SYNTHETIC MODIFIED VACCINIA ANKARA VACCINES TO STIMULATE ORTHOPOX AND MONKEYPOX VIRUS IMMUNITY
WO - 25.01.2024
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/US2023/070704 Solicitante CITY OF HOPE Inventor/a DIAMOND, Don J.
Disclosed are methods of preventing or treating a *coronavirus* infection and a *poxvirus* infection in a subject by administration of a synthetic MVA-based vaccine.

2.20240024461VACCINE BOOSTER COMPOSITIONS FOR RESPIRATORY VIRAL DISEASES
US - 25.01.2024
Clasificación Internacional A61K 39/215 Nº de solicitud 18452741 Solicitante Centre for Virology, Vaccinology and Therapeutics Limited Inventor/a Kin Hang KOK
The present application provides chimeric proteins comprising comprising a receptor binding domain ("RBD") of a SARS-CoV-2 spike protein ("S protein") fused to a booster enhancer domain ("BED") and uses thereof as vaccine or vaccine booster compositions. Also provided are method of boostering SARS-CoV-2 vaccines by administering to a vaccinated individual an effective amount of the vaccine booster composition, wherein the vaccine booster composition comprises a spike protein or a fragment thereof, and optionally wherein the vaccine booster composition is administered intranasally.

3.WO/2024/017103COVID-19 BOOSTER VACCINE BASED ON SARS1 VIRUS.
WO - 25.01.2024
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/CN2023/106896 Solicitante BAYVAX BIOTECH LIMITED Inventor/a HUANG, Jiandong
A COVID-19 booster vaccine based on the SARS1 virus. The COVID-19 booster vaccine is a vaccine against the SARS1 virus, and is a boost vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Animal experiment results show that an additional boost injection against the SARS1 virus is superior to vaccines against a variety of SARS-CoV-2 strains (including virus strain, Delta strain and Omicron strain), and has a better effect in neutralization titer and neutralization spectrum. Therefore, the vaccine against the SARS1 virus can be used as the boost vaccine against SARS-CoV-2.

4.20240024447POULTRY DRINKING WATER-BASED VACCINE DELIVERY SYSTEM AND METHOD
US - 25.01.2024
Clasificación Internacional A61K 39/012 Nº de solicitud 17868571 Solicitante The United States of America, as represented by the Secretary of Agriculture Inventor/a Mark C. JENKINS
The drinking water-based avian coccidiosis vaccine formulation and delivery system is structured to deliver a vaccine containing live *Eimeria* oocysts to poultry house brood chamber chicks. The vaccine is delivered to the chicks in a diluted form through the poultry house drinking water system. The chicks are inoculated with the drinking water-based avian coccidiosis vaccine when they consume the water containing the vaccine. The timing of the chicks' drinking water access to the diluted drinking water vaccine is critical. During the inoculation process, water is temporarily withheld from the chicks for a waiting period of about 3-5 hours, and access to the diluted drinking water-based vaccine is limited to an accessibility period of about 2 hours. Additionally, metering valves and/or terminal metering valve assemblies are manually or automatically closed when the when the drinking water lines are fully charged with the diluted vaccine.

5.WO/2024/020472COMBINATION THERAPY WITH NEOANTIGEN VACCINE
WO - 25.01.2024
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/US2023/070550 Solicitante BIONTECH US INC. Inventor/a BALOGH, Kristen, N.
The present disclosure relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject

6.WO/2024/018083A VACCINE FOR TREATMENT OR PREVENTION OF VEROTOXIN-PRODUCING ESCHERICHIA COLI (VTEC) INFECTION
WO - 25.01.2024
Clasificación Internacional A61K 39/ Nº de solicitud PCT/EP2023/070365 Solicitante UNIVERSITY COLLEGE DUBLIN Inventor/a MCCLEAN, Siobhan

A vaccine comprising one or more VTEC immunogens. The vaccine is for use in vaccine therapy to treat or prevent VTEC infection in a mammal and for use in vaccine therapy to treat or prevent HUS in a mammal. A method of diagnosing VTEC infection in a subject is also provided.

7.WO/2024/017250MRNA VACCINE FOR NOVEL CORONAVIRUS VARIANTS AND USE THEREOF
WO - 25.01.2024
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/CN2023/107926 Solicitante SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor/a LI, Linxian
The present invention relates to an mRNA vaccine for novel coronavirus variants and a use thereof. The mRNA vaccine can protect against infection by SARS-CoV-2 virus and Delta virus strain, can cause a strong and continuous novel coronavirus antibody titer, and has small toxic side effects and high safety.

8.4308601ANTIGENANTIKÖRPER GEGEN VACCINIAVIRUS UND ZUGEHÖRIGE ZUSAMMENSETZUNGEN UND VERFAHREN
EP - 24.01.2024
Clasificación Internacional C07K 16/08 Nº de solicitud 22770138 Solicitante ADMARE THERAPEUTICS SOC Inventor/a CUMMINS EMMA J
Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion proteins and conjugates of the present disclosure are also provided, as are methods of using such compositions, e.g., for therapy, in vivo imaging and/or the like. In certain aspects, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual, wherein the individual comprises cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cells by VV B5 antigens expressed on the surface of the infected cells.

9.WO/2024/018033BACTERIAL VACCINE COMPRISING PROBIOTIC COMPETITOR AND INACTIVATED PATHOGEN
WO - 25.01.2024
Clasificación Internacional A61K 35/74 Nº de solicitud PCT/EP2023/070222 Solicitante UNIVERSITÄT BASEL Inventor/a WETTER SLACK, Emma
The invention relates to a pharmaceutical composition capable of protecting a patient from disease caused by a pathogenic strain of a bacterium, that displays a wild type surface antigen. It comprises a probiotic component comprising a live avirulent bacterial strain of said pathogen, which displays a variant of said surface antigen, said variant being capable of escaping binding by immunoglobulins capable of specifically recognizing the wild-type surface antigen. The composition further comprises a vaccine component of an inactivated vaccine strain of said bacterium, which displays said wild type surface antigen.

10.WO/2024/019579ATTENUATED STRAIN OF AVIAN INFECTIOUS BRONCHITIS VIRUS AND VACCINE COMPOSITION CONTAINING SAME
WO - 25.01.2024
Clasificación Internacional C12N 7/00 Nº de solicitud PCT/KR2023/010551 Solicitante KHAV CO., LTD. Inventor/a YOUN, Ha Na
The present invention relates to an attenuated strain of avian infectious bronchitis virus and a vaccine composition containing same. With weak pathogenicity and high immunogenicity, the attenuated strain of the present invention can induce defensive capabilities against the avian infectious bronchitis virus and thus can be advantageously used as an attenuated live vaccine.

11.20240024453ZIKA VIRUS VACCINE
US - 25.01.2024
Clasificación Internacional A61K 39/12 Nº de solicitud 18338612 Solicitante CureVac SE Inventor/a Benjamin PETSCH
The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Zika virus or a disorder related to such an infection. In particular, the present invention concerns a Zika virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

12.20240024456HA STEM VACCINE FOR HA ANTIBODY-POSITIVE TARGETS
US - 25.01.2024
Clasificación Internacional A61K 39/145 Nº de solicitud 18043944 Solicitante Intervet Inc. Inventor/a Martijn Alexander Langereis
The present invention relates to vaccines against influenza virus infection or disease for targets with pre-existing antibodies against influenza virus HA head domain. The invention regards a recombinant vector expressing a HA stem polypeptide, a vaccine comprising the vector or a host cell with said vector, uses of the vector, the host cell, or the vaccine, and methods for reducing influenza virus infection or disease. The recombinant vector can be a nucleic acid such as a eukaryotic expression plasmid or an RNA, a virus, or a replicon particle (RP). This vaccination allows for the induction of an early- and effective immune-response against Influenza virus induced infection or disease, not hindered by pre-existing anti-HA head domain antibodies.

13.20240024437IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY
US - 25.01.2024
Clasificación Internacional A61K 39/00 Nº de solicitud 18147627 Solicitante Transgene SA Inventor/a Philippe SLOS
The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and/or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s).

14.20240024462NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS
US - 25.01.2024
Clasificación Internacional A61K 39/215 Nº de solicitud 18465353 Solicitante INSTITUT PASTEUR Inventor/a Etienne SIMON-LORIERE
The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

15.20240024457DIFFERENTIAL COATING OF MICROPROJECTIONS AND MICRONEEDLES ON ARRAYS
US - 25.01.2024
Clasificación Internacional A61K 39/145 Nº de solicitud 18356837 Solicitante Vaxxas Pty Limited Inventor/a Michael Carl JUNGER

The present invention relates to devices and methods for coating microprojection or microneedle arrays including arrays that contain vaccine formulations, more specifically to multivalent vaccine formulations where components of the multivalent vaccine might be incompatible. The present invention further relates to stable vaccine formulations for administration via a microprojection array in which the microprojections are densely packed and in which the vaccine formulations are sprayed on to the microprojections such that the formulations dry quickly

16.4308596NANOTRÄGER AUF BASIS EXTRAZELLULÄRER VESIKEL
EP - 24.01.2024
Clasificación Internacional C07K 14/705 Nº de solicitud 22772363 Solicitante OHIO STATE INNOVATION FOUNDATION Inventor/a HIGUITA-CASTRO NATALIA
Disclosed herein is a system that engages skin-resident APCs by directly delivering a vaccine composition, and a system that turns skin cells into a vaccine dispatch center to amplify immunity via the production of engineered extracellular vesicles (EVs) functionalized with targeting ligands and loaded with the vaccine composition that can be targeted to extracutaneous APCs. In particular, disclosed herein is a vaccine composition that involves a first polynucleotide encoding or comprising a viral, bacterial, or tumor antigen, and a second polynucleotide encoding a fusion protein comprising an APC-targeting ligand and an exosomal or lysosomal transmembrane protein. Also disclosed is a method of vaccinating a subject that involves transfecting skin cells of the subject with the disclosed vaccine composition. Also disclosed herein is a method of vaccinating a subject that involves administering to the subject the disclosed EV vaccine.

17.WO/2024/019113METHOD FOR REDUCING PYROGENIC ACTIVITY OF INACTIVATED WHOLE INFLUENZA VIRUS PARTICLE VACCINES
WO - 25.01.2024
Clasificación Internacional A61K 39/145 Nº de solicitud PCT/JP2023/026580 Solicitante DENKA COMPANY LIMITED Inventor/a GOTANDA, Takuma
Provided, with respect to the production of inactivated whole influenza virus particle vaccines using the embryonated chicken egg method, is a method for reducing pyrogenic activity. With respect to the method for producing an inactivated whole influenza virus particle vaccine using the embryonated chicken egg method, there is provided a method for reducing the pyrogenic activity of this vaccine, comprising a step for reducing the content of avian-derived microRNA in the virus solution containing whole influenza virus particles that is recovered from the embryonated chicken egg.

18.WO/2024/017375CYCLIC SUBSTITUTED COMPOUND FOR RNA CAPPING AND USE THEREOF
WO - 25.01.2024
Clasificación Internacional C07H 21/02 Nº de solicitud PCT/CN2023/108697 Solicitante GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. Inventor/a ZHANG, Jiancun
A cyclic substituted compound for RNA capping and use thereof, belonging to the technical field of genetic engineering. The compound has a structure represented by formula (VI). The compound is used for capping an mRNA 5' end, such that good capping efficiency is achieved, and the capped mRNA can stably express proteins with high yields. The use of the compound as a cap structure for the preparation of an RNA vaccine or medicine can greatly reduce the cost. The compound has wide application prospects in the preparation of the RNA vaccine or medicine.

19.20240025999T CELLS AGAINST HUMAN PAPILLOMAVIRUS
US - 25.01.2024
Clasificación Internacional C07K 16/28 Nº de solicitud 18144142 Solicitante BioVentures, LLC Inventor/a Mayumi Nakagawa

Recombinant T cell clonotypes are provided that express T cell receptor alpha and T cell receptor beta polypeptides with specificity for human papillomavirus (HPV) type 16 E6 protein and that amplify in response to a therapeutic vaccine and traffic to ovarian lesional tissue in a patient whose HPV lesions regressed in response to the vaccine. Recombinant T cells expressing appropriate TCR alpha and beta complimentarity determining sequences for HPV 16 E6 binding and treating HPV-cased cancers are provided. Bifunctional proteins having TCR alpha and beta segments that bind to HPV 16 E6 residues 91-115 and a single chain Fv anti-CD3 antibody domain are provided. These bifunctional proteins can direct T cells to HPV-infected cells.

20.4309670NEISSERIA-MENINGITIDIS-IMPFSTOFF
EP - 24.01.2024
Clasificación Internacional A61K 39/095 Nº de solicitud 23214012 Solicitante SANOFI PASTEUR INC Inventor/a KENSINGER RICHARD DAVID
Provided herein are compounds, compositions, formulations, kits, uses, and methods for vaccinating a subject against Neisseria meningitidis.

21.20240024464MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY
US - 25.01.2024
Clasificación Internacional A61K 39/275 Nº de solicitud 18258501 Solicitante EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET Inventor/a Ralf AMANN
The present invention relates to a modified Parapoxvirus, preferably a Parapoxvirus vector, having an increased immunogenicity, a biological cell containing said modified Parapoxvirus, a pharmaceutical composition, preferably a vaccine, containing said modified Parapoxvirus and/or said cell, and a new use of said modified Parapoxvirus.

22.WO/2024/017253MRNA FOR SARS-COV-2 S PROTEIN AND USE THEREOF
WO - 25.01.2024
Clasificación Internacional C12N 15/50 Nº de solicitud PCT/CN2023/107936 Solicitante SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor/a HUANG, Hui
Provided are an RNA encoding a SARS-CoV-2 S protein, a vaccine comprising the RNA and a use thereof. Also provided is a universal polynucleotide molecule, comprising a 5'-UTR and/or a 3'-UTR, and a nucleic acid sequence encoding a protein and/or polypeptide of interest, and optionally comprising polyA.

23.20240027434METHOD FOR QUANTIFYING CPG-CONTAINING OLIGONUCLEOTIDES IN COMPOSITIONS COMPRISING ALUM
US - 25.01.2024
Clasificación Internacional G01N 33/53 Nº de solicitud 18267083 Solicitante Dynavax Technologies Corporation Inventor/a Martin GOHLKE
The present disclosure relates to methods for characterizing formulations comprising aluminum hydroxide particles (alum), an antigen bound to the alum, and an unmethylated cytidine-phospho-guanosine-containing oligodeoxynucleotide (CpG ODN). In particular, the present disclosure provides methods for determining concentration of CpG ODN in a vaccine formulation through use of a colorimetric assay for measuring total phosphorus.

24.WO/2024/017827CONTINUOUS PROCESS FOR VACCINE PRODUCTION
WO - 25.01.2024
Clasificación Internacional A61K 39/102 Nº de solicitud PCT/EP2023/069770 Solicitante GLAXOSMITHKLINE BIOLOGICALS SA Inventor/a JEHOULET, Philippe Raymond

The present invention relates *inter alia* to a continuous process for producing an immunogenic composition using a micro-fluidic or milli-fluidic (MF) system and filling one or more vessels with the immunogenic composition.

25.WO/2024/020453IMMUNE SYSTEM MODULATORS AND USES THEREOF
WO - 25.01.2024
Clasificación Internacional A61K 47/69 Nº de solicitud PCT/US2023/070510 Solicitante HDT BIO CORP. Inventor/a BERGLUND, Lars Peter Aksel
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Compositions optionally comprising a nanoparticle carrier and nucleic acid sequence(s) encoding for (i) a cytokine; and (ii) an innate immune stimulator are provided. Further provided are compositions optionally comprising a nanoparticle carrier; an innate immune stimulator; and a nucleic acid sequence encoding for a cytokine. Methods of using the compositions as a therapeutic vaccine for the treatment of a cancer are also provided.

26.20240024469VACCINE ADJUVANTS BASED ON TLR RECEPTOR LIGANDS
US - 25.01.2024
Clasificación Internacional A61K 39/39 Nº de solicitud 18446041 Solicitante THE UNIVERSITY OF MONTANA Inventor/a Helene Bazin-Lee
Lipidated oxoadenines of formula (I) are TLR7/8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmune disorders.

27.4308129IMPFSTOFFZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON
EP - 24.01.2024
Clasificación Internacional A61K 31/713 Nº de solicitud 22772215 Solicitante EXCEPGEN INC Inventor/a MERTINS BARBARA
The present disclosure provides compositions and methods for use in vaccines, comprising polynucleotides encoding one or more viral antigen proteins and an enhancer protein, wherein the enhancer protein is a picornavirus leader (L) or a functional variant thereof. The compositions and methods provided herein may improve the production of functional viral-like particles (VLP).

28.20240024448M Hyo Multivalent Vaccine and Uses Thereof
US - 25.01.2024
Clasificación Internacional A61K 39/02 Nº de solicitud 18343081 Solicitante BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. Inventor/a Keith Wilson
The present invention relates to compositions or vaccines for combating *Mycoplasma hyopneumoniae* (*M hyo*), Porcine Circovirus type 2 (PCV2), and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infections in animals and for increasing the ability of pigs to gain weight and/or improve death loss, methods of vaccination against the infections, and kits for use with such methods and compositions.

29.4310186REKOMBINANTES MASERNVIRUS
EP - 24.01.2024
Clasificación Internacional C12N 15/45 Nº de solicitud 21931645 Solicitante YONEDA MISAKO Inventor/a YONEDA MISAKO
The present invention provides a recombinant measles virus useful as a live vaccine against COVID-19 and a vector used for production of the recombinant measles virus. That is, the present invention relates to a recombinant measles virus having a gene encoding a protein of the coronavirus SARS-CoV-2

inserted between the N gene region and the P gene region in a measles virus genome; the recombinant measles virus in which the protein is a spike protein of SARS-CoV-2 or a partial protein thereof; and a DNA in which a gene encoding a protein of SARS-CoV-2 is inserted in a region ranging from the 1 ,686th base to the 1 ,694th base of a base sequence set forth in SEQ ID NO: 2.

30.20240024238NONCOMPETITIVE RECEPTOR-TARGETED VACCINE DELIVERY TO PLASMACYTOID DENDRITIC CELLS
US - 25.01.2024
Clasificación Internacional A61K 9/127 Nº de solicitud 18221262 Solicitante Washington University Inventor/a Shiva Kumar Jai Sumha Rudra
Disclosed herein are compositions comprising a hydrogel scaffold, methods of generating a hydrogel scaffold, and systems for and methods of using the hydrogel scaffold to produce biologically active molecules.

31.20240024459METHOD FOR PRODUCING AN ANTIGEN CORRESPONDING TO THE INACTIVATED SARS-COV-2 VIRUS, ANTIGEN CORRESPONDING TO THE INACTIVATED SARS-COV-2 VIRUS, ANTIGENIC COMPOSITION, KITS, AND USES THEREOF
US - 25.01.2024
Clasificación Internacional A61K 39/215 Nº de solicitud 18041541 Solicitante INSTITUTO BUTANTAN Inventor/a RICARDO DAS NEVES OLIVEIRA
The present invention relates to techniques and methods for producing, purifying, inactivating and analyzing SARS-CoV-2. The present invention relates to the method for producing an antigen corresponding to the SARS-COV-2 virus inactivated by gamma radiation. The method for producing an antigen corresponding to the SARS-COV-2 virus inactivated by gamma radiation is intended for use in the production of a novel vaccine, the antigen being used in the production of hyperimmune plasma in horses for serum therapy, and in different animal species for the production of antibodies/research inputs and the establishment of serum diagnosis techniques. The present invention relates to the antigenic composition including the antigen corresponding to the inactivated SARS-COV-2 virus and a pharmaceutically acceptable diluent excipient. The invention also relates to a method for producing anti-SARS-CoV-2 immunoglobulins using the SARS-COV-2 virus inactivated by gamma radiation.

32.20240027453METHOD FOR DETECTION AND QUANTITATIVE MONITORING OF INFECTIONS WITH HERPESVIRUSES
US - 25.01.2024
Clasificación Internacional G01N 33/569 Nº de solicitud 18006035 Solicitante The Trustees of Princeton University Inventor/a Ileana M. Cristea

Described are systems and assays that monitor presence and/or quantity of herpesviruses viral proteins. Embodiments offer accurate detection and quantification of viral proteins from all temporal classes of viral replication. Three exemplary assays provide specific detection of: herpes simplex vims type 1 (HSV1), human cytomegalovirus (HCMV), and Kaposi's sarcoma-associated herpesvirus (KSHV). These assays can be utilized in combination with drug treatments, genetic modifications, or other perturbations to assess the impact of the intervention on viral protein production. Also provided are kits for use with such assays, peptides useful in the describes assays (including labeled peptides and collections of a plurality of different peptides), nucleic acids and other genetic constructs encoding such peptides, systems for carrying out the described assays (including computer-based or computer-assisted systems), and methods for using the assays for instance in drug development and analysis, vaccine development and analysis, genetic analysis, environmental analysis, etc.

33.4309178VERFAHREN ZUR OPTIMIERUNG DER TUMORVAKZINANTIGENABDECKUNG FÜR HETEROGENE MALIGNOME
EP - 24.01.2024
Clasificación Internacional G16B 20/20 Nº de solicitud 22717471 Solicitante AMAZON TECH INC Inventor/a PRICE LAYNE CHRISTOPHER
Disclosed herein are methods for selecting tumor-specific neoantigens from a tumor of a subject that are suitable for subject-specific immunogenic compositions.

34.20240026412IMPROVED METHODS OF PRODUCING A LIPIDATED PROTEIN
US - 25.01.2024
Clasificación Internacional C12P 21/02 Nº de solicitud 17917016 Solicitante Valneva Austria GmbH Inventor/a Robert Schlegl
The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.G5) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C-TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by *Clostridium difficile* or hMPV and/or of SARS-CoV-2 (COVID-19).

35.20240024443AUGMENTATION OF SURVIVIN MODIFIED MRNA VACCINE EFFICACY USING DENDRITIC CELLS
US - 25.01.2024
Clasificación Internacional A61K 39/00 Nº de solicitud 18358432 Solicitante Regen Biopharma, Inc. Inventor/a Thomas ICHIM
Disclosed are methods, and compositions useful for stimulation of immunity towards cancer by utilizing dendritic cells and products therefrom that have been stimulated and/or incorporated mRNA encoding survivin and/or related gene sequences, defined herein as “survivin modified mRNA”. In one embodiment dendritic cells generated from allogeneic “off the shelf” sources are transfected with survivin modified mRNA and the cells are administered in an immunogenic manner. In some embodiments transfected dendritic cells are induced to undergo immunogenic cell death ex vivo subsequently to which they are used as immunogenic stimuli. In other embodiments preparation of the injection site is performed prior to administration of dendritic cells that have been transfected with survivin modified mRNA by pre-administration of agents increasing the number of local dendritic cells in the skin. In embodiments in vivo, transfection of survivin modified mRNA is performed by administration of dendritic cell accumulating agents followed by in vivo transfection.

36.3430030TRANSFICEREDE T-CELLER OG T-CELLERECEPTORER TIL ANVENDELSE I IMMUNOTERAPI MOD CANCER
DK - 22.01.2024
Clasificación Internacional C07K 14/435 Nº de solicitud 17710955 Solicitante Immatics Biotechnologies GmbH Inventor/a MAURER, Dominik
The present description relates to T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The present description further relates to peptides, proteins, nucleic acids

and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

37.20240029823PEPTIDE BASED VACCINE GENERATION SYSTEM WITH DUAL PROJECTION GENERATIVE ADVERSARIAL NETWORKS
US - 25.01.2024
Clasificación Internacional G16B 15/30 Nº de solicitud 18479423 Solicitante NEC Laboratories America, Inc. Inventor/a Renqiang Min
A computer-implemented method is provided for generating new binding peptides to Major Histocompatibility Complex (MHC) proteins. The method includes training, by a processor device, a Generative Adversarial Network GAN having a generator and a discriminator only on a set of binding peptide sequences given training data comprising the set of binding peptide sequences and a set of non-binding peptide sequences. A GAN training objective includes the discriminator being iteratively updated to distinguish generated peptide sequences from sampled binding peptide sequences as fake or real and the generator being iteratively updated to fool the discriminator. The training includes optimizing the GAN training objective while learning two projection vectors for a binding class with two cross-entropy losses. A first loss discriminating binding peptide sequences in the training data from non-binding peptide sequences in the training data. A second loss discriminating generated binding peptide sequences from non-binding peptide sequences in the training data.

38.20240029821PEPTIDE BASED VACCINE GENERATION SYSTEM WITH DUAL PROJECTION GENERATIVE ADVERSARIAL NETWORKS
US - 25.01.2024
Clasificación Internacional G16B 15/30 Nº de solicitud 18479409 Solicitante NEC Laboratories America, Inc. Inventor/a Renqiang Min
A computer-implemented method is provided for generating new binding peptides to Major Histocompatibility Complex (MHC) proteins. The method includes training, by a processor device, a Generative Adversarial Network GAN having a generator and a discriminator only on a set of binding peptide sequences given training data comprising the set of binding peptide sequences and a set of non-binding peptide sequences. A GAN training objective includes the discriminator being iteratively updated to distinguish generated peptide sequences from sampled binding peptide sequences as fake or real and the generator being iteratively updated to fool the discriminator. The training includes optimizing the GAN training objective while learning two projection vectors for a binding class with two cross-entropy losses. A first loss discriminating binding peptide sequences in the training data from non-binding peptide sequences in the training data. A second loss discriminating generated binding peptide sequences from non-binding peptide sequences in the training data.

39.20240029822A PEPTIDE BASED VACCINE GENERATION SYSTEM WITH DUAL PROJECTION GENERATIVE ADVERSARIAL NETWORKS
US - 25.01.2024
Clasificación Internacional G16B 15/30 Nº de solicitud 18479416 Solicitante NEC Laboratories America, Inc. Inventor/a Renqiang Min
A computer-implemented method is provided for generating new binding peptides to Major Histocompatibility Complex (MHC) proteins. The method includes training, by a processor device, a

Generative Adversarial Network GAN having a generator and a discriminator only on a set of binding peptide sequences given training data comprising the set of binding peptide sequences and a set of non-binding peptide sequences. A GAN training objective includes the discriminator being iteratively updated to distinguish generated peptide sequences from sampled binding peptide sequences as fake or real and the generator being iteratively updated to fool the discriminator. The training includes optimizing the GAN training objective while learning two projection vectors for a binding class with two cross-entropy losses. A first loss discriminating binding peptide sequences in the training data from non-binding peptide sequences in the training data. A second loss discriminating generated binding peptide sequences from non-binding peptide sequences in the training data.

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES